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Abstract 
This thesis involves the preparation and exploration of the reactivity of a variety 
of organocopper complexes with N-heterocyclic carbene (NHC) ligands. The 
ligands contain either pyridyl/picolyl/allyl N-substituents or a xanthine-derived 
backbone. 
Structural modifications were made to the NHC ligands which were investigated 
for their catalytic activity when coordinated with Cu(I) in situ in an Ullmann-type 
etherification reaction. The ligand found to be the most active in catalysis was 
1-allyl-3-picolylbenzimidazol-2-ylidene. 
The catalytic reaction was studied in more detail to assess deactivation pathways 
through reductive elimination of aryl-imidazolium, dehalogenation and/or 
homocoupling of aryl iodide. In order to quantify the deactivation pathways, the 
preparation of novel aryl-imidazolium salts via C-2 selective arylation of 
imidazole, and of a biaryl via a Pd-catalysed was necessary, which led to more 
understanding the Cu-catalysed reaction and further side-reactions. 
The arylation of NHC-related species was exploited in the C-2-arylation of 
xanthine-derived compounds. The reactions were investigated via Cu-NHC 
complexes, prepared using an electrochemical method. The kinetics of the 
arylation of a xanthine-derived Cu-NHC complex were studied using in situ 
1H NMR and IR spectroscopies. Optimisation and a full understanding of this 
reaction has potential application in the detection of mismatched DNA bases. 
Further to the non-innocent behaviour of NHCs, an unusual Cu-mediated 
annulation reaction involving an allyl N-substituent was investigated. The 
reaction is proposed to occur via oxidative addition of C-Br to a Cu2Br2 cluster, 
Br migration and reductive elimination of the annulated product. Although most 
of the reactions discussed in this thesis are thought to proceed via a Cu(III) 
intermediate, the isolation of a Cu(III)-NHC has not been achieved to date. 
Attempts were therefore made to stabilise a Cu(III)-NHC using the macrocyclic 
effect, which may allow more understanding of the elusive Cu(III)-NHC 
intermediate in a variety of reactions. 
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LCMS liquid chromatography – mass spectrometry 
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mA milliamperes 
 
 
xx 
 
Mes mesityl (2,4,6-trimethylphenyl) 
MHz Megahertz 
ms spin quantum number 
NBS N-bromosuccinimide 
NHC N-heterocyclic carbene 
OTf
-
 triflate (trifluoromethanesulfonate) 
PF6
-
 hexafluorophosphate 
PhCN benzonitrile 
ppm parts per million 
pyH protons attached to a pyridyl ring 
pyrrolH protons attached to a saturated part of a dihydropyrollo-
imidazolium 
s singlet resonance (NMR) 
Selectfluor 1-chloromethyl-4-fluoro-1,4-diazoniabicyclo[2.2.2]octane 
bis(tetrafluoroborate) 
SIMes 1,3-bis(mesityl)-4,5-dihydroimidazol-2-ylidene 
sept septet resonance (NMR) 
t triplet resonance (NMR) 
Th thrianthrene 
Th•+ thrianthrenyl 
THF tetrahydrofuran 
THP tetrahydropyranyl 
V Voltage 
%Vbur percentage of buried volume (sterics) 
XnH protons attached to a xanthine or xanthinium ring 
 
Compounds are labelled throughout chapter 1 as A – DD 
Compounds are labelled throughout chapter 2 – 5 as follows: 
P#  imidazole (precursor) 
 
 
xxi 
 
L# ligand 
PS#  precursor of substrate 
S#  substrate, 
Cy#  annulated product, 
Ar#, ArIm anisolyl-imidazolium 
ArH anisole 
ArNu 1-(4-anisolyl)-3,5-dimethylbenzene 
ArAr bianisolyl 
ArI 4-iodoansiole 
C# metal complex of ligand 
 
 
 
1 
 
Chapter 1  
Introduction 
1.1 Carbenes and electronic states 
Carbenes are neutral species which house a divalent carbon centre with six 
valence electrons (Figure 1-1).1-4 They are considered to be electron poor due 
to disobeying the octet rule, hence are highly reactive.1,2 
 
Figure 1-1: Electronic configuration of possible carbenes (A – F).1 
A carbene can be linear or bent. The linear type (A and B, Figure 1-1), a rare 
case, has a triplet ground state with sp-hybridisation. The two degenerate 
p-orbitals are non-bonding, with each possessing an electron in the same spin 
quantum number, ms (Figure 1-2).1,5 The bent carbene centre (C – F, Figure 1-1) 
has sp2-hybridisation which removes the degeneracy of the two non-bonding 
orbitals. Despite the absence of degeneracy, bent carbenes can exist in either 
singlet or triplet ground state.1,4 The multiplicity of a carbene centre is determined 
by the energy gap between σ and pπ orbitals, which is influenced by the steric 
and electronic properties of the α-substituents neighbouring the carbene centre.6 
For instance, bulky α-substituents lead to a pseudo linear geometry to minimise 
the steric interaction, and a triplet carbene is favoured when the energy gap 
between σ and pπ orbitals is below 1.5 eV (Figure 1-3). A singlet carbene is 
favoured when the α-substituents are π-donating, which increases the p-orbital 
energy, hence contains a larger energy gap (Figure 1-4).4 
 
 
 
2 
 
 
Figure 1-2: Energy diagram for the linear methylene carbene.1 
 
Figure 1-3: Energy diagram for the bent triplet methylene carbene.1 
 
Figure 1-4 Energy diagram for the bent singlet methylene carbene.1 
1.2 N-Heterocyclic carbenes (NHCs) 
An N-heterocyclic carbene (NHC) is an example of a singlet carbene. It is a ring 
(usually 5-membered) with a carbene centre having two adjacent 
π-electron-donating nitrogen atoms.1 The electronic properties of the nitrogen 
atoms are the main key to NHC stabilisation. The sp2-hybridised non-bonding 
lone pair of an NHC is stabilised by a σ-inductive withdrawing effect from the 
electronegative nitrogen atoms, thus lowering the HOMO orbital energy.3,4,7,8 
Moreover, the orbital π-interaction of the empty NHC p-orbital with two electron 
lone pairs of two α-amino groups, namely mesomeric effect, raises the LUMO 
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orbital energy (Figure 1-5).2-4,7-9 These electronic properties render NHCs stable 
and strong Lewis base donors. 
 
Figure 1-5: Electronic stabilising factors of an NHC.10 
In addition to the electronic factors, bulky N-substituents help stabilise an NHC. 
For example, bulky adamantyl N-substituents make the free NHC more 
kinetically stable due to steric protection of the carbene centre.2,4,7,9 The first free 
(uncoordinated) NHC, 1,3-di(1'-adamantyl)imidazole-2-ylidene (IAd, Scheme 
1-1), was established in 1991 by Arduengo,2,9,11 which sparked a significant 
amount of interest in NHC research. The persistent NHC was synthesised by 
deprotonation of its imidazolium precursor using a strong base (NaH). 
 
Scheme 1-1: Preparation of IAd, the first isolated free NHC.9  
1.3 Metal-NHC complexes and their synthesis 
The idea of utilising carbenes as ligands was suggested in 1962 by Wanzlick.12 
Although the isolation of a free NHC was not initially reported, the first 
metal-NHCs were reported in 1968 independently by Ӧfele13 and Wanzlick.14 
The real spark for NHCs occurred in 1991 with the first isolation of IAd, which 
allowed for thorough examination of electronic and steric properties of NHCs.9 
NHCs are strong σ-electron donors, generally stronger than phosphine ligands.15 
Another major difference of NHCs compared to phosphines are the steric 
properties of the ligand.2,10 Phosphines have their substituents pointing away 
from the metal centre, with tetrahedral geometry around the phosphorus atom, 
which results in a cone shape. NHCs derived from imidazolium salts give an 
umbrella-shape, with their N-substituents pointing towards the metal centre. 
Tolman angles, θ, are used for phosphine ligands to compare their steric 
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parameters, while NHC complexes use the percentage of buried volume, %Vbur 
(Figure 1-6).16,17 The %Vbur is the percentage of occupied volume by a ligand 
inside a sphere of 3 Å radius, which is roughly the distance between a metal 
centre and a nitrogen atom.  
 
Figure 1-6: Comparison of the different shapes of steric encumbrance imposed by 
phosphine and NHC ligands.16  
Several methods can be used to prepare metal-NHC complexes, with the NHC 
precursor often being an imidazolium salt. Imidazolium salts can be prepared by 
functionalisation of imidazole derivatives at the N-1 and N-3 positions, building 
an imidazolium ring via condensation reactions or a combination of both 
methods.2 
i) Deprotonation of H-imidazolium and metallation 
Arduengo employed a strong base to deprotonate an imidazolium salt to give a 
free NHC,9 which can subsequently be reacted with a metal salt, or a metal 
complex bearing a labile ligand, to give a metal-NHC complex. However, a strong 
base may be unsuitable in the case of some imidazolium salts that have acidic 
protons other than the H-imidazolium. In addition, isolation of the NHC may be 
difficult due to instability in the absence of bulky groups. Alternatively, a free NHC 
can be formed in situ, a method that does not require such a strong base. Weaker 
bases such as K2CO3,18-21 Cs2CO3,22,23 NaOAc24 and KOtBu,25,26 which are 
generally stable to air and moisture, can be used to prepared the complex. As 
an example, Li et. al. utilised an imidazolium G with K2CO3 and PdCl2 in pyridine, 
which acts as both solvent and ligand, to form the corresponding Pd-NHC 
complex H (Scheme 1-2).18 
 
Scheme 1-2: Preparation of a Pd-NHC complex H via in situ deprotonation.18 
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Another synthetic method uses a basic metal precursor, which combines base 
and metal source together, and was used by Ӧfele and Wanzlick to form the first 
example of metal-NHCs.13,14 Nowadays, the metal precursors are usually 
oxide,27-33 acetate34,35 or amide36 salts. For example, Ag2O is commonly used for 
the preparation of Ag-NHC complexes, with the solvent used being varied due to 
the differing solubility of imidazolium precursors (usually DCM, MeOH, MeCN or 
THF).37-40 For example, an imidazolium bromide salt J is soluble in MeOH, while 
a PF6
-
 salt K is soluble in MeCN (Scheme 1-3).40  
 
Scheme 1-3: Preparation of a Ag-NHC complex L using the basic metal precursor 
Ag2O.
40 
ii) Silver transmetallation 
Ag-NHC complexes can act as an NHC source, from which the ligand can be 
transmetallated on to another metal.24,41-44 The first reported example of this 
method was the preparation of PdCl2(NHC)2 N and AuBr(NHC) P complexes 
from a Ag-NHC complex M, which produced AgBr or AgCl as a by-product 
(Scheme 1-4).45 The formation and precipitation of Ag halides makes the 
transmetallation exothermic and thermodynamically favourable. 
 
Scheme 1-4: Examples of silver transmetallation.45 
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iii) Oxidative addition 
H-imidazolium and halo-imidazolium salts can be activated by transition metals 
to form metal-NHC complexes with higher oxidation state such as Ni(II), Pd(II) 
and Pt(II). This method may also be used in catalytic C-H or C-X activation and 
forms a metal-NHC complex as a reaction intermediate. For example, an 
H-imidazolium Q cation can be activated by a Ni(0) complex R and forms a 
Ni(II)-NHC complex S (Scheme 1-5).46 This is followed by an alkene 
π-coordination, β-migration and reductive elimination of an alkyl-imidazolium ion 
product W. 
 
Scheme 1-5: Ni-catalysed reaction between imidazolium (Q) and alkene (T) via 
Ni-NHC complex intermediates (S, U and V).46 
Another example of the formation of a metal-NHC through oxidative addition is 
prepared from an imidazole. A C-H bond of an alkenyl benzimidazole Z was 
oxidatively added to Rh(I) and formed a Rh(III) complex AA.47 This was followed 
by a proton migration, which reduced the metal centre and oxidised the anionic 
ligand to form an H-N-substituted NHC ligand on a Rh(I) complex AB, a rare 
example of such type (Scheme 1-6).  
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Scheme 1-6: Formation of a Rh-NHC complex via oxidative addition of an imidazole 
and H-migration.47 
iv) Electrochemical synthesis 
For some types of imidazolium N-substituents, deprotonation to form free NHC, 
or metallation with in situ deprotonation can be unsuccessful in preparing metal-
NHCs, often a result of other acidic protons in the imidazolium precursor.48,49 
Electrolysis can be used as an alternative method to form metal-NHC 
complexes. At the sacrificial anode, the metal is oxidised to an accessible metal 
ion, for example Cu(I), Ag(I), Ni(II) and Fe(II), releasing ions into solution.49,50 
Simultaneously, at the cathode, the imidazolium ion is reduced to a free carbene 
with the release of hydrogen gas. The generated carbene then forms a complex 
with the metal ions in solution (Scheme 1-7).  
 
Scheme 1-7: Electrolysis to form metal-NHC complexes.49 
1.4 Metal-NHC complexes in catalysis 
An NHC ligand can be used to improve a ligand-free metal catalyst, and often 
enhances the reaction over other types of ligands such as phosphines. As a 
consequence of the strong electron donation of NHCs, the stability of the catalyst 
may improve.15,51 Moreover, the steric protection of the metal by the ligand also 
helps reduce catalyst decomposition.10 Metathesis reactions,52-57 catalysed by 
ruthenium complexes, and cross-coupling reactions52,58-63 to form C-C, C-B, C-N, 
C-O, and C-S bonds, catalysed by Pd and other metals, are the most commonly 
studied reactions by metal-NHC complexes. 
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An example showing significantly enhanced performance by an NHC ligand is 
the second generation Grubbs catalyst (Grubbs II) (Figure 1-7).1,55 Mechanistic 
studies of Grubbs II catalyst shows that replacing a phosphine ligand (Grubbs I) 
with SIMes further stabilises the metallacyclobutane intermediate.16  
 
Figure 1-7: The structure of Grubbs I and Grubbs II catalysts.55 
1.4.1 Cu-NHC complexes in cross-coupling reactions 
Pd complexes have been applied as catalysts in many well-known 
cross-coupling reactions such as Heck,64,65 Suzuki66 and Stille67 reactions. 
Cu-catalysed cross-coupling reactions started their history in the early 20th 
century when Ullmann reported the use of stoichiometric amounts of Cu to 
prepare diaryl compounds, and later other types of C-X bond couplings e.g. C-O, 
C-N and C-S.68-70 However, due to the requirement for excess Cu, high reaction 
temperatures (above 200 °C), harsh bases and limited substrates, the 
Cu-mediated cross-coupling reactions were not developed at that time. Bidentate 
ligands such as bipyridines and phenanthrolines were developed as they were 
found to promote cross-coupling reactions without the need for such harsh 
conditions.71,72 The use of Cu in industry has significant advantages over Pd, as 
it is much more abundant and has lower toxicity. Furthermore, unlike Pd 
catalysts, which usually require expensive, complicated and air-sensitive ligands, 
ligands for Cu catalysts are not as complex,73 such as bipyridine, acac, acNac 
and NHC ligands. Still, the knowledge of Cu-NHC cross-coupling reactions is 
limited, as there are few examples of the application.38,60-64 However, as the 
electronic and structural properties of NHCs can be easily modified, this provides 
promise to the field.41,74-78 
Biffis and co-workers reported the first example of Cu-NHC catalysts for 
cross-coupling reactions in 2008. A tri-nuclear Cu-NHC complex AC was found 
to be an active catalyst in C-N, C-O and C-Calkyne bond forming reactions, with 
various aryl halide substrates, at 100 °C using 3 mol % AC catalyst (or 9 % 
equivalents of Cu) (Scheme 1-8).74,75 It was noted that aryl iodide is more efficient 
than its aryl bromide counterpart, and that electron-poor aryl iodides lead to a 
higher conversion to arylated product than electron-rich aryl iodides, which is 
typical for Cu-catalysed reactions.79,80 
 
 
9 
 
 
Scheme 1-8: A tri-nuclear Cu-NHC complex and its application as a catalyst in 
cross-coupling reactions.74 
In 2014, our group demonstrated that pyridyl-tethered NHC ligands can stabilise 
Cu(II) bromide complexes despite them being neutral ligands. The Cu(I)-NHC 
complexes were screened in the etherification of an electron-rich aryl halide with 
dimethylphenol, at 90 °C in MeCN, which was shown to promote catalytic activity 
compared to a ligand-free system.41 It is possible that the chelating NHC can 
stabilise higher oxidation state intermediates (as demonstrated by the 
stabilisation of Cu(II)) and also push the substrate into a cis-coordination. In 
2018, Tahsini showed the application of Cu-NHCs e.g. AD with pincer ligands in 
Sonogashira-type reactions, at 140 °C in DMF, using K2CO3 as the base.81 The 
chelating effect of the ligand leads to a stable complex which enables the 
reaction to be carried out successfully in air, which gave 80 – 96 % of the coupled 
products (Scheme 1-9).  
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Scheme 1-9: A Cu-NHC pincer complex and its application in a Sonogashira-type 
reaction.81 
1.5 Non-innocent activities of NHC ligands at metals 
Although metal-NHC bonds are considered strong, there is evidence for the 
involvement of NHC ligands in reactivity at metals,82 such as reductive 
elimination,34,41,83-91 ligand insertion,87,92-96 NHC ring opening,92,97-99 ligand 
substitution,100 and N-substituent activation.101 
1.5.1 Reductive elimination of alkyl/aryl-imidazolium salts 
i) Observed as side-reactions during catalysis 
NHC ligands are most likely to become involved in reductive elimination when 
they are coordinated to a metal in high oxidation state. Cavell first reported NHC 
ligands coordinated to Pd(II) undergoing reductive elimination of methyl-
imidazolium and forming Pd(0) as a by-product.102 The Pd(II) complexes AE and 
AF are stable at high temperatures and were screened for their catalytic activity 
in the Heck coupling reaction of 4-bromoacetophenone (AG) and n-butylacrylate 
(AH) to form n-butyl-(E)-4-formylcinnamate (AJ), whereas complex AK was not 
stable at 120 °C in DMSO, and led to complex decomposition. The 
decomposition pathway of complex AK was unknown, so it was treated with 
AgNO3 to remove a chloride ligand, which resulted in complex AL. Complex AL 
was found to undergo reductive elimination of methyl-imidazolium nitrate (AM) 
and form Pd(0) species. 
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Scheme 1-10: Pd(II)-NHC complexes AE and AF, and their application in a Heck 
coupling reaction.102 
 
Scheme 1-11: Decomposition of a Pd(II)-NHC complex AL via reductive elimination 
of the imidazolium salt AM.102 
Reductive elimination of an NHC can also occur with intramolecular substrates. 
An imidazolium salt bearing a but-3-enyl N-substituent (AN) ultimately led to the 
formation of a 5-membered ring (AR) when reacted with Ni(0) (Scheme 1-12).103 
The reaction was suggested to occur via the oxidative addition of the H-Cimidazolium 
bond to the Ni(0) centre, with subsequent alkene coordination to form a 
Ni(II)-NHC complex AP. H-insertion of the metal hydride to the alkene to form 
AQ, and reductive elimination would produce the cyclic imidazolium ion AR. 
 
Scheme 1-12: Cyclisation of a but-3-enyl N-substituent.103 
Reductive elimination of a bis(imidazolium) ion (BC) has been found to occur 
from a Cu(III) centre, following silver transmetallation of the NHC with one 
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equivalent of CuBr2. The reaction was found to only occur when the 
N-substituents of the NHC were a mesityl and a 2-pyridyl group (Scheme 1-13).84 
DFT calculations demonstrated that the reaction occurs via formation of a Cu(II)-
NHC complex AU, which reversibly dimerises through halide (μ-Br)2-bridges 
(AV). The dimer undergoes disproportionation to a mixed Cu(III)-Cu(I) species 
(AW), followed by reductive elimination at the Cu(III), resulting in formation of a 
bromoimidazolium salt AZ and a Cu(I)-NHC complex BA (Figure 1-8). This step 
is slightly endothermic (+2.2 kJ mol-1).  
 
Scheme 1-13: Formation of Cu(II)-NHC containing mesityl and pyridyl N-substituents 
leading to formation of bis(imidazolium) cuprate salt.84 
 
Figure 1-8: DFT calculations for the formation of a bromoimidazolium cuprate salt 
(AZ) and a Cu(I)-NHC (BA).84 
Bromoimidazolium AZ is oxidatively added to complex BA and forms an 
octahedral Cu(III)-NHC complex BB, which has NHCs cis to each other (Figure 
1-9). The intermediate BB is stabilised by the π-π stacking interaction between 
the relatively electron rich mesityl N-substituents of one ligand and relatively 
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electron poor pyridyl substituent of the others. Reductive elimination at BB 
occurs with a comparatively low energy barrier (ΔG‡ = 9.4 kcal mol-1) and forms 
the bis(imidazolium) salt BC. Overall the reaction is exothermic (-12.4 kJ mol-1) 
and accessible, likely due to the stabilisation of BB and the low energy barrier of 
the reductive elimination of BC. 
 
Figure 1-9: DFT calculations for the formation of 
bis(imidazolium) cuprate salt BC.84 
The involvement of NHCs in reductive elimination becomes an issue when it 
occurs during catalysis, as it consumes both the substrate and the active 
metal-NHC catalyst.104,105 This may also occur when reactions are performed in 
imidazolium ionic liquids, which can result in arylation of imidazolium, consuming 
aryl halides.106 
Efforts have been made to reduce the reactivity of NHCs by using chelating 
N-substituents to block aryl/alkyl substrates coordinating cis to the NHC.90,91,107 
Cavell used amino (BD) and pyridine (BF) groups as N-substituents to form 
tridentate complexes with Pd(II) and a methyl ligand (Scheme 1-14). The stability 
of the complex BF increased tremendously compared to non-chelating 
Pd(II)-NHC complexes and complex BD and slow reductive elimination of BG 
from BF only occurred at temperatures above 120 °C. 
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Scheme 1-14: Reductive elimination from a tridentate Pd-NHC complex.107 
ii) Exploited for synthesis 
Cavell and co-workers took advantage of the reductive elimination of a 
methyl-imidazolium BJ from complex BH (pre-catalyst) to generate an active 
bent Pd(0)-diphosphene complex (BK) upon heating (Scheme 1-15).89 BK can 
then undergo oxidative addition with aryl halide, with coupling of substrates to 
give desired products. 
 
Scheme 1-15: Pd(0) catalyst is generated from reductive elimination of 
methyl-imidazolium BJ.89 
The reductive elimination of an aryl-imidazolium was used to study the catalytic 
mechanism of a Heck reaction catalysed by a Pd(0)-bis(NHC) complex BL 
(Scheme 1-16).104 The reaction was proposed to take place via oxidative addition 
of aryl halide to BL to form the Pd(II) complex BM, followed by insertion of the 
alkene and β-hydride elimination. To confirm the formation of the intermediate 
BM, AgBF4 was added to the reaction mixture, which removed I- from BM and 
trapped the reaction (Scheme 1-17), making the Pd complex less stable and 
resulting in the formation of aryl-imidazolium BR, alkyl-imidazolium BT and 
H-imidazolium ions BV. 
 
 
15 
 
 
Scheme 1-16: Proposed mechanism of a Heck reaction using Pd(0)-bis(NHC) BL as 
the catalyst.104 
 
Scheme 1-17: Proposed mechanism in the formation of imidazolium side-products BR, 
BT and BV.104 
The aryl/alkyl-imidazolium salts can be used to prepare mesoionic NHC 
ligands.108-110 Instead of a coordination site at the C-2 position, the site is blocked 
and the ligand coordinates at the C-4 or C-5 position. For example, Reichmann 
demonstrated a coupling reaction between an NHC and aryl halide using a Pd(0) 
catalyst, followed by metallation with CuI to afford a mesoionic Cu-NHC CA 
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(Scheme 1-18).111 The mesoionic NHC complex has often outperformed catalytic 
activities compared to its normal NHC complex.112-116 For example, mesoionic 
Ru(II)-NHC complex CB has a higher catalytic activity and higher selectivity 
towards product CF than complex CC in addition of benzoic acid CE to terminal 
alkyne (phenylacetylene, CD).115 
 
Scheme 1-18: Preparation of a mesoionic Cu-NHC complex.111  
 
Scheme 1-19: Structures of Ru(II)-NHC CB and CC, and Ru-catalysed addition of 
benzoic acid CE to phenylacetylene CD.115 
1.5.2 Reductive elimination of halo-imidazolium salts 
NHCs are considered soft bases and unsuitable for highly charged metals, hence 
are likely to take part in reductive elimination. An attempt to prepare a 
Cu(III)-NHC complex via oxidation of a Cu(I)-NHC halide complex using 
Selectfluor as the oxidant led instead to reductive elimination of a 
halo-imidazolium salt.83 In addition to the unsuitable Cu(III)-NHC pairing, Cu(III) 
compounds are usually unstable and easily reduced to Cu(II) in aqueous 
solutions (E1/2 = +1.57 V).117 
Although Cu(II) compounds are common, the preparation of Cu(II)-NHCs is more 
challenging due to the hard acid – soft base interaction. A Cu(II)-NHC acetate 
CJ complex can be prepared and isolated but the preparation of a Cu(II)-NHC 
bromide complex of the same ligand is not possible.34 The acetate ligand has an 
advantage that it is bidentate, which can form a Cu(II) complex that has 19 
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electrons with two acetate ligands. Similarly, Cu(II)-NHC complexes CK and CL 
are examples of Cu(II)-NHC complexes bearing an anionic alkoxy group, which 
are stable and have 17 electrons.118,119 A Cu(II)-NHC complex with bromides has 
only 15 electrons, though can undergo (μ-Br)2 dimerisation to form a 17-electron 
species CM.34 However, the bridging of CM decomposes to CN and CP, which 
was proposed to occur via disproportionation of the two Cu(II) centres to Cu(I) 
and Cu(III) and reductive elimination of CP at Cu(III). However, the mechanism 
had not been confirmed in the work. 
 
Scheme 1-20: Preparation of a Cu(II)-NHC acetate complex (top left),34 structure of 
complexes CK and CL (top right),118 and reductive elimination from a Cu-NHC 
bromide to give a bromo-imidazolium salt (bottom).34  
Subsequently, our group demonstrated that the preparation of a Cu(II)-NHC 
bromide CQ with a neutral ligand is possible when the N-substituent has a 
coordinating pyridine group.41 This would help stabilise the Cu(II) centre (17 
electrons) and the bridging dimerisation of the complex does not occur. However, 
when excess CuBr2 is present, (μ-Br)2 bridging does occur with the excess 
CuBr2, forming CR (Scheme 1-21).84 The bridging leads to disproportionation 
(CS) and reductive elimination of a bromo-imidazolium ion CT. DFT calculations 
also support this observation, which occurs at room temperature. The bridged 
CR forms irreversibly, and disproportionation takes place with a low energy 
barrier (9.0 kcal mol-1). The low barrier is likely a result of the pyridine group 
helping stabilise the Cu(III) centre. The reductive elimination of CT is also facile, 
with a calculated energy barrier of 3.0 kcal mol-1. 
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Scheme 1-21: DFT calculations showing favourable reductive elimination of a bromo-
imidazolium ion.84 
1.5.3 Selectivity of reductive elimination 
The reductive elimination of C-imidazolium ions has been observed to be more 
prominent than the reductive elimination of halo-imidazolium ions when both 
carbon species and halides are present on the metal-NHC.28,104,120-122 The 
selectivity of such reactions on Cu were studied by Ariafard using DFT 
calculations.123 He showed that the selectivity is due to the stability of the Cu(I) 
by-product (CW), which governs both the kinetics and thermodynamics of the 
reaction. Hence, soft bases such as halides, CN
-
 and CF3
-
 ions are less likely to 
cleave as they form more stable Cu(I) salts than hard bases such as alkyls and 
aryls. The DFT calculations demonstrate that reductive elimination of bromo-
imidazolium ions (CV) are unfavourable when anionic hydrocarbon ligands are 
present (Scheme 1-22, Figure 1-10). 
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Scheme 1-22: Reductive elimination of bromo-imidazolium ion (CV) from Cu(III) 
(CU) when X is present. 
  
Figure 1-10: Correlation between kinetic and thermodynamic energies in the reductive 
elimination of CV in the presence of an X ligand (X = Cl, I, Br, CN, CF3, Ph, vinyl, Me 
and Bn). 
1.6  Stable copper(III) complexes  
In order to further demonstrate the oxidative addition / reductive elimination 
mechanism in Cu-catalysed cross-coupling reactions, attempts to synthesise 
Cu(III) species have been carried out. However, Cu(III) compounds are usually 
unstable and easily reduced to Cu(II) in aqueous solutions.117 In addition, the 
reduction potential of Cu(III) to Cu(II) is +1.57 V. Cu(III) complexes usually have 
a square planar geometry which is common for d8 electronic configurations. 
Square planar Cu(III) complexes are diamagnetic, whereas rare cases of 
octahedral Cu(III) complexes are paramagnetic.124,125 
Cu(III) may be stabilised through coordination with oxides and fluorides such as 
Cs3CuF6 and K3CuF6, which are paramagnetic octahedral complexes. KCuO2 
(CZ) and K7[Cu(IO6)2] (DA) are examples of diamagnetic square planar Cu(III) 
complexes (Figure 1-11). Hence, early reported stable Cu(III) complexes are 
square planar and contain anionic binding sites. Their chelating ligands have 
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anionic thiolate (DB), alkoxide and amide (DC) binding sites (Figure 1-12). These 
complexes showed ligand-dependent reduction potentials of Cu(III) to Cu(II), 
which decreases to a range of -1.0 to +0.1 V. Therefore, Cu(III) can be stabilised 
by strong electron donors. 
 
Figure 1-11: Examples of Cu(III) oxide anions124 
 
Figure 1-12: Examples of Cu(III) complexes bearing anionic-tethered ligands124 
Upon attempts to study intermediates in Cu catalysed reactions, the preparation 
of organo-Cu(III) complexes became an interesting challenge. Ribas used 
macrocyclic ligands that combine square planar binding sites and an anionic site 
to successfully isolate complex DD (Figure 1-13).126 
 
Figure 1-13: A macrocyclic Cu(III) complex126 
Several mechanisms for the Ullmann reaction have been proposed, including 
Cu(I)/Cu(II) single electron transfer and atom transfer, and Cu(I)/Cu(III) oxidative 
addition / reductive elimination.73,124,127 The most accepted is the latter, and with 
the demonstration of the macrocyclic aryl-Cu(III) complex DD, the mechanism is 
more convincing. A range of nucleophiles such as carboyxlic acids, amides, 
alcohols, thiols and halides have been shown to undergo a coupling reaction with 
the aryl ligand (Scheme 1-23).128-132 However, the clear evidences of such 
mechanism are limited to those ligand systems and cannot be used to imply that 
Cu-catalysed cross-coupling would universally undertake the same mechanism. 
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Scheme 1-23: Reductive elimination of aryl-Nu from the macrocyclic aryl-Cu(III) 
complex.128-132 
1.7 Project aims 
It has been shown in the literature that NHC ligands are able to enhance catalysis 
in some instances. However, NHC ligands may also become involved in 
non-innocent reactivity. The aim of this project was to prepare a range of 
imidazolium salts as NHC ligand precursors, and examine the resulting 
Cu(I)-NHC complexes as catalysts in an Ullmann-type etherification reaction. 
Past examples have shown that bidentate N,N-, N,O-, O,O- donor ligands73,133,134 
and pyridyl-tethered NHCs41 can enhance the catalytic activity of Cu complexes 
when compared to the ligand free system. Our aim was to extend this by varying 
the electronic and/or physical properties of NHCs, with both donor and non-donor 
N-substituents and altering the NHC backbones. As Cu complexes formed in situ 
were previously demonstrated to perform as efficiently as the preformed 
complexes, our focus was on in situ formed complexes for catalytic screening 
and evaluation. 
In addition to screening the catalytic competency of the different ligands, another 
aim was to examine the catalytic species and potential side-reactions that lead 
to catalyst deactivation. It became evident that reductive elimination of 
aryl-imidazolium was in operation, hence the synthesis of an aryl-imidazolium 
salt was desired for calibration to enable quantification of these reactions. 
Conditions that led to the aryl-imidazolium side-product were to be examined 
such as type of NHC ligand and equivalents of base, Cu complex and 
nucleophile. A further objective was to identify other possible side-reactions in 
these metal-catalysed cross-coupling reactions, with more knowledge in this 
area enabling the design of more efficient ligands for catalysis. 
It was anticipated that the side-reactions of Cu-NHCs through reductive 
elimination of imidazolium salts may be exploited for synthesis. This part of the 
project was to focus on the functionalisation of xanthine-derived compounds that 
are based on imidazole, and can form or react via a metal-NHC complex. 
 
 
22 
 
Examination of the kinetics of this reaction would aid in the understanding of the 
mechanism, so that it may be applied to more challenging syntheses such as the 
arylation of nucleic acid strands. 
As the mechanisms of both Cu-NHC catalysed reactions and deactivation 
reactions are thought to be proceed via higher oxidation state Cu, a further part 
of this project focuses on the stabilisation/isolation and examination of Cu-NHC 
complexes with higher oxidation states (+2 and +3). The ultimate goal would be 
to prepare the first example of a Cu(III)-NHC complex. 
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Chapter 2  
Effects of N-Heterocyclic Carbene Ligand N-Substituents on 
Copper-Catalysed Etherification 
2.1 Introduction 
Cross-coupling reactions have played a pivotal role in organic synthesis as they 
allow bond formation for complex molecules, which are widely used in the 
pharmaceutical industry.1-5 Different types of bond formation have been achieved 
with the application of various transition metals, including Pd,4-9 Au,10,11 Ag12-14 
and Cu.15 In the history of Cu catalysts, harsh reaction conditions such as high 
temperatures and stoichiometric loadings of Cu were required.16-21 However, the 
involvement of ligands has played a significant role in development, allowing for 
lower catalyst loadings and reaction temperatures, shorter reaction times and 
enabled application of milder bases.22-24 Some classes of ligands such as 
bidentate N-donors and O-donors have been studied for reaction mechanism 
and selectivity.25-29 However, knowledge on Cu-NHC cross-coupling catalysts is 
limited and there are only a few examples of the application of Cu-NHCs in 
cross-coupling.30-35 
Recently, our group has observed the noteworthy stability of Cu(I)-NHC and 
Cu(II)-NHC complexes with pyridine and alkene N-substituents.35 This showed 
the potential of these ligands for stabilising high oxidation state catalytic 
intermediates that occur during the proposed Cu(I)/Cu(II) or Cu(I)/Cu(III) 
pathways (Scheme 2-1). The energy barrier of an aryl-halide bond activation may 
be reduced and the catalyst decomposition, especially during the high oxidation 
state, is potentially suppressed. Lake screened a series of Cu(I)-NHC complexes 
in a challenging etherification reaction using an electron-rich aryl iodide.35 Such 
types of aryl iodide are unfavourable to oxidative addition and have given poor 
conversions to ether product when catalysed by [Cu(IMes)Cl] (15 %) or ligand-
free CuI (20 %). From these results it was noted that NHCs bearing pyridine and 
picolyl N-substituents did enhance the product yield compared to the ligand-free 
system, whereas a mesityl N-substituent hindered the reaction, presumably due 
to it being too bulky and its inability to chelate. 
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Scheme 2-1: Cu-catalysed cross-coupling reaction via atom transfer (CuI/CuII) and 
oxidative addition / reductive elimination (CuI/CuIII). 
This chapter will expand the scope of N-substituents, such as methyl, trityl, t-butyl 
and allyl groups, in combination with pyridyl and picolyl groups. The allyl 
N-substituent is a fascinating subject as it was utilised in Lake's work and was 
observed to be more catalytically active than a mesityl N-substituent. Although 
an intramolecular π-interaction between Cu and alkene was not observed in the 
solid-state structures of either the Cu(I) or Cu(II) complexes, the alkene group 
may interact with the Cu centre in the solution phase. This is especially possible 
during a catalytic cycle, in which the catalytic intermediate has a high oxidation 
state (Cu(II) or Cu(III)). Further possible NHC variations include changing the 
NHC ring structure or changing the backbone substituents, which will mainly alter 
the electronic properties of the NHC.  
2.2 Modification of the non-chelating N-substituents 
Willans demonstrated that an NHC bearing picolyl, allyl N-substituents led to 
higher catalytic activity in an etherification reaction than an NHC bearing pyridyl, 
allyl N-substituents.35 In this work, the picolyl-tethered NHCs were expanded 
further (Figure 2-1). To examine the effect of the alkene group, comparison 
between allyl (L1) and propyl (L2) groups was undertaken. Variation of the steric 
bulk of the N-substituent was carried out with methyl (L3), t-butyl (L4), chlorotrityl 
(L5) and mesityl (L6) groups. 
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Figure 2-1: Proposed NHC ligands (L1-L6). 
The preparation of the imidazolium precursors to L1 – L6 (i.e. HL1Br – HL6Br) 
requires a nucleophilic substitution of P1 – P6 with 2-(bromomethyl)pyridine. 
P1 – P6 were either commercially available or available in the group. HL2Br and 
HL4Br were prepared by other group members. HL1Br was prepared through 
reaction of P1 with the HBr salt of 2-bromomethylpyridine in MeCN at room 
temperature in the presence of K2CO3 (Scheme 2-2). After vigorous stirring for 
24 hours, the reaction mixture was filtered and the crude product recrystallised 
from MeCN / Et2O and DCM / Et2O to obtain a dark red oil as the final product. 
The same procedure was used for the preparation of HL6Br. 
 
Scheme 2-2: Preparation of HL1Br and HL6Br. 
Imidazolium precursor HL3Br was prepared using the same method as for HL1Br 
and HL6Br, but required a higher reaction temperature (75 °C) (Scheme 2-2). 
During the recrystallisation of HL3Br, if P3 is still present and the mixture 
contains H-bonding-source water, it became challenging to separate from the 
imidazolium. Hence, the reaction mixture was dried with Na2SO4 prior to 
recrystallisation.  
In the case of a novel trityl,picolyl imidazolium salt (HL5Br), clotrimazole (P5) 
was used as the precursor. Attempts were made using 1-tritylimidazole (P5ʹ) but 
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the trityl group was cleaved during the reaction and resulted in a mixture of trityl, 
picolyl imidazolium and bis(picolyl)imidazolium ions, which were observed in the 
HR mass spectrum (Scheme 2-3, bottom). The chloride atom in chlorotrityl 
makes the cation less stable than the trityl cation, and hence the cleavage of the 
chlorotrityl group is not as facile. To further prevent the dissociation of the 
chlorotrityl group, the reaction was carried out under anhydrous conditions with 
molecular sieves (4 Å) to remove the water by-product (Scheme 2-3).  
 
Scheme 2-3: Preparation of HL5Br and attempted preparation of HL5'Br. 
A number of analytical techniques have been used to confirm formation of the 
desired imidazolium products. Using HRMS, the formation of the imidazolium ion 
as [M – X]+ can be observed. 1H NMR spectroscopy reveals the H-imidazolium 
(HA) signal (singlet or triplet, depending on the strength of the coupling from the 
backbone protons), the chemical shift of which is more downfield (a range of 
δ 12 – 8 ppm) than other aromatic proton resonances (δ 7.6 – 6.5 ppm). This is 
because the positive charge in the proton's environment results in deshielding 
and a downfield shift. Additionally, the chemical shift of the H-imidazolium may 
be used to predict the electronic properties of the corresponding NHC ligand as 
the chemical shift represents the electron density in the region.  
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For example, HA of HL1Br is at δ 10.46 ppm (Figure 2-2). The HA proton signal 
is easily distinguished from the rest of the other aromatic protons, of which the 
most downfield is HB at δ 8.56 ppm. The HB proton signal shows a fascinating 
splitting pattern, appearing as a ddd with couplings of 3J = 5 Hz, 4J = 2 Hz and 
5J = 1 Hz. The aromatic 3J coupling is normally in the range of 6 – 9 Hz, but this 
rare coupling of 4 – 6 Hz is characteristic of the doublet coupling to the pyridine 
ring.36,37 Furthermore, it can be observed that the HA peaks of HL1Br, HL3Br, 
HL5Br and HL6Br are at different chemical shifts (δ 10.46, 10.26, 9.55 and 10.43 
ppm respectively). This may suggest that L5 will be the strongest electron donor 
as HL5Br has the least acidic proton. However, the assumption is not truly 
reliable as the chemical shift may also be affected by the aromaticity of the 
N-substituents. Still, the chemical shift of HA is one of the factors used in 
computational experiments to generate a ligand map of chemical space to study 
the ligand effects,38 and compare to the experimental results. 
 
Figure 2-2: 1H NMR spectra (300 MHz, CDCl3) of HL1Br, HL3Br, HL5Br and HL6Br 
(top to bottom). 
2.2.1 Ligand evaluation of catalytic activity 
To study ligand effects in a Cu-catalysed cross-coupling reaction, the ligands 
were screened in the etherification reaction of 4-iodoanisole with 
3,5-dimethylphenol (Scheme 2-4). Initially the reaction was attempted using 
10 mol % of catalyst and 2 equivalents of Cs2CO3 under nitrogen, but negligible 
conversion to ether was attained (0 – 21 %).  
The conditions were modified to 4 equivalents of Cs2CO3 and the reactions were 
conducted under argon (Scheme 2-4), which improved the conversion to 
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36 – 65 % and allowed significant distinction between ligands. The observation 
is consistent with Lake's work that increasing the base loading can improve the 
reaction yield. 
 
Scheme 2-4: Cu-catalysed etherification reaction for the screening of ligand effects. 
In situ generated ligands L1-L6 were screened in the etherification of 
4-iodoanisole with 3,5-dimethylphenol using 10 mol % of the ligand precursor, 
10 mol % of CuI and 4 equivalents of Cs2CO3 (Scheme 2-4b). There is a 
significant difference in the catalytic activities between the Cu catalysts of L1 and 
L2 (63 and 37 % conversion respectively, Table 2-1). L1 contains an allyl 
N-substituent whereas L2 contains an n-propyl N-substituent; this result may 
indicate that the allyl of L1 coordinates or interacts with the Cu centre during the 
catalytic cycle to stabilise higher oxidation state Cu intermediates and prevent 
catalyst decomposition. Scheme 2-5 shows the stabilisation effects of the allyl 
group with the speculation that the catalysis takes place via oxidative addition / 
reductive elimination pathway. 
Catalyst 
(10 mol %) 
R1 R2 
NHC ring 
based on 
% conversion 
CuI N/A N/A N/A 29 
CuI + HL1Br picolyl allyl imidazole 63 
CuI + HL2Br picolyl propyl imidazole 37 
CuI + HL3Br picolyl methyl imidazole 46 
CuI + HL4Br picolyl t-butyl imidazole 56 
CuI + HL5Br picolyl chlorotrityl imidazole 61 
CuI + HL6Br picolyl mesityl imidazole 25 
CuI + HL7Br 6-methylpicolyl methyl imidazole 46 
Table 2-1: Ligand screening in the Cu-catalysed etherification reaction of 4-iodoanisole 
with 3,5-dimethylphenol (conversion determined by GC using p-cymene as an internal 
standard). 
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Scheme 2-5: Potential Cu(III) intermediate stabilised by an allyl interaction and 
reductive elimination of cross-coupled product to regenerate the Cu(I)-NHC catalyst. 
Ligands L3-L6 have varying steric bulk in the order L3 < L6 < L4 < L5 which can 
be assumed based on the % Vbur of related ligands L3ʹ, L4ʹ and L6ʹ (Figure 2-3). 
These were calculated by Nolan and co-workers to have values of 25.4, 36.2 and 
32.7 respectively using a radius of 3.5 Å.39 Similarly, the catalytic trend was L6 
< L3 < L4 < L5 in the etherification reaction (25, 45, 56 and 61 % conversion to 
ether respectively). This suggests that the steric protection of NHC ligands is 
likely to promote the catalytic activity of the Cu complex as the steric bulk can 
inhibit catalyst decomposition. 
 
Figure 2-3: Structure of L3', L4' and L6'.39 
The mesityl group (L6) was observed to be deactivating and did not follow the 
steric trend. Unlike the t-butyl and methyl groups, the mesityl group can 
inductively withdraw electrons from the carbene ring due to the higher 
electronegativity of sp2-hybridised carbon than sp3-hybridised carbon.40,41 This 
makes L6 a weaker donor than L3. The electron poor L6 is evident by 1H NMR 
spectroscopy, which shows HA of HL6Br more downfield than HA of HL3Br 
(Figure 2-2). Hence, the steric effects alone cannot be used to determine the 
catalytic activity, with electronic properties of the NHC also requiring 
consideration. 
In conclusion, varying the second N-substituent in picolyl-substituted NHCs 
demonstrated that an allyl group promotes catalysis when compared to non-
coordinating alkyl substituents. The alkene group may play a significant role in 
Cu-NHC catalysis due to its π-donor ability. Furthermore, steric protection of the 
N-substituents i.e. t-butyl and chlorotrityl groups also helps promote the catalyst 
performance. However, the mesityl group is an exception to this rule. It is 
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proposed that the group makes the NHC a weaker donor and consequently 
lowers the catalytic activity.  
2.3 Modification of the chelating N-substituents 
A further ligand precursor (HL7Br) was prepared with a methyl N-substituent and 
a picolyl N-substituent bearing a methyl group on the C-6 position of the pyridine 
ring. The methyl group is electron donating so will increase the Lewis basicity of 
the pyridyl, and may also have a steric effect at the Cu centre. HL7Br was 
prepared using a similar method to the imidazolium precursors of L1-L6 (Scheme 
2-6). In this case a base was not required as the picolyl precursor is in a neutral 
form rather than the HX salt.  
 
Scheme 2-6: Preparation of HL7Br. 
The formation of the novel HL7Br was confirmed by 1H and 13C {1H} NMR 
spectroscopy and HRMS. The 1H NMR spectrum was compared to that of HL3Br 
(Figure 2-4) to determine if there is any difference in electronic properties. All of 
the imidazolium proton peaks of HL7Br (HA, HB and HC) are more upfield than 
HL3Br, suggesting that the NHC of L7 is a stronger donor than L3. In addition, 
the pyridine ring of HL7Br is more electron rich than that of HL3Br, as all of the 
pyridine proton peaks of HL7Br (HE, HF and HG) are more upfield than their 
respective peaks of HL3Br. 
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Figure 2-4: 1H NMR spectra (300 MHz, CDCl3) of HL7Br (top) and HL3Br (bottom). 
In situ generated ligands L3 and L7 were screened in the same Cu-catalysed 
etherification reaction as previously, and both gave conversions of 46 % (Table 
2-1). Willans previously studied substituents at the C4 position of the pyridyl 
N-substituent, and found that catalytic activity increased Me < H < OMe (Figure 
2-5).35 It is possible that L7 is electronically deactivating, with the stronger 
pyridine donor hindering nucleophilic substitution and/or reductive elimination of 
the cross-coupled product (as proposed in Willans's work). However, L7 also has 
added steric protection which may counter the electronic drawback, resulting in 
the same conversion as when L3 was used. 
 
Figure 2-5: Willans's modified pyridyl-NHC ligands and our modified picolyl-NHC 
ligands, and % etherification of their Cu-NHC complexes.35 
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The CH2 linker in picolyl provides flexibility into the ligand and allows for greater 
steric protection of the metal when compared to a pyridyl substituent. It also 
hinders the electron-withdrawing effect from the pyridine ring on the carbene 
centre. To examine the effect of this, pyridyl-substituted ligand precursors HL8Br 
and HL9Br were synthesised. P8 was prepared by a Cu-catalysed coupling 
reaction between 2-bromopyridine and imidazole in DMSO under basic 
conditions at 90 °C (Scheme 2-7). DL-proline was used as a ligand in the 
reaction, and Cs2CO3 was used as the base, which has been shown to promote 
Cu-catalysed reactions compared to K2CO3.42,43 P8 was allylated to form the 
desired imidazolium precursor HL8Br, which was obtained from recrystallisation 
using MeCN / Et2O. The product was characterised by 1H and 13C {1H} NMR 
spectroscopy and HRMS, and the data was consistent with the prior cases.44 
The imidazolium proton resonance appears at δ 11.98 ppm (300 MHz, CDCl3). 
 
Scheme 2-7: Preparation of P8 and HL8Br. 
HL9Br was prepared by another group member by heating P9 with 
2-bromopyridine without solvent at 160 °C, via a nucleophilic substitution on the 
SNAr-capable pyridine ring (Scheme 2-8).39,44,45  
 
Scheme 2-8: Preparation of HL9Br.44 
Attempts were made to prepare ligand precursors with an aminoethyl 
N-substituent, as this would contain an sp3 lone-pair which has a higher basicity 
than the sp2 lone-pair. Aminoethyl-bearing NHCs have been reported as suitable 
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ligands for Ag, Au and Pd catalysts for cross-coupling reactions.45-47 P1 and P6 
were each added to an HBr salt of 2-bromoethylamine in MeCN. However, the 
reaction using P1 resulted in a mixture of HL10Br, HL10*Br and HL10**Br, as 
observed in both NMR spectra and the HR mass spectrum (Scheme 2-9). The 
same was observed when using the L11 precursor. Unfortunately, HL10Br and 
HL11Br cannot be separated from other impurities by recrystallisation or column 
chromatography. 
 
Scheme 2-9: Attempted preparation of HL10Br and HL11Br. 
As the allyl substituent was found to enhance catalytic activity (likely due to the 
potential of an allyl group coordinating or interacting with the Cu centre), ligand 
precursors HL12Br and HL13Br (Figure 2-6) were introduced for screening, and 
were prepared by other group members. 
 
Figure 2-6: Structure of allyl-substituted NHC ligands. 
In situ generated ligands L8, L9, L12 and L13 were screened and evaluated for 
their catalytic activities in the same etherification reaction as previously. In the 
case of ligands bearing an allyl N-substituent, the catalytic activity increased 
when the second N-substituent was modified mesityl (L13) < pyridyl (L8) < allyl 
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(L12) < picolyl (L1) (Table 2-2). The opposite trend was observed in the case of 
ligands bearing a mesityl N-substituent, with the catalytic activity increasing with 
the second N-substituent being picolyl (L6) < pyridyl (L9) < allyl (L13).  
Catalyst 
(10 mol %) 
R1 R2 
NHC ring 
based on 
% conversion 
CuI N/A N/A N/A 29 
CuI + HL1Br picolyl allyl imidazole 63 
CuI + HL6Br picolyl mesityl imidazole 25 
CuI + HL8Br pyridyl allyl imidazole 53 
CuI + HL9Br pyridyl mesityl imidazole 41 
CuI + HL12Br allyl allyl imidazole 58 
CuI + HL13Br allyl mesityl imidazole 47 
Table 2-2: Ligand screening in the Cu-catalysed etherification reaction of 4-iodoanisole 
with 3,5-dimethylphenol (conversion determined by GC using p-cymene as an internal 
standard). 
L6 was demonstrated to be the least active ligand, performing worse than the 
ligand free system, which may be due to steric saturation around the metal with 
the bulky mesityl substituent combined with the picolyl group. Exchanging picolyl 
for pyridyl (L9) improved catalytic activity, despite the fact that the carbene will 
be a weaker donor when compared to L6. This strongly suggests that steric 
factors have a stronger influence than electronics in this system, with the less 
bulky (non-coordinating) allyl group (L13) improving catalytic activity further. 
Ligands bearing an allyl N-substituent improve catalytic activity compared to the 
mesityl N-substituent. This may be due to the potential coordination behaviour of 
the allyl group, inducing stabilisation of Cu intermediates during the catalytic 
cycle. In addition, the electron withdrawal capability of the mesityl substituent will 
make the NHC a weaker donor, inhibiting the oxidative addition step and 
destabilising intermediates. While, the strong coordination ability and flexibility of 
the picolyl will aid in the stabilisation of catalytic intermediates. Furthermore, the 
NHC will be a stronger donor when compared to L8 (with a pyridyl group), which 
will further stabilise the intermediates and promote oxidation of the Cu(I). 
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2.4 Modification of the NHC Backbone Substituents 
Whilst the N-substituents of NHCs tend to have the greatest influence on steric 
effects of the ligand, modification of the backbone can provide diverse electronic 
properties.48 The benzimidazole-based NHC (L15) is a weaker σ-donor than the 
imidazole-based NHC (L3) (Figure 2-7). Similarly, changing the backbone 
substituents from protons to inductively electron-withdrawing chlorine atoms 
(L14) affects the NHC electronic properties.  
 
Figure 2-7: Proposed backbone-modified NHCs. 
The novel HL14X and HL15X imidazolium salts can be prepared in a similar way 
to previous imidazolium salts, with functionalisation of 4,5-dichloroimidazole and 
benzimidazole with picolyl and methyl groups. It has previously been found that 
addition of the picolyl group before the methyl group reduces side-product 
formation. Therefore, 1-picolyl-4,5-dichloroimidazole (P14*) was synthesised by 
nucleophilic substitution of 4,5-dichloroimidazole with picolyl bromide.HBr in the 
presence of base (Scheme 2-10a). However, the methylation of P14* led to 
formation of both HL14I and of HL14*I (Scheme 2-10b), where the major product 
was the undesired HL14*I due to the imidazolium ring containing electron-
withdrawing chlorine atoms. This lowers the nucleophilicity of the N-imidazole, 
hence the formation of HL14I is less favourable compared to HL14*I. Instead, 
HL14Br was prepared from reaction of 1-methyl-4,5-dichloroimidazole (P14) with 
picolylbromide.HBr (Scheme 2-10c,d). 
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Scheme 2-10: Synthetic routes to imidazolium ligand precursors of L14. 
The synthetic route via 1-methylbenzimidazole (P15) was chosen for the 
preparation of benzimidazolium salt HL15Br, to avoid methylation at the pyridine 
ring (Scheme 2-11). Base is required in the reaction to removed HBr from the 
picolyl in the imidazolium product. This was added to the reaction mixture after 
consumption of picolylbromide to prevent the electrophilic bromoalkane attacking 
the pyridine ring, which would lead to side-products that are hard to separate.  
 
Scheme 2-11: Preparation of P15 and HL15Br. 
Both HL14Br and HL15Br were fully characterised by 1H and 13C {1H} NMR 
spectroscopy and HRMS. The formation of the imidazolium salt was indicated by 
the imidazolium proton resonances (11.02 and 11.47 ppm respectively). 
Theoretically both chlorine atoms and the benzimidazole make the 
H-imidazolium less basic and a weaker NHC donor. However, the resonances 
cannot be used to directly compare the electron density between L14 and L15 
because the chemical shift is heavily affected by the differing aromaticity of the 
benzimidazolium. The higher aromaticity of benzimidazole can cause the 
resonance to shift downfield due to the higher magnetic field generated by the 
π-system, in addition to the σ-electron density of the H-2 imidazolium. 
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In situ formed Cu(I) complexes of L14 and L15 were evaluated in the same 
etherification reaction as previously (Scheme 2-4), and compared to the ligand-
free system and to ligand L3 (Figure 2-7). Among these 3 ligands, L15 gave the 
highest conversion to the ether product (62 %), with L3 and L14 being similar to 
each other (46% and 47% respectively, Table 2-3). The steric and chelating 
abilities of all three ligands should be similar, hence the difference in conversion 
is likely to be an electronic effect. The benzimidazole-derived ligand is a weaker 
donor which will aid in reductive elimination of the ether. However, if this were 
the main governing factor then L14 should perform more efficiently than L15. 
This indicates that a fine balance of electronic properties is required; a weaker 
donor aids the nucleophilic substitution and reductive elimination steps, though 
if it is too weak the Cu intermediates may not be sufficiently stabilised and 
oxidative addition may be supressed. 
Catalyst 
(10 mol %) 
R1 R2 NHC ring based on % conversion 
CuI N/A N/A N/A 29 
CuI + HL3Br picolyl methyl imidazole 46 
CuI + HL14Br picolyl methyl 4,5-dichloroimidazole 47 
CuI + HL15Br picolyl methyl benzimidazole 62 
Table 2-3: Ligand screening in the Cu-catalysed etherification reaction of 4-iodoanisole 
with 3,5-dimethylphenol (conversion determined by GC using p-cymene as an internal 
standard). 
2.5 Allyl-N-substituted NHC ligands 
Further studies on picolyl/pyridyl derivatives were carried out in the group by 
Joseph Sheppard (MChem research project).49 The same etherification reaction 
was screened under the same conditions but for 22 hours. Interestingly, in his 
screen, among the allyl-N-substituted NHC ligands, when the second 
N-substituent was a methyl group (L16), the ligand performed as effectively as 
L1 (picolyl), L8 (pyridyl) and L17 (6-methylpyridyl) in the catalysis (39 – 42 % 
conversion) (Figure 2-8).  
 
 
41 
 
 
Figure 2-8: Structure of L16 and L17. 
In this work, we have expanded on this further, with the second N-substituent 
being replaced by sterically bulky groups: trityl and chlorotrityl (Figure 2-9) were 
chosen. 
 
Figure 2-9: Proposed trityl-bearing NHCs. 
The preparation of HL19Cl was carried out by another group member. The ligand 
precursor, HL18Cl, was prepared by reaction of 2-chlorotritylchloride with 
1-allylimidazole in MeCN at 80 °C (Scheme 2-12). The imidazolium salt was 
purified by recrystallisation and fully characterised using 1H and 13C {1H} NMR 
spectroscopy and HRMS. The imidazolium protons of HL18Cl and HL19Cl 
appear at δ 9.23 and 9.62 ppm (300 MHz, CDCl3) respectively in the 1H NMR 
spectrum. 
 
Scheme 2-12: Preparation of HL18Cl. 
The allyl-bearing NHC ligands L1, L8, L17, L18 and L19 were compared in the 
Cu-NHC catalysed etherification reaction. All NHC ligands with an N-donor group 
performed better than the NHCs without this group (Table 2-4). This illustrates 
that the N-donor group is more significant than a sterically bulky group in 
stabilising Cu intermediates during catalysis. Coordination of the picolyl group 
forces the coordination of aryl and nucleophile reagents to be adjacent to each 
other so that they can be coupled easily. Contrarily, a bulky group may protect 
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the Cu centre but does not necessarily force the close proximity of the substrates 
as the group is not coordinated. 
Catalyst 
(10 mol %) 
R1 R2 NHC ring 
based on 
% conversion 
CuI N/A N/A N/A 23 
CuI + HL1Br picolyl allyl imidazole 36 
CuI + HL8Br pyridyl allyl imidazole 31 
CuI + HL17Br 6-methylpyridyl allyl imidazole 36 
CuI + HL18Cl chlorotrityl allyl imidazole 29 
CuI + HL19Cl trityl allyl imidazole 27 
Table 2-4: Ligand screening in the Cu-catalysed etherification reaction of 4-iodoanisole 
with 3,5-dimethylphenol (conversion determined by GC using p-cymene as an internal 
standard). 
It should be noted that in this catalytic screening and subsequent screens (in 
sections 2.5 and 2.6), the catalytic performance of the ligand-free system and L1 
and L8 dropped significantly. This demonstrates the highly sensitive nature of 
Cu-catalysed reactions, with challenges in reproducibility being common in the 
field.50,51 Cu-catalysed reactions are sensitive towards various conditions. 
Nguyen previously showed that different suppliers of the base Cs2CO3 have a 
large impact on the Cu(I)-catalysed Ullmann-Goldberg C-N coupling reaction.50 
Comparison among milled base supplied by Chemetall, Sigma-Aldrich and Acros 
Organic, it was observed that the base supplied by Chemetall, which has a 
smaller particle size and narrower distribution than the base from Sigma-Aldrich, 
had an induction period and slowed the catalysis. The Acros Organic base has 
a larger and more evenly distributed particle size and non-porous morphology. It 
resulted in the fastest reaction.  
In our case, Cs2CO3 bottles were ordered from just Sigma-Aldrich but with 
different time of exposure to air, which might the moisture to be trapped in the 
base and change its morphology or particle size. Contrarily, our MChem student 
found that storing bases (Cs2CO3, K2CO3 and K3PO4) in an oven cause the % 
conversion of our model Cu-catalysed etherification to drop significantly (Table 
2-5).49 Other factors might be involved in the greatly sensitive reproducibility, 
such as the rate of stirring and the time taken for the reaction mixture to reach 
the desired temperature (90 °C). However, trend across the ligands in the parallel 
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screen can be compared, as they were observed to have the same trend across 
the screening e.g. L1 is better than L3 and L8. 
base 
% conversion 
normal stored in an oven 
Cs2CO3 39 3 
K2CO3 2 1 
K3PO4 63 17 
Table 2-5: Base screening in the Cu-catalysed etherification reaction of 4-iodoanisole 
with 3,5-dimethylphenol using L8 as a supporting ligand (conversion determined by 
GC using p-cymene as an internal standard).49 
2.6 Tridentate ligands 
NHC ligands with two strongly coordinating N-substituents can coordinate to a 
metal in a tridentate fashion, with this type of coordination being observed in Pd 
complexes that are active in Heck coupling of 4-bromoacetophenone with n-butyl 
acrylate52 and in Cu-(pincer NHC) complexes that are active in Sonogashira-type 
reactions of aryl iodide and aryl acetylene.53 The tridentate ligand can prevent 
reductive elimination of methyl-imidazolium from the Pd centre, which is facile at 
room temperature,54 and can be considered as a catalyst deactivation pathway. 
Tridentate ligand precursors to L20 and L21 were prepared, which may 
coordinate to Cu in a tridentate manner (Figure 2-10).  
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Figure 2-10: Bis(picolyl) and pyridyl-picolyl NHC ligands, and their proposed Cu-
NHC complexes. 
HL20Br is a symmetric imidazolium so can be prepared by heating imidazole 
with a slight excess of 2-(bromomethyl)pyridine.HBr under reflux in the presence 
of NaHCO3 in MeOH (Scheme 2-13). 
 
Scheme 2-13: Preparation of HL20Br. 
HL21Br is a novel compound and was prepared in 2 steps (Scheme 2-14), via 
an Ullmann-type coupling reaction to form P21, followed by picolylation in MeCN 
in the presence of a base to give HL21Br. Bidentate ligand HL17Br was also 
prepared for comparison in catalysis, through allylation of P17. The 1H NMR 
spectrum of HL17Br showed the imidazolium proton signal at δ 11.89 ppm, which 
is the same as that of HL21Br, indicating that the NHCs will have similar donor 
strengths. 
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Scheme 2-14: Preparation of P27, HL27Br and HL17Br. 
Ligands L1, L17, L20 and L21 were formed in situ and examined in the same 
Cu-catalysed etherification reaction as previously (Scheme 2-4, Table 2-6). 
Surprisingly, it was observed that the tridentate ligands L20 and L21 led to lower 
conversions (30% and 9% respectively) than the allyl-bearing NHCs L1 (36 %), 
L8 (31 %) and L17 (36%). This suggests that an allyl group enhances catalysis 
compared to a picolyl group, when it is on the same NHC as another N-donor 
group. The weak π-donor allows equilibrium coordination so that more suitable 
sites are available for the cross-coupling reaction. L21 appears to shut down 
catalysis which may be due to saturated coordination and sterics. 
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Catalyst 
(10 mol %) 
R1 R2 
NHC ring 
based on 
% conversion 
CuI N/A N/A N/A 23 
CuI + HL1Br picolyl allyl imidazole 36 
CuI + HL17Br 6-methylpyridyl allyl imidazole 36 
CuI + HL20Br picolyl picolyl imidazole 30 
CuI + HL21Br 6-methylpyridyl picolyl imidazole 9 
Table 2-6: Ligand screening in the Cu-catalysed etherification reaction of 4-iodoanisole 
with 3,5-dimethylphenol (conversion determined by GC using p-cymene as an internal 
standard). 
Further ligand precursors were prepared which contain a benzimidazole 
backbone and a combination of allyl and picolyl substituents, as these are the 
leading N-substituents (Figure 2-11).  
 
Figure 2-11: Proposed benzimidazole-based NHC ligands 
Ligand precursor HL22Br was prepared by another group member. A novel 
compound, HL23Br was prepared through nucleophilic substitution of 
benzimidazole with picolyl bromide, followed by allylation (Scheme 2-15). A 
novel compound, HL24Br was synthesised using the same method as for 
HL20Br. 
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Scheme 2-15: Preparation of P23, HL23Br and HL24Br. 
The ligands were screened in the same etherification reaction as previously and 
compared to the imidazole-based ligands (Table 2-7). Ligand L23, with a 
combination of allyl and picolyl substituents, led to the highest conversion. This 
is in keeping with the previous observations with L1 and L23, in which a mixed 
allyl/picolyl NHC is more active ligand in catalysis. Comparing NHCs of the same 
N-substituents shows that benzimidazole-based NHCs L23 and L24 exhibit 
higher catalytic activity than the imidazole derivatives L1 and L20. This 
observation is consistent with previous results, which found the benzimidazole 
ligand L15 to be more catalytically active than the imidazole derivative L3. This 
may be due to the benzimidazole-based ligands being weaker donors, leading 
to faster reductive elimination of the cross-coupled product. 
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Catalyst 
(10 mol %) 
R1 R2 NHC ring 
based on 
% conversion 
CuI N/A N/A N/A 23 
CuI + HL22Br allyl allyl benzimidazole 27 
CuI + HL1Br picolyl allyl imidazole 36 
CuI + HL23Br picolyl allyl benzimidazole 52 
CuI + HL20Br picolyl picolyl imidazole 30 
CuI + HL24Br picolyl picolyl benzimidazole 43 
Table 2-7: Ligand screening in the Cu-catalysed etherification reaction of 4-iodoanisole 
with 3,5-dimethylphenol (conversion determined by GC using p-cymene as an internal 
standard). 
To summarise, a benzimidazole backbone on the NHC benefits the catalytic 
activity of Cu-NHCs in the etherification reaction studied, indicating that a weaker 
donor ligand is more advantageous. The N-substituents that enhance catalytic 
activity are picolyl and allyl groups, especially when both of them are cooperated 
on the same NHC ligand. The picolyl group is a strong donor and is likely to 
promote nucleophilic substitution and oxidative addition of an aryl halide, while 
the weak π-donor allyl group may not provide an active site at the metal centre 
but stabilise Cu intermediates when required. 
2.7 Comparison with Other Bidentate Ligands 
There are many literature examples of N-donor and O-donor ligands that were 
found effective in enhancing Ullmann reactions.28,29 To compare these to the 
NHC ligands, N-donor ligands 2,2ʹ-bipyridyl (L25), 1,10-phenanthroline (L26) 
and N,N,Nʹ,Nʹ-tetramethyl ethylenediamine (L27) were examined in the 
etherification reaction studied in this chapter. The electron lone pairs of L25 and 
L26 are in sp2 orbitals, while the nitrogen atoms of L27 have sp3 configurations. 
O-donor ligands that were examined are dimethoxyethylene (L28), glycolate 
(L29), ketocyclohexanone (L30) and acetyl acetonate (L31) (Figure 2-12). 
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Figure 2-12: Ligands with O,Oʹ-donors or N,Nʹ-donors 
In general, the trend in ligand performance follows acac-type (L30 and L31) > 
N,Nʹ-donors (L25, L26 and L27) > neutral O,Oʹ-donor (L28) > glycolate (L29) 
(Table 2-8). Acac-type ligands have been demonstrated to be selective towards 
C-N coupling over C-O coupling, as the electron rich ligands disfavour the 
coordination of the O-nucleophile.28,29 However, the ligands did show reasonable 
activity in the etherification reaction, as the negative charge is likely to stabilise 
high oxidation-state intermediates enhancing catalytic activity more than neutral 
N,Nʹ-donors. L31 showed higher activity than L30, likely due to the steric effect 
of the isopropyl group, which probably protects the Cu centre from 
decomposition.  
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Catalyst (10 mol %) % conversion 
CuI 29 
CuI + HL1Br 63 
CuI + L25 46 
CuI + L26 49 
CuI + L27 50 
CuI + L28 35 
CuI + L29 24 
CuI + L30 55 
CuI + L31 61 
Table 2-8: Ligand screening in the Cu-catalysed etherification reaction of 4-iodoanisole 
with 3,5-dimethylphenol (conversion determined by GC using p-cymene as an internal 
standard). 
N,Nʹ-donor ligands (L25, L26 and L27) were found to improve catalytic activity 
over dme (L28) ligand. When both N and O atoms are neutral, N can denote 
more electron density than O because of lower electronegativity. The stronger 
donor helps promote the nucleophilic substitution step and stabilise the Cu 
intermediate. Moreover, L27 gave the highest conversion among its group 
because its lone pair lies in an sp3 orbital, which has higher energy and is more 
electron donating than an sp2 orbital. Glycolate (L29) was the least active ligand 
despite bearing a negative charge, which should benefit the stabilisation of 
higher oxidation state Cu intermediates. However, unlike the acac-type ligands, 
glycolate contains 2 nucleophilic sites: carboxylate and hydroxyl groups, both of 
which may compete with the phenol. If both sites react with the aryl iodide, they 
can consume up to 20% of the aryl iodide. The side-reaction is also deactivating 
as it transforms the negatively charged ligand to a neutral O-donor ligand (aryl 
glycolate), which is less electron donating and hence less catalytically active. 
To summarise, the acac-type diketonic ligands and N,Nʹ-donors were 
demonstrated to enhance Cu-catalysed etherification and hence their Cu 
complexes have been used in cross-coupling reactions.28,29 In this work, electron 
rich ligands generally lead to higher catalytic activity with the exception of L29, 
which can compete as a nucleophile. In addition, the amine sp3 donor may 
enhance the catalytic activity compared to the pyridine sp2 donor. Hence, it is 
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possible that an NHC with this substituent (i.e. L10 or a derivative) would perform 
better than their pyridyl/picolyl derivatives. 
2.8 Conclusions 
A range of NHC ligands, N,Nʹ-donors and O,Oʹ-donors have been evaluated for 
their activity in the Cu-catalysed Ullmann-type etherification of 4-iodoanisole with 
3,5-dimethylphenol. The ligands that were found to show good activity are L1, 
L5, L23, L27 and L31. Overall, increased steric bulk was observed to enhance 
the catalytic activity in the case of bidentate ligands L5 and L31. Bidentate 
ligands are more active than tridentate and non-chelating ligands as they afford 
the non-strained close proximity of the aryl and nucleophile. Electron-rich ligands 
favour nucleophilic substitution and are likely to stabilise the Cu(III) 
intermediates. Contrarily, electron poor NHCs can be beneficial for the 
coordination of the nucleophile and reductive elimination of the cross-coupled 
product. Hence, L23, which contains both picolyl and allyl N-substituents on a 
benzimidazole-based NHC, was found to have the greatest catalytic activity. 
2.9 Future work 
The N,Nʹ-donors are selective for C-O bond formation, whereas acac-type 
ligands are selective for C-N bond formation.28,29,55 From the selectivity, it was 
proposed that O-nucleophilic substitution occurs prior to nucleophile 
deprotonation, followed by oxidative addition in the case of N,Nʹ-donors. In the 
case of acac-type ligands, the catalytic cycle steps are proposed to be halide 
dissociation, oxidative addition, coordination of N-nucleophile, deprotonation of 
nucleophile and reductive elimination. Since, NHC ligands are comparable to 
N,Nʹ-donors and acac-type ligands, screening Cu-NHC complexes with amino-
alcohol groups such as aminoethanol in C-O and C-N bond formation would 
allow us to predict the mechanism of the catalytic cycle by comparing the 
selectivity.  
Furthermore, it is desirable to numerically correlate the performance and 
properties of NHC ligands for comparison. Comparison of electronic, geometric 
and steric properties of ligands can be challenging when more than one 
component has been modified, especially comparing across different types of 
ligands (e.g. NHCs, N,N- and N,O-donors). A computational ligand map can be 
used to numerically distinguish these differences,38,56-58 which is a multi-
dimensional plot of principle component (PC) scores. The role of PC analysis is 
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to include as many differences in the data as possible but in a few numbers of 
dimensions (or PCs). As a result, each PC score is generated by different 
loadings or coefficients of each descriptor. Descriptors are physical properties 
such as energies of HOMO and LUMO of the free ligand, proton affinity, metal-
ligand bond lengths, etc. Due to different loadings of descriptors, each PC can 
be dominated by certain properties such as steric effects, metal-ligand 
interactions (σ and π), or electronic and geometric differences of ligands. 
Utilising the ligand map may help us reveal any correlations between ligand 
properties and catalytic activities and enable improved ligand design and 
predictability through a more knowledge-based approach. A ligand map has 
been calculated in collaboration with Dr Natalie Fey (Bristol). Currently, there are 
not enough data points to establish statistically significant correlation between 
the ligand map and the catalytic activity (Figure 2-13).  
 
Figure 2-13: Ligand map of NHC ligands with % conversion in the Cu-catalysed 
etherification reaction. 
2.10 Experimental 
2.10.1 General considerations 
General considerations are applied to experimental throughout this thesis. 
Unless otherwise stated, manipulations were performed using standard Schlenk 
line and Glovebox techniques. N2 was passed through a twin-column drying 
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apparatus containing molecular sieves (4Å) and phosphorus pentoxide. 
Anhydrous solvents were prepared by passing the solvent over activated 
alumina to remove water, via the Dow-Grubbs solvent system. Anhydrous 
CD3CN, CDCl3 and d6-DMSO were dried over CaH2, cannula filtered or distilled, 
and then freeze-pump-thaw degassed or bubbled by Ar prior to use. All other 
chemicals were obtained from commercial sources and used as received. Cu foil 
(99.9 % purity) was used as electrode surface directly without further purification 
(purchased from Goodfellow Cambridge Ltd). 
1H and 13C {1H NMR spectra were recorded by automated procedures on either 
a Bruker Avance (500/126 MHz) or DPX (300/75 MHz) NMR spectrometer, using 
the residual solvent as an internal standard. The values of chemical shift are 
reported in parts per million (ppm) with the multiplicities of the spectra assigned 
as follows: singlet (s), doublet (d), triplet (t), quartet (q), septet (sept) and multiplet 
(m), values for coupling constants (J) are assigned in Hz.  
High-resolution electrospray mass spectra (ESI-MS) were measured on an 
open-access Bruker Daltonics (micro TOF) instrument operating in the 
electrospray mode. Samples were injected directly from feed solutions and 
acquired over the m/z range 50 – 4000. All spectra were recorded using an 
MeCN / water mix as the eluent and a sodium formate solution as a calibrant. 
LC-MS analyses were conducted on a Thermo Scientific Ultimate 3000 using 
UHPLC+ technology. All experiments were run through a Kinetix C-18 
50×2.1 mm LC-Column, 2.6 μm particle size, using a 5-95 % gradient 
(MeCN:water, 0.1 % formic acid) over 1.7 min. Samples were ionised by 
electrospray. 
Samples for microanalysis were dried under vacuum prior to analysis and the 
elemental composition determined by Ms. Tanya Marinko-Covell of the 
University of Leeds or by Mr Stephen Boyer at London Metropolitan University.  
Fourier-transform IR spectra were recorded as solid phase or in MeCN or DMF 
phase on a Perkin-Elmer Spectrum One spectrophotometer. Reactions were 
monitored in situ using a Mettler Toledo ReactIR ic10 with K6 conduit SiComp 
(silicon) probe and MCT detector. 
Thin-layer chromatography (TLC) was carried out using Merck S554 
aluminum-backed silica plates (silica gel 60 F254), and spots were visualised by 
UV light (at 254 nm). Flash and fractional column chromatography was 
performed using Merck 60 silica gel (particle size 40 – 63 μm) and a solvent 
system as reported in the text. 
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Electrochemical measurements were conducted using an Autolab PGSTAT204 
voltammetric analyser under an Ar atmosphere, solvated in pre-dried MeCN 
containing 0.10 M [n-Bu4N](PF6) as a supporting electrolyte. Voltammetric 
experiments utilised a Pt disk working electrode, a Pt rod auxiliary electrode and 
a Ag/AgCl reference electrode. All potentials quoted are referenced to an internal 
ferrocene/ferrocenium standard. 
Single crystal X-ray diffraction data were collected on an Agilent SuperNova 
diffractometer fitted with an Atlas CCd detector with Mo Kα radiation 
(λ = 0.7107 Å) or Cu Kα radiation (λ = 1.5418 Å). Crystals were mounted under 
oil on nylon fibres. Crystals were held at 120 K using an Oxford Cryosystems low 
temperature device during unit cell determination and data collection. Data sets 
were corrected for absorption using a multiscan method, and the structures were 
solved by direct methods using SHELXS-97 or SHELXT and refined by 
full-matrix least squares on F2 using ShelXL-97, interfaced through the program 
Olex2. Molecular graphics for all structures were generated using POV-RAY in 
the X-Seed program. 
GC analyses were performed using a Bruker 430-GC equipped with a CP-8400 
autosampler and a BR-5 column (30 m × 0.25 mm (ID) × 0.25 μm film thickness) 
with carrier gas flow rate of 2.0 mL min-1 and a temperature ramp from 50 → 310 
°C at 20 °C min-1. The injection volume was 1.0 μL with a split ratio of 10. The 
response factors for the internal standard (p-cymene), substrate and authentic 
product were calculated using an appropriate calibration for this GC, method and 
column. 
2.10.2 Preparation of imidazoles 
i) Preparation of P5' 
Imidazole (1.47 g, 21.52 mmol) was added to a three-necked 
round-bottomed flask. Trityl chloride (2.00 g, 7.17 mmol) was 
added to a Schlenk flask. DMF (18 mL) was added to both 
flasks via syringe and stirred until full dissolution. The trityl 
chloride solution was transferred to a dropping funnel attached to the three-
necked flask via syringe and added dropwise to the reaction vessel, and the 
resulting solution stirred for 24 hours. The solution turned cloudy after 2-3 hours 
of mixing. The reaction mixture was partitioned between water (100 mL) and 
chloroform (100 mL), and the aqueous layer was extracted with CHCl3 (3 × 100 
mL). The combined organic phase (including first partition) were washed with 
water (100 + 5 × 50 mL), dried over Na2CO3, and the solvent removed in vacuo. 
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The extraction and washing steps were repeated to give a white solid. The crude 
product was dissolved in hot MeCN, and the solvent was allowed to slowly 
evaporate until a solid precipitated. The mixture was cooled in an ice bath to yield 
more white precipitate, which was collected by filtration and was washed with 
cold MeCN. Yield: 1.23 g, 3.96 mmol, 55 %. 
1H NMR (300 MHz, CDCl3) δ (ppm) 7.48 (t, J = 1.4 Hz, 1H, imH-2), 7.38 – 7.33 
(m, 9H, Trt), 7.20 – 7.13 (m, 6H, Trt), 7.09 (t, J = 1.4 Hz, 1H, imH), 6.85 (t, J = 
1.4 Hz, 1H, imH). 13C {1H} NMR (75 MHz, CDCl3) δ (ppm) 142.5 (C), 129.8 (CH), 
128.3 (CH), 128.0 (CH), 127.9 (CH), 121.8 (CH), 75.2 (C). HRMS (ESI+): m/z 
311.1538 [M + H]+, calculated [M + H]+ 311.1543. 
Consistent with data previously reported.35 
ii) Preparation of P8 
Imidazole (3.93 g, 57.7 mmol), Cs2CO3 (10.87 g, 78.7 mmol), 
CuI (0.50 g, 2.6 mmol), and DL-proline (0.45 g, 3.9 mmol) were 
added to a Schlenk flask and placed under Ar. 2-Bromo-
pyridine (5.0 mL, 52.4 mmol) and anhydrous DMSO (10 mL) were added to the 
flask, and the mixture was stirred at 100 ºC for 22 hours. After cooling to room 
temperature, DCM (100 mL) was added and the suspension was filtered through 
Celite. The filtrate was washed with water (100 mL) and the aqueous layer was 
extracted with DCM (3 × 100mL). The combined organic phase was reduced in 
vacuo to give a green liquid, which was dissolved in DCM (100 mL) and washed 
with water (3 × 100 mL) and the aqueous layers were combined and extracted 
with CHCl3 (3 × 100 mL). The organic layers were combined, washed with water 
(6 × 100 mL), and the solvent removed in vacuo. The green liquid was dissolved 
in DCM (100 mL) and washed with saturated EDTA solution (3 × 100 mL), water 
(3 × 100 mL) and brine (100 mL), dried over Na2SO4, and the solvent was 
removed in vacuo to give a yellow oil. The crude product was purified by flash 
column chromatography (silica gel), eluting with EtOAc / petroleum ether (50: 50) 
 EtOAc / petroleum ether / MeOH (45: 45: 10). The pure product was obtained 
as an orange oil. Yield: 4.25 g, 29.3 mmol, 56 %. 
1H NMR (300 MHz, CDCl3) δ (ppm) 8.47 (ddd, J = 4.9, 1.9, 0.8 Hz, 1H, pyH-6), 
8.33 (t, J = 1.4 Hz, 1H, imH), 7.81 (ddd, J = 8.2, 7.5, 1.9 Hz, 1H, pyH-4), 7.63 (t, 
J = 1.4 Hz, 1H, imH), 7.35 (dt, J = 8.2, 0.8 Hz, 1H, pyH-3), 7.23 (ddd, J = 7.5, 
4.9, 0.9 Hz, 1H, pyH-5), 7.18 (t, J = 1.4 Hz, 1H, imH). 13C {1H} NMR (75 MHz, 
CDCl3) δ (ppm) 149.3 (CH), 149.2 (C), 139.1 (CH), 135.1 (CH), 130.7 (CH), 
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122.2 (CH), 116.3 (CH), 112.5 (CH). HRMS (ESI+): m/z 146.0744 [M + H]+, 
calculated [M + H]+ 146.0713. 
Consisted with data previously reported.44,52  
iii) Preparation of P14* 
4,5-Dichloroimidazole (0.50 g, 3.65 mmol), 
2-(bromomethyl)pyridine.HBr (0.92 g, 3.65 mmol) and KOH 
(0.82 g, 14.6 mmol) were placed in a round-bottomed flask and 
THF (20 mL) was added. The mixture was heated to 60 ºC for 
24 hours under N2 and hydrous condittons then allowed to cool 
to room temperature and the solvent removed in vacuo. The 
crude mixture was partitioned between DCM (50 mL) and water (50 mL) and the 
aqueous layer was extracted with DCM (2 × 50 mL). The organic layers were 
combined, dried over Na2SO4 and the solvent removed in vacuo. The dark oil 
was dissolved in Et2O (50 mL), filtered, and the filtrate was reduced in vacuo to 
obtain an orange oil. Yield: 0.23 g, 1.00 mmol, 28%. 
1H NMR (300 MHz, CDCl3) δ (ppm) 8.55 (ddd, J = 4.8, 1.7, 0.8 Hz, 1H, pyH-6), 
7.66 (td, J = 7.7, 1.7 Hz, 1H, pyH-4), 7.51 (s, 1H, imH), 7.23 (ddd, J = 7.7, 4.8, 
0.8 Hz, 1H, pyH-5), 7.02 (dt, J = 7.7, 0.8 Hz, 1H, pyH), 5.17 (s, 2H, NCH2-py). 
13C {1H} (75 MHz, CDCl3) δ (ppm) 154.1, 149.9, 137.5, 135.1, 126.4, 123.4, 
121.5, 113.6, 51.1. HRMS (ESI+): m/z 228.0107 [M + H]+, calculated [M + H]+ 
228.0090. 
iv) Preparation of P14 
4,5-Dichloroimidazole (0.30 g, 2.19 mmol) was dissolved in MeCN 
(15 mL). KOH (0.54 g, 9.64 mmol) was added, and the mixture was 
stirred at room temperature for 2 hours under N2 and hydrous 
conditions. The reaction mixture was filtered and iodomethane 
(0.136 mL, 2.19 mmol) was added to the light brown filtrate. The reaction mixture 
was stirred for 24 hours. The white precipitate was filtered off, and the solvent 
was removed from the filtrate in vacuo. The crude oil was dissolved in DCM (50 
mL) and washed with water (3 × 50 mL). The aqueous layers were combined 
and back-extracted with DCM (3 × 50 mL). All organic layers were combined, 
dried over Na2SO4 and the solvent removed in vacuo. The product was obtained 
as a yellow solid. Yield: 0.22 g, 1.46 mmol, 67%. 
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1H NMR (300 MHz, CDCl3) δ (ppm) 7.34 (s, 1H, imH), 3.59 (s, 3H, NCH3). 13C 
{1H} NMR (75 MHz, CDCl3) δ (ppm) 134.61, 125.9, 113.9, 32.6. HRMS (ESI+): 
m/z 150.9826 [M + H]+, calculated [M + H]+ 150.9824. 
v) Preparation of P15 
Benzimidazole (1.0 g, 8.46 mmol) and KOH (0.95 g, 16.93 mmol) 
were stirred in DMF (10 mL) for 3 hours. MeI (0.53 mL, 8.46 mmol) 
was added, and the reaction mixture was stirred for 18 hours under 
N2 and hydrous conditions. The mixture was partitioned between 
water (25 mL) and CHCl3 (10 mL). The aqueous layer was extracted with CHCl3 
(3 × 10 mL). The combined organic layers were washed with water (3 × 50 mL), 
which were combined and extracted with CHCl3 (3 × 30 mL). All organic layers 
were combined, dried over MgSO4 and the solvent removed in vacuo to give a 
colourless oil. Yield: 0.73 g, 5.52 mmol, 65%. 
1H NMR (300 MHz, CDCl3) δ (ppm) 7.81 (s, 1H, BzmH), 7.79 – 7.75 (m, 1H, 
BzmH), 7.37 – 7.32 (m, 1H, BzmH), 7.32 – 7.27 (m, 1H, BzmH), 7.26 – 7.20 (m, 
1H, BzmH), 3.78 (s, 3H, NCH3). 13C {1H} NMR (75 MHz, CDCl3) δ (ppm) 143.8, 
143.5, 134.6, 122.9, 122.1, 120.3, 109.3, 31.0. HRMS (ESI+): m/z 133.0767 [M 
+ H]+, calculated [M + H]+ 133.0760. 
vi) Preparation of P17 
DL-proline (0.10 g, 0.9 mmol), Cs2CO3 (4.0 g, 13 mmol), CuI 
(0.084 g, 0.45 mmol) and imidazole (0.38 g, 5.3 mmol) were 
added to a Schlenk flask. DMSO (5 mL) was added, followed 
by 2-bromo-6-methylpyridine (0.5 mL, 4.4 mmol). The reaction 
mixture was stirred at 90 °C for 23 hours under Ar. The mixture was allowed to 
cool to room temperature and DCM (50 mL) was added and the mixture filtered 
through Celite. The filtrate was washed with water (4 × 50 mL) and the aqueous 
layers were combined and extracted with DCM (4 × 150 mL). The extracted 
organic layers were combined and the volume reduced to about 50 mL in vacuo. 
The washing/extracting steps were repeated twice. These organic layers were 
combined, dried over Na2SO4 and the solvent removed in vacuo to obtain a 
brown liquid. The crude product was purified by flash column chromatography 
(silica gel), eluting with EtOAc / hexane (1: 2)  EtOAc / petroleum ether / MeOH 
(40: 50: 10). The pure product was obtained as a colourless oil. Yield: 0.29 g, 
1.82 mmol, 41 %. 
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1H NMR (300 MHz, CDCl3) δ (ppm) 8.37 (s, 1H, imH), 7.71 (dd, J = 8.1, 7.6 Hz, 
1H, pyH-4), 7.67 (s, 1H, imH), 7.22 (s, 1H, imH), 7.17 (d, J = 8.1 Hz, 1H, pyH-5), 
7.11 (d, J = 7.6 Hz, 1H, pyH-3), 2.59 (s, 3H, pyCH3). 13C {1H} NMR (75 MHz, 
CDCl3) δ (ppm) 158.8, 139.0. 121.5, 109.2, 24.3. HRMS (ESI+): m/z 160.0870 
[M + H]+, calculated [M + H]+ 160.0869. 
vii) Preparation of P23 
KOH (0.52 g, 9.3 mmol) was dissolved in THF (20 mL) and the 
reaction mixture stirred for 15 minutes. Benzimidazole (0.5 g, 4.2 
mmol) was added and the mixture was heated to 60 °C under N2 
and hydrous conditions. 2-(Bromomethyl)pyridine.HBr (1.12 g, 
4.4 mmol) was added to the heating solution and the reaction 
mixture was held at reflux for 27 hours. The mixture was allowed 
to cool to room temperature, filtered, and the filtrate reduced in 
vacuo. EtOAc (50 mL) was added and washed with water (3 × 50 mL). The 
aqueous layers were combined and extracted with DCM (3 × 100 mL). All organic 
layers were combined, dried over Na2SO4, and the solvent removed in vacuo. 
The crude brown oil was sonicated in Et2O (50 mL) for 30 minutes, filtered and 
the filtrate was reduced in vacuo to obtain a brown solid. Yield: 0.32 g, 1.5 mmol, 
36 %. 
1H NMR (300 MHz, CDCl3) δ (ppm) 8.64 (ddd, J = 5.1, 1.8, 0.7 Hz, 1H, pyH-6), 
8.08 (s, 1H, BzmH-2), 7.86 (ddd, J = 6.3, 2.1, 0.8 Hz, 1H, BzmH), 7.62 (td, J = 
7.7, 1.8 Hz, 1H, pyH-4), 7.36 – 7.30 (m, 3H, BzmH), 7.24 (ddd, J = 7.7, 5.1, 1.5 
Hz, 1H, pyH-5), 6.93 (ddd, J = 7.7, 0.7, 1.5 Hz, pyH-3), 5.52 (s, 2H, NCH2-py). 
13C {1H} NMR (75 MHz, CDCl3) δ (ppm) 155.5 (C), 149.8 (CH), 143.9 (C), 143.4 
(CH), 137.2 (CH), 133.9 (C), 123.2 (CH), 123.0 (CH), 122.4 (CH), 121.1 (CH), 
120.5 (CH), 110.0 (CH), 50.6 (CH2). HRMS (ESI+): m/z 210.1031 [M + H]+, 
calculated [M + H]+ 210.1026. 
2.10.3 Preparation of imidazolium salts 
i) Preparation of HL1Br  
2-(Bromomethyl)pyridine.hydrobromide (2.50 g, 9.88 mmol) 
and K2CO3 (0.68 g, 4.94 mmol) were added to a round-
bottomed flask, followed by addition of MeCN (160 mL) and 
dropwise addition of N-allyl imidazole (1.15 mL, 10.67 
mmol). The resulting pale red mixture was stirred at room 
temperature under N2 for 24 hours, over which time a colour 
change from red to yellow was observed. The yellow solution was dried over 
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CaCl2 and the volume reduced in vacuo to 10 mL. Et2O (150 mL) was added to 
precipitate a dark yellow-brown oil. The oil was washed with Et2O (2 × 100 mL). 
Yield: 2.14 g, 7.63 mmol, 77 %. 
1H NMR (300 MHz, CDCl3) δ (ppm) 10.46 (t, J = 1.7 Hz, 1H, imH-2), 8.56 (ddd, 
J = 4.9, 1.8, 1.1 Hz, 1H, pyH-6), 7.93 (dt, J = 7.7, 1.1 Hz, 1H, pyH-3), 7.80 (td, J 
= 7.7, 1.8 Hz, 1H, pyH-4), 7.70 (t, J = 1.7 Hz, 1H, imH), 7.33 (ddd, J = 7.7, 4.9, 
1.1 Hz, 1H, pyH-5), 7.21 (t, J = 1.7 Hz, 1H, imH), 6.02 (ddt, J = 16.7, 10.3, 6.5 
Hz, 1H, CH=CH2), 5.83 (s, 2H, NCH2-py), 5.54 – 5.44 (m, 2H, CH=CH2), 4.94 
(dt, J = 6.5, 1.3 Hz, 2H, NCH2-vinyl). 13C {1H} NMR (75 MHz, CDCl3) δ (ppm) 
152.1 (C), 149.4 (CH), 138.3 (CH), 137.7 (CH), 129.3 (CH), 124.6 (CH), 124.3 
(CH), 123.2 (CH), 123.0 (CH), 120.9 (CH2), 53.7 (CH2), 52.4 (CH2). HRMS 
(ESI+): m/z 200.1214 [M – Br]+, calculated [M – Br]+ 200.1182. 
Consistent with data previously reported.35,59 
ii) Preparation of HL3Br 
1-Methylimidazole (1.7 mL, 21.7 mmol) was dissolved in 
MeCN (100 mL), 2-(bromomethyl)pyridine.hydrobromide 
(5.0 g, 19.8 mmol) was added and stirred vigorously, 
followed by Na2CO3 (1.05 g, 9.9 mmol). The red reaction 
mixture was then heated and stirred at 80 °C under N2 for 24 
hours. The mixture was allowed to cool to room temperature, dried over Na2SO4, 
filtered and the volume reduced to about 5 mL. Et2O (150 mL) was added to 
precipitate a dark red-brown oil. The oil was dissolved in MeOH (20 mL), dried 
over Na2SO4, the volume reduced to 5 mL and EtOAc (100 mL) was added to 
precipitate a dark red-brown oil. Yield: 2.29 g, 9.0 mmol, 46 %. 
1H NMR (300 MHz, CDCl3) δ (ppm) 10.26 (s, 1H, imH-2), 8.50 (d, J = 4.7 Hz, 1H, 
pyH-6), 7.79 – 7.68 (m, 2H, pyH), 7.63 (s, 1H, imH), 7.42 (s, 1H, imH), 7.29 – 
7.23 (m, 1H, pyH), 5.73 (s, 2H, NCH2-py), 4.05 (s, 3H, NCH3). 13C {1H} NMR (101 
MHz, CDCl3) δ (ppm) 152.5 (C), 149.9 (CH), 149.4 (CH), 137.9 (CH), 137.8 (CH), 
124.1 (CH), 122.9 (CH), 122.8 (CH), 54.0 (CH2), 36.8 (CH3). HRMS (ESI+): m/z 
174.1025 [M – Br]+, calculated [M – Br]+ 174.1026. 
Consistent with data previously reported.60,61  
  
 
 
60 
 
iii) Attempted synthesis of HL5'Br  
To freshly activated 4Å molecular sieves, 2-(bromo-
methyl)pyridine hydrobromide (0.045 g, 0.177 mmol) 
and Cs2CO3 (0.029 g, 0.089 mmol) were added. MeCN 
(10 mL) was transferred into the flask via cannula. The 
resulting mixture was stirred at room temperature for 3 
hours. P5' (0.050 g, 0.161 mmol) was added and the reaction mixture stirred at 
room temperature for 24 hours. The yellow mixture was filtered and the filtrate 
volume was reduced in vacuo to 2 mL. A mixture of Et2O and pentane (50 mL) 
was added, which precipitated a pale orange solid and the solid was collected 
from filtration. Yield: 0.0061 g.  
HRMS (ESI+): m/z 160.0869 [picolyl imidazole + H]+, calculated [picolyl imidazole 
+ H]+ 160.0869; 243.1184 [tritryl]+, calculated [trityl]+ 243.1168; 251.1292 
[dipicolyl imidazolium]+, calculated [dipicoly imidazolium]+ 251.1291; 402.1970 
[M - Br]+, calculated [M - Br]+ 402.1965; 553.2645 [ditrityl imidazolium]+ 
calculated [ditrityl imidazolium]+ 553.2638. From the MS data it is clear that a 
mixture of products were formed in this reaction. 
iv) Preparation of HL5Br  
To freshly activated 4Å molecular sieves, 2-(bromo-
methyl)pyridine hydrobromide (1.00g, 3.95 mmol) and 
caesium carbonate (1.35 g, 4.15 mmol) were added,. 
MeCN (10 mL) was transferred into the flask via 
cannula. The resulting mixture was stirred at room 
temperature for 3 hours. Clotrimazole (1.43 g, 4.15 
mmol) was added and the reaction mixture stirred at room temperature for 18 
hours. The yellow mixture was filtered and the filtrate volume was reduced in 
vacuo to 2 mL. Et2O (50 mL) was added to precipitate a pale orange solid. The 
solid was washed with Et2O (2 × 50 mL). Yield: 0.32 g, 0.62 mmol, 16 %. 
1H NMR (300 MHz, CDCl3) δ (ppm) 9.55 (t, J = 1.8 Hz, 1H, imH-2), 8.47 (ddd, J = 
4.9, 1.8, 0.9 Hz, 1H, pyH-6), 8.18 (t, J = 1.8 Hz, 1H, imH), 8.01 (dt, J = 7.8, 1.0 
Hz, 1H), 7.73 (td, J = 7.7, 1.8 Hz, 1H, pyH-4), 7.51 – 7.38 (m, 8H), 7.33 (ddd, J = 
8.0, 7.0, 2.0 Hz, 1H), 7.29 – 7.23 (m, 1H), 7.17 – 7.10 (m, 4H, Trt), 7.07 (dd, J = 
8.0, 1.4 Hz, 1H), 6.94 (t, J = 1.8 Hz, 1H, imH), 6.08 (s, 2H, im-CH2-py). 13C {1H} 
NMR (75 MHz, CDCl3) δ (ppm) 152.7, 149.4, 138.3, 138.2, 138.1, 137.7, 137.4, 
135.3, 132.9, 131.5, 131.3, 129.8, 129.4, 129.0, 127.8, 124.7, 123.9, 123.4, 
122.7, 54.2. HRMS (ESI+): m/z 436.1604 [M - Br]+, calculated [M - Br]+ 436.1575. 
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Analysis Calculated for C28H23N3ClBr 0.8H2O: C, 63.30; H 4.67; N, 7.91. Found: 
C, 63.30; H, 4.45, N, 7.70. 
v) Preparation of HL6Br 
1-Mesitylimidazole (0.20 g, 1.07 mmol) and 
2-(bromomethyl)pyridine.HBr (0.25 g, 0.98 mmol) 
were dissolved and stirred in MeCN (5 mL) for 24 
hours under N2. K2CO3 (0.067 g, 0.49 mmol) was 
added and the mixture stirred for a further 1 hour. The 
reaction mixture was filtered, and the filtrate reduced in vacuo. The resulting 
mixture was recrystallised from MeCN / Et2O to give a red brown solid. Yield: 
0.073 g, 0.20 mmol, 21 %. 
1H NMR (300 MHz, CDCl3) δ (ppm) 10.43 (t, J = 1.7 Hz, 1H, imH-2), 8.57 (ddd, 
J = 4.9, 1.8, 0.7 Hz, 1H, pyH-6), 8.19 (dt, J = 7.8, 0.7 Hz, 1H, pyH-4), 8.12 (t, J = 
1.7 Hz, 1H, imH), 7.85 (td, J = 7.7, 1.7 Hz, 1H, pyH-3), 7.37 (ddd, J = 7.6, 4.9, 
0.9 Hz, 1H, pyH-5), 7.09 (t, J = 1.7 Hz, 1H, imH), 7.01 (s, 2H, MesH), 6.23 (s, 
2H, im-CH2-py), 2.35 (s, 3H, Mes-CH3), 2.07 (s, 6H, Mes-2CH3).13C {1H} NMR 
(75 MHz, CDCl3) δ (ppm) 152.2, 148.8, 141.6, 139.2, 138.5, 137.5, 134.4, 130.1, 
124.6, 123.9, 122.6, 53.2 (CH2), 21.2 (CH3), 17.8 (CH3). HRMS (ESI+): m/z 
278.1664 [M - Br]+, calculated [M - Br]+ 278.1652. 
Consistent with data previously reported.62  
vi) Preparation of HL7Br 
2-(Bromomethyl)-6-methylpyridine (0.50 g, 2.69 mmol) was 
dissolved in MeCN (50 mL). 1-methylimidazole (0.22 mL, 
2.82 mmol) was added, and the pale red solution was stirred 
at room temperature under N2 for 24 hours. The volume was 
reduced in vacuo to 5 mL. Et2O (75 mL) was added to 
precipitate brown oil, which was sonicated in Et2O (2 × 75 
mL) to obtain a light orange-brown oil. Yield: 0.70 g, 2.61 mmol, 97 %. 
1H NMR (300 MHz, CDCl3) δ (ppm) 9.82 (t, J = 1.7 Hz, 1H, imH-2), 7.51 (t, J = 
1.7 Hz, 1H, imH), 7.38 (t, J = 1.7 Hz, 1H, imH), 7.27 (t, J = 7.6 Hz, 1H, pyH-4), 
7.15 (d, J = 7.6 Hz, 1H, pyH-3), 6.81 (d, J = 7.7 Hz, 1H, pyH-5), 5.33 (s, 2H, N-
CH2-im), 3.79 (s, 3H, im-CH3), 2.15 (s, 3H, py-CH3). 13C {1H} NMR (75 MHz, 
CDCl3) δ (ppm) 156.8, 149.4, 135.5, 134.8, 121.6, 121.5, 120.6, 118.33, 51.8 
(CH2), 34.6 (im-CH3), 22.2 (py-CH3). HRMS (ESI+): m/z 188.1189 [M - Br]+, 
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calculated [M - Br]+ 188.1182. Analysis Calculated for C11H14BrN3 2.25H2O: C, 
42.80; H 6.04; N, 13.61. Found: C, 42.80; H, 5.90, N, 13.80. 
vii) Preparation of HL8Br 
1-(2-Pyridyl)imidazole (P8, 1.50 g, 10.3 mmol) was 
dissolved in MeCN (100 mL). Allyl bromide (4.5 mL, 51.7 
mmol) was added to the solution, and the solution was 
stirred at 85 ºC under N2 for 24 hours. Additional allyl 
bromide (0.5 mL, 5.8 mmol) was added and the reaction heated for a further 1 
hour. The volume was reduced in vacuo to 10 mL, and Et2O (150 mL) was added 
slowly to precipitate a white solid. The solid was collected by filtration and 
repeatedly recrystallised in MeCN / Et2O. The solid collected was then 
suspended in Et2O (150 mL) for 1 hour, and the solid was collected from filtration, 
washed repeatedly with Et2O, and dried in vacuo to give a white solid. Yield: 2.54 
g, 9.54 mmol, 92.4 %. 
1H NMR (300 MHz, CDCl3) δ (ppm) 11.98 (d, J = 1.9 Hz, 1H. imH-2), 8.52 (dt, J 
= 8.3, 0.9 Hz, 1H, pyH-3), 8.46 (ddd, J = 4.9, 1.9, 0.9 Hz, 1H, pyH-6), 8.23 (t, J 
= 1.9 Hz, 1H, imH), 8.01 (ddd, J = 8.3, 7.5, 1.9 Hz, 1H, pyH-4), 7.41 (ddd, J = 
7.5, 4.9, 0.9 Hz, 1H, pyH-5), 7.27 (d, J = 1.9 Hz, 1H, imH), 6.05 (ddt, J = 16.7, 
10.1, 6.6 Hz, 1H, CH=CH2), 5.57 – 5.45 (m, 2H, CH=CH2), 5.17 (dt, J = 6.6, 1.3 
Hz, 2H, NCH2-vinyl). 13C {1H} NMR (75 MHz, CDCl3) δ (ppm) 149.0, 140.7, 136.0, 
129.5, 125.2, 123.4, 121.8, 118.9, 115.1, 52.7. HRMS (ESI+): m/z 186.0845 [M - 
Br]+, calculated [M - Br]+ 186.1031. Analysis Calculated for C11H12BrN3: C, 49.64; 
H 4.54; N, 15.79. Found: C, 49.40; H, 4.50, N, 15.70. 
Consisted with data previously reported.44 
viii) Attempted synthesis of HL10Br 
2-Bromoethylamine.HBr (0.50 g, 2.44 mmol) was dissolved in 
MeOH or MeCN (5 mL) and 1-allylimidazole (0.29 mL, 2.68 
mmol) was added. The reaction solution was stirred in a closed 
ampoule for 16 hours under N2 at 75 ºC. A pale brown precipitate 
was observed in the case of MeCN. The crude products were obtained after 
solvent removal in vacuo. They were recrystallised in MeOH / Et2O. 
ix) Attempted synthesis of HL14I via P14' 
P14ʹ (0.1 g, 0.44 mmol) was dissolved in MeCN (2 mL). MeI (30 μL, 0.48 mmol) 
was added to the solution. The solution was stirred at 30 ºC under N2 and 
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hydrous conditions for 24 hours. More MeI (60 μL, 0.96 mmol) was added. A pale 
white solid precipitated in the reaction vessel. Et2O (70 mL) was added to the 
reaction mixture. The precipitate was collected via filtration and washed with 
Et2O (3 × 25 mL). Yield: 0.18 g. 
x) Preparation of HL14Br 
P14 (0.05 g, 0.33 mmol) and 2-(bromomethyl)pyridine.HBr 
(0.08 g, 0.32 mmol) were dissolved in MeCN (15 mL) and 
heated under reflux under N2 and hydrous conditions for 24 
hours. The reaction mixture volume was reduced in vacuo to 
5 mL. Et2O (70 mL) was added to precipitate the product, 
which was isolated by filtration. Yield: 0.088 g, 0.27 mmol, 
82%. 
1H NMR (300 MHz, CDCl3) δ (ppm) 11.02 (s, 1H, imH), 8.48 (dd, J = 4.7, 1.7 Hz, 
1H, pyH-6), 7.76 (td, J = 7.8, 1.7 Hz, 1H, pyH-4), 7.58 (d, J = 7.8 Hz, 1H, pyH-
3), 7.28 (dd, J = 7.8, 4.7 Hz, 1H, pyH-5), 5.82 (s, 2H, NCH2-py) 4.08 (s, 3H, 
NCH3). 13C {1H} NMR (75 MHz, CDCl3) δ (ppm) 151.0, 150.0, 138.7, 137.7, 
124.1, 122.9, 52.9, 34.5. HRMS (ESI+): m/z 242.0247 [M + H]+, calculated 
[M + H]+ 242.0246. 
xi) Preparation of HL15Br 
P15 (0.29 g, 2.17 mmol) was dissolved in MeCN (5 mL). 
2-(Bromomethyl)pyridine.HBr (0.50 g, 1.98 mmol) was 
added and the solution stirred for 2 hours under N2 and 
hydrous conditions. K2CO3 (0.14 g, 0.99 mmol) was added 
and the reaction mixture was stirred for further 18 hours. The 
mixture was filtered, and the filtrate volume reduced in vacuo 
to 2 mL. Et2O (50 mL) was added to precipitate an orange 
solid. The solid was recrystallised from MeCN / Et2O. The orange brown solid 
was collected via filtration and dried in vacuo. Yield: 0.54 g, 1.77 mmmol, 81%. 
1H NMR (300 MHz, CDCl3) δ (ppm) 11.47 (s, 1H, BzmH-2), 8.47 (ddd, J = 4.9, 
1.6, 0.9 Hz, 1H, pyH-6), 7.92 – 7.86 (m, 2H), 7.77 – 7.64 (m, 3H), 7.63 – 7.56 
(m, 2H), 7.23 (ddd, J = 7.5, 4.9, 1.0 Hz, 1H, pyH-5), 6.03 (s, 2H, im-CH2-py), 4.26 
(s, 3H, NCH3). 13C {1H} NMR (75 MHz, CDCl3) δ (ppm) 152.4 (C), 149.7 (CH), 
143.5 (CH), 137.7 (CH), 131.9 (C), 131.6 (C), 127.2 (CH), 127.2 (CH), 124.0 
(CH), 123.9 (CH), 114.5 (CH), 112.5 (CH), 52.4 (CH2), 33.8 (CH3). HRMS (ESI+): 
m/z 224.1186 [M - Br]+, calculated [M - Br]+ 224.1182. 
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xii) Preparation of HL17Br 
P17 (0.1 g, 0.6 mmol) was dissolved in MeCN (5 mL) and 
allyl bromide (0.1 mL, 1.2 mmol) was added. The solution 
was stirred at 75 °C under N2 and hydrous conditions for 
24 hours and the reaction mixture was allowed to cool to 
room temperature. Et2O (100 mL) was added to precipitate 
a light brown-grey solid, which was collected by filtration and dried in vacuo. 
Yield: 0.10 g, 0.36 mmol, 57 %.  
1H NMR (400 MHz, CDCl3) δ (ppm) 11.87 (s, 1H, imH-2), 8.24 (d, J = 7.9 Hz, 1H, 
pyH), 8.23 (s, 1H, imH), 7.85 (t, J = 7.9 Hz, 1H, pyH), 7.26 (s, 1H, imH), 7.23 (d, 
J = 7.9 Hz, 1H, pyH), 6.03 (ddd, J = 16.5, 10.1, 6.5 Hz, 1H, CH=CH2), 5.51 (d, J 
= 16.5 Hz, 1H, CH=CH2 cis), 5.47 (d, J = 10.1 Hz, 1H, CH=CH2 trans), 5.17 (d, 
J = 6.5 Hz, 2H, NCH2-vinyl), 2.53 (s, 3H, CH3-py). 13C {1H} NMR (101 MHz, 
CDCl3) δ (ppm) 159.0 (C), 140.8 (CH), 136.3 (C), 129.6 (CH), 124.8 (CH), 123.3 
(CH2), 121.2 (CH), 118.9 (CH), 112.0 (CH), 52.7 (CH2), 42.1 (CH3). HRMS 
(ESI+): m/z 200.1180 [M – Br]+, calculated [M – Br]+ 200.1182. 
xiii) Preparation of HL18Cl 
2-Chlorotrityl chloride (0.093 g, 0.3 mmol) was dissolved 
in MeCN (5 mL) and 1-allylimidazole (34 μL, 0.315 mmol) 
was added. The yellow solution was stirred at 80 °C for 
18 hours. The volume was reduced to about 1 mL in 
vacuo, and Et2O (50 mL) was added to precipitate a pale 
yellow oil. The crude oil was recrystallised from DCM (1 mL) / Et2O (50 mL) and 
dried in vacuo to obtain a pale-yellow sticky solid. Yield: 0.048 g, 0.11 mmol, 38 
% 
1H NMR (300 MHz, CDCl3) δ (ppm) 9.23 (s, 1H, imH), 7.49 – 7.28 (m, 13H), 7.15 
– 7.08 (m, 2H), 6.70 (dd, J = 7.9, 1.5 Hz, 1H), 6.00 (ddt, J = 17.0, 10.1, 6.3 Hz, 
1H, CH=CH2), 5.51 (d, J = 10.1 Hz, 1H, CH=CH2 trans), 5.43 (d, J = 17.0 Hz, 1H, 
CH=CH2 cis), 4.91 (d, J = 6.3 Hz, 2H, NCH2-vinyl). HRMS (ESI+): m/z 385.1457 
and 387.1442 [M - Br]+, calculated [M - Br]+ 385.1466 and 387.1437; 277.0788 
and 279.0754 [chlorotrityl]+, calculated [chlorotrityl]+ 277.0779 And 279.0749. 
Consistent with data previously reported.63 
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xiv) Preparation of HL20Br 
In air, imidazole (0.068 g, 1 mmol) and NaHCO3 (0.256 g, 
3.05 mmol) were dissolved in MeOH (10 mL) and stirred. 
2-(Bromomethyl)pyridine.HBr (0.518 g, 2.05 mmol) was 
added and the mixture was stirred at 70 °C under hydrous 
conditions for 18 hours. The solvent was removed in 
vacuo. DCM (50 mL) was added, the mixture filtered, and the filtrate dried with 
MgSO4, and the solvent removed in vacuo. The crude red liquid was triturated in 
THF (50 mL) to give a red-brown oil. The oil was recrystallised from DCM (5 mL) 
/ Et2O (70 mL) twice, to obtain a sticky red-brown solid. Yield: 0.13 g, 0.39 mmol, 
39 % 
1H NMR (300 MHz, CDCl3) δ (ppm) 10.65 (s, 1H, imH), 8.54 (d, J = 4.7 Hz, 2H, 
pyH-6), 7.79 – 7.73 (m, 4H, pyH), 7.57 (s, 2H, imH), 7.29 (dd, J = 8.3, 4.3 Hz, 
2H, pyH-5), 5.68 (s, 4H, NCH2-py). 13C {1H} NMR (75 MHz, CDCl3) δ (ppm) 152.3 
(C), 149.9 (CH), 137.9 (CH), 124.2 (CH), 124.1 (CH), 122.4 (CH), 110.0 (CH), 
54.2 (CH2). HRMS (ESI+): m/z 251.1295 [M - Br]+, calculated [M - Br]+ 251.1291. 
Consisted with data previously reported.61 
xv) Preparation of HL21Br 
P17 (0.1 g, 0.6 mmol) and was stirred in MeCN (5 mL) 
and heated to 50 °C. 2-(Bromomethyl)pyridine.HBr 
(0.16 g, 0.6 mmol) was added and stirred at 50 °C under 
N2 and hydrous conditions for 8 hours. The reaction 
mixture was allowed to cool to room temperature, stirred 
with K2CO3 (0.17 g, 1.2 mmol) for 30 minutes and filtered. The filtrate was 
reduced in vacuo and the resulting oil was dissolved in DCM (20 mL), dried over 
MgSO4 and filtered. The volume was reduced to about 3 mL, and Et2O (50 mL) 
was added to precipitate a dark brown oil. Yield: 0.11 g, 0.35 mmol, 56 %. 
1H NMR (300 MHz, CDCl3) δ (ppm) 11.95 (s, 1H, imH-2), 8.56 (ddd, J = 4.8, 1.8, 
0.8 Hz, 1H, picH-6), 8.21 (s, 1H, imH), 8.14 (d, J = 7.9 Hz, 1H, pyH), 7.99 (d, J = 
7.9 Hz, 1H, pyH), 7.89 (t, J = 7.9 Hz, 1H, pyH), 7.77 (td, J = 7.7, 1.8 Hz, 1H, picH-
4), 7.74 (s, 1H, imH), 7.31 (ddd, J = 7.7, 4.8, 0.8 Hz, 1H, picH-5), 7.26 (dt. J = 
7.7, 0.8 Hz, picH-3), 5.91 (s, 2H, NCH2-py), 2.58 (s, 3H, pyCH3). 13C {1H} NMR 
(75 MHz, CDCl3) δ (ppm) 159.0 (C), 152.3 (C), 152.2 (C), 149.8 (CH), 145.2 (C), 
140.7 (CH), 137.9 (CH), 136.0 (CH), 124.7 (CH), 124.2 (CH), 122.7 (CH), 120.6 
(CH), 118.2 (CH), 111.6 (CH), 111.3 (CH), 54.4 (CH2), 24.1 (CH3). HRMS (ESI+): 
m/z 251.1286 [M – Br]+, calculated [M – Br]+ 251.1291. 
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xvi) Preparation of HL23Br 
P23 (0.10 g, 0.5 mmol) was dissolved in MeCN (5 mL) and 
allyl bromide (0.1 mL, 1.2 mmol) was added. The yellow 
reaction mixture was held at reflux under N2 and hydrous 
conditions for 24 hours. The reaction mixture was allowed to 
cool to room temperature and Et2O (100 mL) was added to 
precipitate a brown solid, which was collected by filtration 
and dried in vacuo. Yield: 0.11 g, 0.33 mmol, 70 %. 
1H NMR (300 MHz, CDCl3) δ (ppm) 11.49 (s, 1H, BzmH-2), 8.43 (dd, J = 4.6, 1.7 
Hz, 1H, pyH-6), 7.91 – 7.83 (m, 2H, BzmH), 7.70 (td, J = 7.7, 1.7 Hz, 1H, pyH-
4), 7.65 – 7.50 (m, 4H, pyH and BzmH), 6.15 – 6.02 (m, 1H, CH=CH2), 6.00 (s, 
2H, NCH2-py), 5.48 – 5.40 (m, 2H, CH=CH2), 5.18 (d, J = 6.0 Hz, 2H, NCH2-
vinyl). 13C {1H} NMR (75 MHz, CDCl3) δ (ppm) 152.3 (C), 149.6 (CH), 143.2 (CH), 
137.8 (CH), 129.2 (CH), 127.2 (CH), 127.1 (CH), 124.0 (CH), 122.2 (CH), 114.7 
(CH), 113.6 (CH2), 113.2 (CH), 52.43 (CH2), 50.20 (CH2). HRMS (ESI+): m/z 
250.1338 [M – Br]+, calculated [M – Br]+ 250.1339. 
xvii) Preparation of HL24Br 
Benzimidazole (0.24 g, 2 mmol) and NaHCO3 (0.60 g, 7.1 
mmol) were dissolved in MeOH (10 mL). 2-(Bromo-
methyl)pyridine.HBr (1.1 g, 4.1 mmol) was added and the 
mixture was stirred at 70 °C under N2 and hydrous 
conditions for 18 hours. The solvent was removed in 
vacuo. DCM (50 mL) was added, the solution filtered, 
dried with MgSO4 and the solvent removed in vacuo. The 
crude red liquid was triturated in THF (50 mL) to give a red-brown oil. The oil was 
recrystallised from DCM (5 mL) / Et2O (70 mL) twice, to obtain a sticky dark red-
brown solid. Yield: 0.49 g, 1.7 mmol, 86 %. 
1H NMR (300 MHz, CDCl3) δ (ppm) 11.68 (s, 1H, BzmH-2), 8.45 (ddd, J = 4.6, 
1.9, 1.0 Hz, 2H, pyH-6), 7.82 – 7.76 (m, 4H, BzmH and pyH-5), 7.69 (td, J = 7.6 
1.9 Hz, 2H, pyH-4), 7.48 (dd, J = 6.3, 2.2 Hz, 2H, BzmH), 7.21 (dd, J =7.3, 1.0 
Hz, pyH-3), 5.90 (s, 2H, NCH2-py). 13C {1H} NMR (75 MHz, CDCl3) δ (ppm) 152.2 
(C), 149.7 (CH), 143.4 (CH), 137.8 (CH), 131.7 (C), 127.1 (CH), 124.0 (CH), 
123.8 (CH), 114.2 (CH), 52.7 (CH2). δ. HRMS (ESI+): m/z 301.1449 [M – Br]+, 
calculated [M – Br]+ 301.1448. 
Consistent with data previously reported.61 
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2.10.4 Cu-catalysed etherification reaction for ligand screening 
and evaluations 
 
3,5-Dimethylphenol (0.1465 g, 1.2 mmol), 4-iodoanisole (0.2340 g, 1.0 mmol), 
CuI (0.0190g, 0.10 mmol), Cs2CO3 (1.3033 g, 4.0 mmol) and ligand (0.10 mmol) 
were placed in a carousel tube and under Ar. To this was added anhydrous 
MeCN (5 mL) via syringe. The resulting mixture was heated with stirring at 90 °C 
for 24 hours under Ar. After this time, the mixture was cooled to room 
temperature and a 100 μL aliquot was withdrawn from the reaction mixture and 
added to 2 mL of a 10 mM stock solution of p-cymene (internal standard) in DCM. 
The solution containing the reaction mixture and internal standard was filtered 
through Celite and subsequently analysed by GC. 
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Chapter 3  
Non-Innocent Activity of NHCs During Cu-Catalysed Coupling 
Reactions 
3.1 Introduction 
There are many examples in the literature of reductive elimination of alkyl-
imidazolium,1-9 allyl-imidazolium10 and aryl-imidazolium salts,11-15 particularly at 
group 10 metals. Some have demonstrated the reaction as a method to activate 
a catalyst, as the metal is subsequently reduced to the active oxidation state by 
the reductive elimination.5,7 Others have considered the reaction as a catalyst 
deactivation pathway in metal-catalysed coupling reactions.16,17 The reductive 
elimination of aryl-imidazolium consumes both starting material and supporting 
ligand (NHC) (Scheme 3-1).18 This leads to a decrease in catalyst efficiency due 
to the loss of the supporting ligand, leaving the metal centre more exposed and 
less stable.  
 
Scheme 3-1: Representation of a coupling reaction via oxidative addition / reductive 
elimination, and potential deactivation pathway steps. 
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Previous studies in the Willans group have utilised Cu-NHC complexes as cross-
coupling catalysts19,20 (also discussed in Chapter 2), during which the formation 
of aryl-imidazolium cations was observed.20 The arylated imidazolium was 
observed in the HR mass spectrum of the reaction mixture that used an in situ 
formed catalyst through addition of CuI and 1-(but-3-enyl)-3-picolylimidazolium 
bromide (Scheme 3-2). The detected species was proposed to have the aryl 
group substituted at the C-2 position of the imidazolium, which was likely co-
ordinated to the metal centre in the active species. 
 
Scheme 3-2: Observation of aryl-imidazolium formation in an Ullmann-type 
etherification reaction.20 
This part of the project is focused on understanding the reductive elimination of 
aryl-imidazolium which appears to occur during the Cu-NHC-catalysed 
etherification reaction. Other potential reductive elimination reactions were also 
considered e.g. X-imidazolium, Nu-imidazolium, Nu-X.  
3.2 Examination of varying ligand precursors for 
aryl-imidazolium formation 
The coupling reaction of 4-iodoanisole and 3,5-dimethylphenol was carried out 
in the presence of Cs2CO3 and CuI/imidazolium bromide (10 mol%) (Scheme 
3-3). Reactions were carried out at 90 °C for 24 hours. Each reaction mixture 
was quenched by filtration through Celite and was examined for the reductive 
elimination of aryl-imidazolium and other possible species using HRMS. When 
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ligands L1 – L4, L8 and L9 were examined, X-imidazolium or Nu-imidazolium 
ions were not observed in any entries. This supports the DFT theory that 
reductive elimination on a Cu metal centre tends to involve strongly nucleophilic 
ligands (section 1.5.3).21 Hence the aryl group, which is the most nucleophilic, 
participates in the reductive elimination more readily. The observed species in 
these reactions were H-imidazolium (HL) ion, imidazolone (from oxidation or 
hydrolysis of the NHC), the cross-coupled ether product and, in some cases, 
aryl-imidazolium ion. 
 
Scheme 3-3: Ligand screening for reductive elimination of aryl-imidazolium. 
Aryl-imidazolium was observed in the HRMS in the cases of L2, L3 and L4 (Table 
3-1). The conversions to ether (determined by GC using p-cymene as an internal 
standard) in these reactions were 37 %, 46 % and 56 % respectively. Conversion 
to the ether product when using ligands L8 and L9 was also in the same range, 
at 53 % and 41 % respectively; however, no aryl-imidazolium was observed in 
these cases. This indicates that the efficiency of the reaction is not only governed 
by catalyst deactivation via aryl-imidazolium formation. Other factors such as the 
steric and electronic effects of the NHC ligands are also important (as discussed 
in Chapter 2). Nevertheless, it cannot be concluded from these results that the 
picolyl N-substituent consistently leads to the aryl-imidazolium deactivation as 
there was no aryl-imidazolium observed in the case of L1. The etherification 
reaction catalysed by a Cu complex of L1 gave the highest conversion (63 %), 
which may be linked to no aryl-imidazolium being formed. 
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Ligand R1 R2 % ether aryl-imidazolium 
L1 picolyl allyl 63 not observed 
L2 picolyl propyl 37 observed 
L3 picolyl methyl 46 observed 
L4 picolyl t-butyl 56 observed 
L8 pyridyl allyl 53 not observed 
L9 pyridyl mesityl 41 not observed 
Table 3-1: Etherification (% determined by GC using p-cymene as an internal standard) 
and aryl-imidazolium formation (observed by HRMS). Reaction conditions as shown in 
Scheme 3-3. 
Another ligand (L38) was introduced to the investigation to see if there are any 
correlations between catalytic activity of a Cu-NHC complex and the aryl-
imidazolium formation (Scheme 3-4). L38 had previously been found to perform 
poorly in the etherification reaction (14 % conversion),19 hence it might be 
expected that catalyst deactivation may occur via aryl-imidazolium formation. 
The ligand precursor HL38Br was prepared in a similar fashion to HL8Br 
(Scheme 3-4) with analysis by 1H and 13C {1H} NMR spectroscopy and HRMS 
being consistent with previous reported data.19 
 
Scheme 3-4: Preparation of P8 (for comparison), P38 and HL38Br. 
To investigate directly the competing reaction between ether and aryl-
imidazolium formation, stoichiometric reactions were carried out in which the CuI 
and HLBr were increased to 100 mol% (Scheme 3-5). In addition to L38, 
investigations were carried out using L3, which had led to the formation of Ar3 
in previous catalytic reactions, and L1 and L8, which had not led to the side-
reaction. In the stoichiometric reactions, both picolyl-bearing ligands (L1 and L3) 
led to aryl-imidazolium formation although Ar1 was not observed previously 
(Table 3-2). However, L8 with a pyridyl N-substituent still did not result in aryl-
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imidazolium formation. The stoichiometric reaction with L38, which had not 
performed well in the cross-coupling reaction in the past (14 % compared to 20 
% in the ligand-free system),19 also did not lead to aryl-imidazolium formation. 
Therefore, it was concluded that the aryl-imidazolium side-reaction does not 
correlate with the catalytic activity of Cu-NHC complexes, and it appears that 
ligands with a picolyl N-substituent leads to aryl-imidazolium formation, whereas 
ligands with a pyridyl N-substituent do not. In addition, X-imidazolium and Nu-
imidazolium were not observed in any cases, which is consistent with the 
observation in the catalytic reactions. 
 
Scheme 3-5: Competing reactions using stoichiometric amount of CuI and imidazolium 
salt. 
ligand R1 R2 
10 mol % CuI + HLBr 
100 mol % 
CuI + HLBr 
% ether ArIm ArIm 
L1 picolyl allyl 63 not observed observed 
L3 picolyl methyl 46 observed observed 
L8 pyridyl allyl 53 not observed not observed 
L38 5-nitro pyridyl allyl N/A (< 29) N/A not observed 
Table 3-2: Results of screening using 10 and 100 mol % CuI/imidazolium bromide 
(aryl-imidazolium side-product observed by HRMS). 
We have observed that C-2 arylation of an NHC occurs when it contains a picolyl 
N-substituent, whereas replacing this with a pyridyl group inhibits arylation of the 
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NHC. There are several different possibilities for why this is the case. The 
physical difference between these groups is the flexibility of the linkage between 
the pyridine ring and the carbene ring. The pyridyl group has a rigid Cpyridine-NNHC 
bond whereas the picolyl group has a flexible methylene spacer between the 
rings. The distance of the pyridine ring of the picolyl group is further away from 
the carbene, as previously observed in the crystal structures of Cu(I)-NHC-Br 
(C1 and C8) where the angle of CNHC-Cu-Npyridine increases from 81.5 ° in C8 to 
92.2 ° in C1 (Figure 3-1).19,22 The higher steric encumbrance by L1 may promote 
the catalytic activity of this complex by pushing the substrates into closer 
proximity but, at the same time, increase the energy barrier for nucleophilic 
substitution and increase the opportunity for aryl-imidazolium formation. 
However, we postulate that the presence of the nucleophile is essential in the 
formation of aryl-imidazolium (section 3.3.3) and therefore sterics should not 
affect the nucleophilic substitution, and it is more likely that the electronic 
differences cause the aryl-imidazolium in the case of picolyl-NHCs. 
 
Figure 3-1: Structure of C1 and C8.19,22  
1H NMR spectra of imidazolium salts can be used to study the electronic 
properties of the ligands. Considering HL1Br, HL8Br and HL38Br, which all have 
the same second N-substituent (i.e. an allyl group), it can be seen that the 
imidazolium ring of HL1Br is the most electron rich. The 1H NMR spectrum of 
HL1Br shows the imidazolium peak (HA) at δ 10.46 ppm, which is more upfield 
than the HA peaks of HL8Br (δ 11.98 ppm) and HL38Br (δ 12.28 ppm) (Figure 
3-2). The imidazolium backbone (HB and HC) of HL1Br (δ 7.70 and 7.21 ppm) 
are also slightly more upfield than HL8Br (δ 8.23 and 7.27 ppm) and HL38Br 
(δ 8.33 and 7.37 ppm). The N-picolyl-bearing NHC has more electron density at 
the NHC ring than the N-pyridyl analogue, due to the methylene linkage which 
lowers the electron withdrawal by the pyridine ring. Therefore, L1 may perform 
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better in catalysis due to greater stabilisation of the Cu(III) intermediate by the 
stronger base under the assumption that the catalytic cycle proceed via such 
intermediate. However, when the stoichiometric reaction was performed, which 
would also proceed via a Cu(III) intermediate, formation of aryl-imidazolium 
became a competing factor. 
 
Figure 3-2: 1H NMR spectra (300 MHz, CDCl3) of HL1Br (top), HL8Br (middle) and 
HL38Br (bottom). 
It is thought that aryl-imidazolium formation occurs only with picolyl-substituted 
NHCs due to the stability of the regenerated Cu(I)-NHC complex, which governs 
the rate of the reductive elimination of the cross-coupled product. The ΔG of 
reductive elimination from a Cu centre was proposed by Ariafard to rely on the 
stability of the resulting Cu anion [X-Cu-Br]- (Scheme 3-6).21 Furthermore, the 
less negative ΔG leads to the higher ΔGŧ and hence lengthens the lifetime of the 
Cu(III) intermediate (Figure 3-3).  
 
Scheme 3-6: Reductive elimination of bromo-imidazolium, forming [X-Cu-Br]- 
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Figure 3-3: Plot of HOMO energy of Cu-X versus ΔG (left) and ΔG‡ versus ΔG (right) 
for reductive elimination of bromo-imidazolium from trans-(NHC)Cu(Br)2X 
complexes.21 
The same principle may be applied in the case of the reductive elimination of the 
ether product. A more electron rich ligand makes the Cu(I)-NHC complex less 
stable and increases the stability of the Cu(III) intermediate. The ΔG of the 
reductive elimination of the ether product, in the case of L1, is likely to be less 
negative than L8 and L38. As the Cu(III) intermediate is prolonged, the chance 
of the competing reductive elimination of aryl-imidazolium increases (Scheme 
3-7). Therefore, considering the electronic properties, picolyl-NHCs are more 
likely to lead to the reductive elimination of aryl-imidazolium during an Ullmann-
type cross-coupling reaction than pyridyl-NHCs. 
 
Scheme 3-7: Reductive elimination of ArNu or Ar1 
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We have demonstrated that picolyl-substituted NHCs partake in reductive 
elimination of aryl-imidazolium during an Ullmann-type cross-coupling reaction. 
Both physical and electronic properties of the picolyl N-substituent have been 
considered. However, the above screening reactions are qualitative and cannot 
be used to compare other factors that may affect the competing reactions such 
as the second N-substituents (e.g. difference between L1 and L3), base, 
nucleophile and catalyst loadings. 
3.3 Quantification of the arylation reaction 
3.3.1 Preparation of aryl-imidazolium salts 
The previous reactions which examined aryl-imidazolium formation during the 
etherification reaction detected the products using HRMS. Attempts were made 
to use 1H NMR spectroscopy to analyse and quantify each species in the 
quenched reaction mixtures, but this proved futile as the Cu-catalysed reactions 
resulted in a number of different species (Figure 3-4). For example, the methoxy 
singlet peak of 4-iodoanisole resonates at δ 3.76 ppm, but in the reaction mixture, 
there are 6 overlapping peaks between δ 3.90 – 3.72 ppm. This indicates that 
the fate of the anisolyl is not just restricted to the starting material, the cross-
coupled ether product and the aryl-imidazolium ion. 
 
Figure 3-4: 1H NMR spectra (300 MHz, CD3CN) of 4-iodoanisole (4), 
3,5-dimethylphenol (3), HL1Br (2) and the quenched mixture following an 
etherification using stoichiometric amounts of HL1Br and CuI (1). 
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In order to quantify formation of the different species, an analytical technique that 
separates the reaction mixture (i.e. chromatography) would be beneficial, though 
this requires calibration using authentic material. Attempts were therefore made 
to prepare aryl-imidazolium salts Ar1 and Ar3 to enable calibration and 
quantification (Figure 3-5). 
 
Figure 3-5: Structures of target arylated imidazolium salts. 
Several synthetic routes have been attempted for the preparation of Ar1. Bellina 
and co-workers demonstrated the C-2 arylation of imidazoles through reaction 
with aryl iodide in the presence of 0.05 equivalents of Pd(OAc)2 and 
2 equivalents of CuI, in anhydrous DMF at 140 °C (Scheme 3-8a).23-27 A similar 
reaction was carried out starting from 1-allylimidazole; however, arylation 
occurred on the allyl and resulted in the formation of 39 (Scheme 3-8b). The 1H 
NMR spectrum showed that the C-2 proton (HA) had not been substituted, with 
the resonance still present at δ 7.54 ppm (Figure 3-6). Furthermore, the chemical 
shifts and J-couplings of the allylic group are significantly different from the 
starting imidazole. The trans CH=CH2 proton (HE, at δ 5.00 ppm in the starting 
material), which has a 3Jcis coupling constant of 10.2 Hz with the vinylic proton, 
was no longer observed in the spectrum of the product. The vinylic protons (HD), 
allylic protons (HB) and the cis proton (HC) shifted downfield due to the newly 
introduced aryl group, with the trans proton being most downfield as it is closest 
to the aryl group. The NMR data indicates that the arylation occurred at the 
terminal alkene and results in a trans-alkene.  
 
 
79 
 
 
Scheme 3-8: Arylation of 1-benzylimidazole23 and 1-allylimidazole. 
 
Figure 3-6: 1H NMR spectra (500MHz, CDCl3) of 1-allylimidazole (top) and the 
arylated product (bottom). 
1-Picolylimidazole (P1) was synthesised by nucleophilic substitution of imidazole 
with picolyl bromide.HBr in the presence of base, with the aim of arylating this 
precursor (Scheme 3-9).  
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Scheme 3-9: Preparation of P1. 
P1 was arylated using Bellina's method (Scheme 3-10). The arylated imidazole 
40 was obtained in very low isolated yield (1%), even though this was observed 
as a major product in both the crude 1H NMR spectrum and the HR mass 
spectrum. It is therefore proposed that 40 is lost during the work-up, which 
requires removal of Cu species by washing with EDTA solution. As 40 can 
coordinate to Cu, it is possible that it was removed through coordination. 
 
Scheme 3-10: Arylation of P1. 
Arylation of unsubstituted imidazole was carried out, with the aim of 
functionalisation after arylation. The C-2 arylated imidazole (41) was successfully 
synthesised and isolated in a high yield (95%) using Bellina's procedure for 
arylation of imidazole.23 Then N-allylation of 41 was attempted (to prepare 42), 
though several products involving bis- and tris-allylated imidazole were 
observed, and difficult to separate. Hence, the picolyl group was added first to 
give 40, followed by allylation to prepare the desired Ar1. Ar1 was purified by 
recrystallisation in MeCN / Et2O in the same manner as H-imidazolium salts. The 
H-imidazolium resonance was absent in 1H NMR spectrum of Ar1, with a ratio of 
imidazolium / picolyl / anisolyl / allyl resonances of 1: 1: 1: 1, indicating the 
successful addition of the 3 desired groups on to the imidazole ring (Figure 3-7). 
The 13C{1H} NMR spectrum shows 6 resonances corresponding to the aromatic 
protons of the anisolyl group, with the ortho- and meta- carbon pairs being 
inequivalent due to asymmetric N-substituents on the imidazolium (Figure 3-8). 
The imidazolium cation formation can also be confirmed using HRMS (m/z 
[Ar1 – Br]+ 306.1617, calculated 306.1606). 
 
 
81 
 
 
Scheme 3-11: Preparation of arylated imidazolium Ar1. 
 
Figure 3-7: 1H NMR spectrum (300 MHz, CDCl3) of Ar1.  
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Figure 3-8: 13C {1H} NMR spectrum (75 MHz, CDCl3) of Ar1. 
To prepare Ar3, 1-methylimidazole was arylated at the C2 position. Reaction 
with picolyl bromide resulted in successful formation of arylated imidazolium Ar3, 
which was characterised using 1H and 13C {1H} NMR spectroscopies and HRMS. 
As with Ar1, the asymmetry of the anisolyl group was observed in the 13C{1H} 
NMR spectrum of Ar3, with 16 carbon peaks being observed in the aromatic 
region (Figure 3-9). 
 
Scheme 3-12: Preparation of Ar3. 
 
 
83 
 
 
Figure 3-9: 13C {1H} NMR spectrum (75 MHz, CDCl3) of Ar3. 
3.3.2 Preparation of other potential deactivated species 
In addition to examining the reductive elimination of the aryl-imidazolium cation, 
other potential side-reactions involving the aryl iodide species have been 
considered. Possible products of these side-reactions include homo-coupled 
biaryl (ArAr) and dehalogenated anisole (ArH). Starting aryl-iodide or a different 
aryl-halide (as a result of reductive elimination) and the desired cross-coupled 
product may also be observed (Scheme 3-13).28-32  
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Scheme 3-13: Potential products from the aryl-iodide in metal-catalysed cross coupling 
reactions. 
To be able to quantify individual products, the arylated species were prepared 
separately so that calibration and quantification could be carried out using 
GC-UV and HPLC-MS. The 4-iodoanisole (ArI) and anisole (ArH) are 
commercially available, with the ether product (ArNu) and the biaryl (ArAr) being 
synthesised. 
The ether product ArNu was prepared using an Ullmann-type etherification 
reaction and a CuI/acac catalyst that derived from iso-butyryl cyclohexanone 
(Scheme 3-14, section 2.7). The pure product was obtained after column 
chromatography as an off-white solid. The product was fully characterised by 1H 
(Figure 3-10) and 13C {1H} NMR spectroscopy and HRMS.  
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Scheme 3-14: Preparation of ArNu. 
 
Figure 3-10: 1H NMR spectrum (300 MHz, CDCl3) of ArNu. 
Similar to the preparation of the ether, the biaryl was prepared by a metal-
catalysed coupling reaction using an organometallic aryl. The ArI was stirred with 
n-BuLi to generate aryl-lithium (ArLi). The organometallic compound was then 
transferred into a reaction mixture of ArI and a Pd catalyst (Scheme 3-15). The 
crude reaction mixture was partitioned in NH4Cl solution and Et2O, and extracted 
by Et2O. Column chromatography (silica gel) was then used to purify the crude 
mixture and the product was obtained in 16 % yield. ArAr was characterised by 
1H and 13C {1H} NMR spectroscopy. However, the product was not observed in 
the HR mass spectrum (ESI) as it is unlikely to be ionised by electron spray. 
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Scheme 3-15: Preparation of ArAr. 
 
Figure 3-11: 1H NMR spectrum (300 MHz, CDCl3) of ArAr. 
3.3.3 Conditions that affect Ullmann-type etherification and 
competing reactions 
In the previous sections, it was observed that aryl-imidazolium Ar1 (derived from 
L1) formed only when using stoichiometric amount of metal and ligand, whereas 
Ar3 (derived from L3) was observed at 10 mol% of the catalyst. In addition to 
quantifying this data, other factors such as nucleophile, base and catalyst 
loadings can also be studied to see how they affect competing reactions. 
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i) Nucleophile equivalents 
The first factor to be examined was equivalents of nucleophile (i.e. 
3,5-dimethylphenol). Ullmann-type etherification reactions were carried out using 
a stoichiometric amount of the in situ formed Cu complex from L1 (Table 3-3). 
The cross-coupled ether product (ArNu), as expected, increased when the 
nucleophile loadings were higher. The aryl-imidazolium (ArIm) formation also 
increased upon increasing amounts of nucleophile, with similar quantities of 
ArNu and ArIm with up to 1.2 equivalents of 3,5-dimethylphenol. This suggests 
that either the nucleophile or the imidazolium could act as supporting ligand with 
the other reductively eliminating under the speculation that the reaction occurs 
via Cu(III) intermediates. It is therefore likely that nucleophile substitution occurs 
prior to oxidation (Scheme 3-16). 
L 
Cu/L 
eq 
3,5-dimethylphenol 
(HNu) eq 
ArI ArNu ArH ArAr ArIm* 
L1 1 
0 69 0 6 0 <1 
0.6 57 7 5 4 8 
1.2 49 13 6 5 18 
2.4 29 32 11 5 12 
L3 0.1 
0 100 0 0 0 <1 
0.6 91 3 0 0 <1 
1.2 47 42 6 5 9 
2.4 70 13 0 0 3 
Table 3-3: % formation of different aryl species. Reaction conditions: 1.0 mmol 4-
iodoanisole, 0 – 2.4 mmol 3,5-dimethylphenol, 1.0 mmol of CuI/HL1Br or 0.1 mmol of 
CuI/HL3Br, 3.0 mmol Cs2CO3, 5 mL MeCN, 90 °C, 24hr. Yields were determined by 
GC using p-cymene as an internal standard. * Yields were determined by HPLC-MS 
spiking. <1 = the species was observed but calculated to be less than 1%. 
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Scheme 3-16: Simplified competing reactions and deactivation pathways 
However, when the equivalents of nucleophile was increased to 2.4, the ArIm 
formation decreased slightly whilst the ArNu formation continued to increase. 
The same trend for ArIm formation was observed in the case of using catalytic 
amount of the in situ formed Cu complex from L3. However, increasing the 
nucleophile equivalents in this case from 1.2 to 2.4, the % conversion to ArNu 
decreased from 42 to 13. This is possibly due to another deactivation pathway 
involving a bis-nucleophile complex (48) formation (Scheme 3-16), which has 
been observed as a resting state in reported Cu-catalysed C-N bond formation 
reactions.33,34  
ii) Base equivalents 
The amount of base, ranging from 0-4 equivalents Cs2CO3, was also examined 
in the reaction (Table 3-4). Increasing the base loading increased formation of 
ArNu, with the optimum appearing to be 3 equivalents for L1, and 2 equivalents 
for L3 (stoichiometric metal). It has previously been reported that increasing the 
base loading can raise the catalytic activity. As previously shown, increasing the 
base equivalents from 2 to 4 was demonstrated to promote the catalytic yield of 
the etherification model using L1 as a ligand from 42 % to 58 %.19 Furthermore, 
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a base is essential for the deprotonation of imidazolium ligand precursor and 
nucleophile (either before or after ligand substitution) (Scheme 3-17). Hence, 
higher base equivalents would give higher conversions to the desired product. 
L 
Cu/L 
eq 
base 
eq 
ArI ArNu ArH ArAr ArIm* 
L1 1 
0 106 10 none none <1 
2** 14 23 9 75 27 
3 none 43 22 9 7 
4 none 44 21 2 <1 
L3 
1 
0 94 8 none none <1 
2 42 50 8 none 3 
3 9 50 15 none 5 
4 none 53 13 none 3 
0.1 
0 96 none none none <1 
2 57 32 6 none <1 
3 45 44 6 none <1 
4 42 53 6 none <1 
Table 3-4: % formation of different aryl species. Reaction conditions: 1.0 mmol 
4-iodoanisole, 1.2 mmol 3,5-dimethylphenol, 1.0 mmol of CuI/HL1Br/HL3Br or 0.1 
mmol of CuI/HL3Br, 0 – 4.0 mmol Cs2CO3, 5 mL MeCN, 90 °C, 24hr. Yields were 
determined by GC using p-cymene as an internal standard. * Yields were determined 
by HPLC-MS spiking. <1 = the species was observed but calculated to be less than 1%. 
** 48% over theoretical mass balance, error in GC calibration at higher concentration. 
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Scheme 3-17: Base-involved etherification and aryl-imidazolium formation, with the 
proposal that both reactions take place via the oxidative addition / reductive elimination 
pathway 
The effect of base equivalents on dehalogenation has been reported in the 
Suzuki coupling of bromo-pyrazole and aryl boronic acid (Scheme 3-18).35,36 It 
was proposed that the side-reaction of dehalogenation is base induced (8, 59 
and 63 % using 2, 3 and 4 equivalents of K2CO3 respectively). The deprotonation 
of pyrazole was implicated in the dehalogenation reaction (Scheme 3-19). It is 
possible that dehalogenation of 4-iodoanisole takes place via similar mechanism 
(Scheme 3-20), though in this case deprotonation is not required so base loading 
should not affect formation. ArH formation was found to increase in the case of 
stoichiometric CuI + imidazolium salt loadings up to 22 % (L1) and 15 % (L3) 
with 3 equivalents of base. The increase of base equivalents may be involved in 
the removal of the iodine atom (as either iodine cation or iodine anion). 
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Scheme 3-18: Suzuki coupling reaction of bromo-pyrazole and aryl boronic acid, and a 
side-reaction of hydrodehalogenation.36 
 
Scheme 3-19: The mechanism of dehalogenation of bromo-pyrazole, proposed by 
Jedinak.36 
 
Scheme 3-20: A proposed mechanism of dehalogenation of 4-iodoanisole. 
Another side-reaction observed was homocoupling (ArAr), which happened only 
in the case of L1 under stoichiometric conditions. It is not clear why L1 leads to 
ArAr formation, though this decreases upon increasing base loading, likely as a 
result of competing reactions such as etherification being able to take place. 
Increasing the Cs2CO3 can drive etherification by providing sufficient amounts of 
nucleophile. A similar observation was reported in the literature in a Pd-catalysed 
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arylation reaction, in which sufficient amount of active nucleophile leads to the 
successful suppression of homocoupling.37 
Upon increasing the base loading, it was found that aryl-imidazolium formation 
decreased particularly in the case of L1 under stoichiometric conditions (27 % 
with 2 equivalent, decreasing to 7 % with 3 equivalents and negligible with 4 
equivalents, Table 3-4). Decrease in ArIm formation is again likely due to the 
competing cross-coupling reaction (ArNu). 
iii) Metal complex loadings 
Metal/ligand loadings were varied, ranging from a catalytic amount (10 %) to an 
excess amount (200 %) (Table 3-5). The homocoupling (ArAr formation) still 
occurred in the case of L1, which was enhanced by higher catalyst loadings 
(> 100 %). It appears that etherification dominates under catalytic conditions, 
reaching its highest efficiency at 0.5 equivalents. However, as the metal/ligand 
loadings are increased further, reductive elimination of ArIm started to occur at 
high metal/ligand loadings due to higher concentration of NHC in the reaction 
system. Similarly, the homocoupling reaction started to occur at high 
metal/ligand loadings as there is a higher chance of aryl transmetallation due to 
more populated metal species, and the amount of nucleophile substrate to the 
metal centre became insufficient. 
In addition, comparing L1 and L3 in ArIm formation, L3 led to the reductive 
elimination of ArIm (Ar3) at lower catalyst loadings (10%), while Ar1 started to 
be discovered at 50% catalyst loadings. This is consistent with the earlier 
observation (section 3.2) that Ar1 was not observed when a catalytic amount of 
catalyst was used, but was detected in the reaction with a stoichiometric amount 
of catalyst.  
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L 
Cu/L 
eq 
ArI Ether ArH Ar-Ar Ar-im* 
L1 
0 94 none none none none** 
0.1 52 42 6 none none** 
0.5 12 61 15 none <1 
1 none 32 19 21 11 
1.5 7 20 18 29 26 
2 17 17 6 56 25 
L3 
0 93 none none none none** 
0.1 45 43 7 none <1 
0.5 10 67 14 none <1 
1 7 36 13 none 4 
1.5 9 37 13 none 5 
2 9 52 16 none 9 
Table 3-5: % formation of different aryl species. Reaction conditions: 1.0 mmol 4-
iodoanisole, 1.2 mmol 3,5-dimethylphenol, 0 – 2.0 mmol of CuI/imidazolium salt', 3.0 
mmol Cs2CO3, 5 mL MeCN, 90 °C, 24hr. Yields were determined by GC using p-
cymene as an internal standard. * Yields were determined by HPLC-MS spiking. **No 
formation was confirmed by HRMS. <1 = the species was observed but calculated to be 
less than 1% 
Overall, ArNu was generally the major product in these reactions, even when 
stoichiometric amounts of metal/ligand were applied. The homocoupled side-
product ArAr was the least formed except when the metal/ligand loadings were 
used in huge excess. Furthermore, the ArIm was not the major side-product, 
even in the presence of stoichiometric metal/ligand. Instead, formation of the 
dehalogenated product (ArH) appeared to be the major deactivation pathway of 
the aryl iodide starting material in the reaction. 
3.4 Conclusions 
A range of picolyl/pyridyl/allyl-bearing NHC ligands have been used to examine 
the competing reactions in an Ullmann-type etherification reaction. Only ligands 
with a picolyl N-substituent afford the aryl-imidazolium side-product, with its 
formation generally increasing ArNu formation. This is likely due to strongly basic 
NHC ligand being able to stabilise higher oxidation state Cu intermediates, with 
reductive elimination of ArNu and ArIm taking place. 
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The results from varying nucleophile, base and metal/ligand concentrations show 
that etherification is favoured by a sufficient amount of nucleophile and 
metal/ligand, and can be promoted with excess base. However, unlike the ArNu, 
the ArIm reductive elimination can be increased by a sufficient amount of 
nucleophile, excess metal/ligand, but minimal base. Furthermore, the higher 
metal/ligand loadings promote other side-reactions, including dehalogenation 
(ArH) and homocoupling (ArAr). 
3.5 Future Work 
The field of Cu-NHC catalysed cross-coupling reactions is still very much in its 
infancy. Cu is more uncontrolled when compared to precious metal such as Pd 
and Rh, hence the outcome of reactions is very difficult to predicet. The more 
knowledge that can be added to understanding the reactivity of Cu the better 
ligand and reaction design will become to enable Cu to be applied more broadly. 
In this specific study, other variables that may contribute to reaction outcome 
include other types of bases (K3PO4, K2CO3 and CsF), type of nucleophiles 
(phenols, anilines, aryl lithiums), ligand:Cu ratios (2:1 versus 1:1), types of 
counter anions and solvents (DMF, DMAc and DMSO). Furthermore, other 
instruments may be adapted and applied to track the reactions in real time. 
3.6 Experimental 
3.6.1 Preparation of imidazole 
i) Preparation of P38 
2-Bromo-5-nitropyridine (2.0 g, 9.8 mmol) and imidazolyl 
sodium (0.99 g, 11 mmol) were added to a Schlenk flask. 
DMF (40 mL) was transferred into the flask via syringe 
resulting in a dark red-orange mixture. The mixture was stirred at room 
temperature for 3 hours. Water (150 mL) was added resulting in precipitation of 
the product, which was collected as light orange-brown solid by filtration and 
washed with water (3 × 25 mL). The solid was dissolved in hot MeCN (100 mL), 
filtered and dried over Na2SO4. The solvent was removed in vacuo to give a 
brown solid. Yield: 1.35 g, 0.71 mmol, 72%. 
1H NMR (300 MHz, CDCl3) δ (ppm) 9.33 (d, J = 2.7 Hz, 1H, pyH-6), 8.63 (dd, J 
= 8.9, 2.7 Hz, 1H, pyH-4), 8.46 (s, 1H, imH), 7.70 (s, 1H, imH), 7.50 (d, J = 8.9 
Hz, 1H, pyH-3), 7.26 (s, 1H, imH). 13C {1H} NMR (75 MHz, CDCl3) δ (ppm) 152.2 
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(C), 145.7 (CH), 142.3 (C), 135.6 (CH), 134.7 (CH), 132.1 (CH), 116.2 (CH), 
111.5 (CH). HRMS (ESI+): m/z 191.0640 [M + H]+, calculated [M + H]+ 191.0564. 
 Consistent with data previously reported.38 
ii) Preparation of P1 
In air, imidazole (0.27 g, 3.95 mmol) and KOH (0.89 g, 15.8 
mmol) were added to a round-bottomed flask, followed by 
THF (20 mL) and stirred for 20 minutes at room temperature. 
2-(bromomethyl)pyridine.HBr (1.0 g, 3.95 mmol) was added and stirred at 60 °C 
for 48 hours. The mixture was allowed to cool to room temperature and the 
solvent removed in vacuo. The crude mixture was partitioned in DCM (100 mL) 
and water (100 mL). The water layer was extracted with DCM (2 × 100 mL). The 
organic layers were combined, washed with brine (100 mL), dried with Na2SO4 
and solvent removed in vacuo. The dark oil was dissolved and sonicated in Et2O 
(50 mL), filtered, and the solvent removed in vacuo to obtain a dark orange oil. 
Yield: 0.54 g, 3.40 mmol, 86%. 
1H NMR (300 MHz, CDCl3) δ (ppm) 8.55 (ddd, J = 4.9, 1.7, 0.8 Hz, 1H, pyH-6), 
7.62 (td, J = 7.7, 1.8 Hz, 1H, pyH-4), 7.57 (s, 1H, imH-2), 7.22 – 7.16 (m, 1H, 
pyH-5), 7.07 (s, 1H, imH), 6.95 (s, 1H, imH), 6.91 (d, J = 7.8 Hz, 1H, pyH-3), 5.21 
(s, 2H, NCH2-py). 13C {1H} NMR (75 MHz, CDCl3) δ (ppm) 156.1 (C), 149.7 (CH), 
137.6 (CH), 137.3 (CH), 129.8 (CH), 123.0 (CH), 121.2 (CH), 119.5 (CH), 52.5 
(CH2). HRMS (ESI+): m/z 160.0881 [M + H]+, calculated [M + H]+ 160.0869. 
Consistent with data previously reported.39,40 
3.6.2 Preparation of imidazolium salts 
i) Preparation of HL38Br 
In air, P38 (1.0 g, 5.25 mmol) was added to a 
round-bottom flask followed by MeCN (150 mL). 
The mixture was heated to 80 °C to fully dissolve 
P38. Allyl bromide (2.3 mL, 26 mmol) was added 
dropwise to the solution and the mixture was heated to 80 °C and held at reflux 
for 24 hours. The volume was reduced to ca. 30 mL in vacuo. Slow addition of 
Et2O (150 mL) induced the precipitation of a light brown solid, which was filtered 
and dried in air. Yield: 1.52 g, 4.89 mmol, 93 %. 
1H NMR (300 MHz, CDCl3) δ (ppm) 12.28 (dd, J = 1.8, 1.6 Hz, 1H, imH-2), 9.29 
(dd, J = 2.6, 0.6 Hz, 1H, pyH-6), 9.07 (dd, J = 9.0, 0.6 Hz, 1H, pyH-3), 8.79 (dd, 
J = 9.0, 2.6 Hz, 1H, pyH-4), 8.33 (dd, J = 2.1, 1.8 Hz, 1H, imH), 7.37 (dd, J = 2.1, 
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1.6 Hz, 1H, imH), 6.08 (ddt, J = 16.7, 10.1, 6.6 Hz, 1H, CH=CH2), 5.55 (m, 2H, 
CH=CH2), 5.15 (d, J = 6.6 Hz, 2H, NCH2-vinyl). 13C {1H} NMR (75 MHz, CDCl3) 
δ (ppm) 148.9 (C), 144.9 (CH), 144.6 (C), 137.6 (CH), 128.9 (CH), 124.2 (CH), 
122.1 (CH2), 119.2 (CH), 116.3 (CH), 53.1 (CH2). HRMS (ESI+): m/z 231.0882 
[M - Br]+, calculated [M - Br]+ 231.0882. 
Consistent with data previously reported.22 
3.6.3 Preparation of arylated imidazoles/imidazoliums 
i) Arylation of 1-allylimidazole, synthesis of 39 
4-Iodoanisole (0.27 g, 1.16 mmol), Pd(OAc)2 
(0.010 g, 0.046 mmol) and CuI (0.35 g, 1.85 
mmol) were added to a Schlenk flask. DMF 
(5 mL) was added, followed by 1-allylimidazole 
(0.10 mL, 0.92 mmol). The reaction mixture was stirred at 140 °C for 48 hours, 
cooled to room temperature, diluted in EtOAc (30 mL), and poured into a 
saturated solution of NH4Cl (100 mL) and stirred for 30 mins. The organic layer 
was separated, and the aqueous layer was extracted with EtOAc (5 × 30 mL). 
All organic layers were combined, dried with MgSO4 and the solvent removed in 
vacuo. The crude brown product was purified with fractional column 
chromatography, eluting with EtOAc / petroleum ether (40-60 °) / methanol (45: 
45: 10). The pure product was obtained as a pale brown solid. Yield: 0.42 g, 0.20 
mmol, 21%. 
1H NMR (500 MHz, CDCl3) δ (ppm) 7.54 (s, 1H, imH-2), 7.30 (d, J = 8.8 Hz, 2H, 
ArH), 7.09 (s, 1H, imH), 6.96 (s, 1H, imH), 6.86 (d, J = 8.8 Hz, 2H, ArH), 6.49 (dt, 
J = 15.8, 1.2 Hz, 1H, CH=CHAr), 6.14 (dt, J = 15.8, 6.3 Hz, 1H, CH=CHAr), 4.68 
(dd, J = 6.3, 1.2 Hz, 2H, NCH2-vinyl), 3.81 (s, 3H, OCH3). 13C {1H} NMR (126 
MHz, CDCl3) δ (ppm) 159.8 (CH), 137.1 (CH), 133.3 (CH), 129.6 (CH), 128.5 
(C), 127.9 (CH), 127.0 (C), 121.3 (CH), 119.0 (CH), 114.2 (CH), 114.1 (CH), 
55.33 (CH2), 49.1 (CH3). HRMS (ESI+): m/z 215.1184 [M + H]+, calculated [M + 
H]+ 215.1179. 
ii) Preparation of 40 via C-2 arylation of P1 
4-Iodoanisole (0.38 g, 1.25 mmol), Pd(OAc)2 (0.010 g, 0.046 mmol) and CuI 
(0.49 g, 2.57 mmol) were added to a Schlenk flask. DMF (5 mL) was added, 
followed by P1 (0.20g, 1.25 mmol) and the mixture was stirred at 140 °C under 
Ar for 24 hours. The mixture was allowed to cool to room temperature, 
transferred into EtOAc (100 mL) and stirred with a saturated solution of EDTA / 
NH4Cl (100 mL) for 1 hour. The organic layer was collected, and the aqueous 
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layer was extracted with EtOAc (3 × 50 mL). The organic layers were combined 
and volume reduced to 50 mL in vacuo, washed with water (3 × 50 mL) and back-
extracted into EtOAc (3 × 100 mL). The product was purified by fractional column 
chromatography eluting with DCM / methanol (95: 5) to obtain a brown sticky 
solid. Yield: 0.005 g, 0.018 mmol, 1.4 %. 
HRMS (ESI+): m/z 266.1290 [M + H]+, calculated [M + H]+ 266.1288. 1H and 13C 
{1H} NMR spectroscopies were performed later when 40 was synthesised with 
an alternative route. 
iii) Preparation of 41 
Imidazole (0.20 g, 2.94 mmol), 4-iodoanisole (0.86 g, 3.7 mmol), 
Pd(OAc)2 (0.033 g, 0.15 mmol) and CuI (1.12 g, 5.88 mmol) were 
added to a Schlenk flask. DMF (5 mL) was added and the mixture 
stirred at 140 °C under Ar for 48 hours. After cooling to room 
temperature to room temperature, the mixture was poured into EtOAc 
(30 mL) and stirred with a saturated solution of EtOAc / NH4Cl (100 
mL) for 30 minutes. The organic layer was collected, while the 
aqueous layer was extracted with EtOAc (5 × 50 mL). All organic layers were 
combined, dried with MgSO4 and the solvent removed in vacuo. The crude brown 
sticky solid was purified by fractional column chromatography eluting with DCM 
/ methanol (95: 5) to obtain a dark orange sticky solid. Yield: 0.49 g, 2.81 mmol, 
95%. 
1H NMR (300 MHz, CDCl3) δ 7.81 – 7.74 (m, 2H, ArH), 7.10 (s, 2H, imH), 6.93 – 
6.86 (m, 2H, ArH), 3.81 (s, 3H, OCH3). 13C NMR (75 MHz, CDCl3) δ 160.8 (C), 
146.5 (C), 127.4 (CH), 121.7 (C). 120.8 (CH), 114.5 (CH), 55.4 (CH3). HRMS 
(ESI+): m/z 175.0864 [M + H]+, calculated [M + H]+ 175.0866. 
Consistent with data previously reported.41 
iv) Attempted preparation of 42 
NaH (15 mg, 0.63 mmol) and 41 (0.10 g, 0.57 mmol) were added to an ampoule. 
The mixture was cooled to 0 ºC, then THF (3 mL), also cooled to 0 °C, was added 
via syringe and the reaction mixture was stirred for 1 hour. Allyl bromide (60 μL, 
0.69 mmol) was added and the reaction mixture was heated to 65 ºC and stirred 
for 4 hours. The mixture was allowed to cool to room temperature, DCM (50 mL) 
was added to dilute and washed by water (3 × 50 mL). The organic layer was 
dried with Na2SO4 and the solvents removed in vacuo. Several allylated species 
were observed in the HR mass spectrum, including tris-allylated and tetrakis-
allylated species. 
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v) Preparation of 40 via 41 
In air, 41 (0.1 g, 0.5 mmol) was dissolved in THF (20 mL). 
KOH (0.129 g, 2.3 mmol) and 2-(bromomethyl)pyridine.HBr 
(0.145 g, 0.5 mmol) were added and the reaction stirred at 
60 °C for 48 hours. The mixture was allowed to cool to room 
temperature and the solvent was removed in vacuo. The 
crude mixture was partitioned in water (50 mL) and DCM (50 
mL), with the aqueous layer being extracted by DCM (3 x 50 
mL). The combined organic layers were dried with MgSO4 and solvent removed 
in vacuo. The crude product was purified by fractional column chromatography 
eluting with EtOAc / petroleum ether (40 – 60 °) (4: 1). The final product was 
obtained as pale brown sticky solid. Yield: 0.050 g, 0.19 mmol, 33%. 
1H NMR (300 MHz, CDCl3) δ (ppm) 8.53 (d, J = 4.4 Hz, 1H, pyH-6), 7.58 (t, J = 
7.7 Hz, 1H, pyH-4), 7.42 (d, J = 8.5 Hz, 2H, ArH), 7.21 – 7.12 (m, 1H, pyH-5), 
7.11 (s, 1H, imH), 6.96 (s, 1H, imH), 6.84 (d, J = 8.5 Hz, 2H, ArH), 6.81 (d, J = 
7.7 Hz, 1H, pyH-3), 5.24 (s, 2H, NCH2-py), 3.74 (s, 3H, OCH3). 13C {1H} NMR 
(75 MHz, CDCl3) δ (ppm) 159.1 (C), 156.0 (C), 148.8 (CH), 147.3 (C), 136.2 
(CH), 129.1 (CH), 128.0 (CH), 121.8 (CH), 120.1 (CH), 120.0 (CH), 119.8 (CH), 
113.0 (CH), 54.3 (CH3), 51.1 (CH2). HRMS (ESI+): m/z 266.1297 [M + H]+, 
calculated [M + H]+ 266.1288. 
vi) Preparation of Ar1 
In air, 40 (50 mg, 0.19 mmol) was dissolved in MeCN (10 
mL) and allyl bromide (0.2 mL, 2.3 mmol) was added. 
The reaction solution was stirred at 80 ºC for 24 hours. 
The mixture was allowed to cool to room temperature 
and the solvent volume was reduced to 1 mL in vacuo. 
Et2O (50 mL) was added to precipitate a light brown 
solid, which was recrystallised in MeCN / Et2O. Yield: 
41.4 mg, 0.11 mmol, 57 %. 
1H NMR (300 MHz, CDCl3) δ (ppm) 8.59 (d, J = 4.4 Hz, 1H, pyH-6), 8.00 (t, J = 
7.7 Hz, 1H, pyH-4), 7.92 (d, J = 7.7 Hz, 1H, pyH-3), 7.91 (s, 1H, imH), 7.77 (d, J 
= 8.2 Hz, 2H, ArH), 7.59 (s, 1H, imH), 7.50 (dd, J = 7.7, 4.4 Hz, 1H, pyH-5), 7.06 
(d, J = 8.2 Hz, 2H, ArH), 5.97 (ddt, J = 16.6, 10.3, 5.7 Hz, 1H, CH=CH2), 5.82 (s, 
2H, NCH2-py), 5.39 (d, J = 10.3 Hz, 1H, CH=CH2 trans), 5.31 (d, J = 16.6 Hz, 
1H, CH=CH2 cis), 4.71 (d, J = 5.7 Hz, 2H, NCH2-vinyl), 3.87 (s, 3H, OCH3). 13C 
{1H} NMR (75 MHz, CDCl3) δ (ppm) 163.0 (C), 151.0 (CH), 147.4 (C), 147.0 (CH), 
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146.0 (C), 141.1 (CH), 140.6 (CH), 139.8 (CH), 132.7 (CH), 130.1 (CH), 124.9 
(CH), 123.4 (CH), 122.2 (CH), 121.6 (CH2), 115.4 (CH), 111.8 (CH), 55.7 (CH3), 
51.8 (CH2), 51.6 (CH2). HRMS (ESI+): m/z 306.1617 [M - Br]+, calculated [M - 
Br]+ 306.1601. 
vii) Preparation of 43 
4-Iodoanisole (1.06 g, 4.52 mmol), Pd(OAc)2 (42 mg, 0.19 mmol) and 
CuI (1.43 g, 7.53 mmol) were added to a Schlenk flask. Anhydrous 
DMF (3 mL) and 1-methyl imidazole (0.3 mL, 3.76 mmol) were added 
via syringe. The reaction mixture was stirred at 140 ºC under N2 for 
24 hours. The resulting mixture was diluted in EtOAc and stirred with 
an aqueous solution of EDTA / NH4Cl (100 mL) for 1 hour. The 
organic layer was collected, while the aqueous layer was extracted with ethyl 
acetate (3 × 50 mL). The organic layers were combined and the solvent removed 
in vacuo. The crude product was purified using fractional column 
chromatography eluting with DCM / methanol (96: 4) to give a brown oil. Yield: 
0.15 g, 0.80 mmol, 21%. 
1H NMR (300 MHz, CDCl3) δ (ppm) 7.53 (d, J = 8.5 Hz, 2H, ArH), 7.07 (s, 1H, 
imH), 6.99 – 6.88 (m, 3H, ArH and imH), 3.80 (s, 3H, CH3), 3.70 (s, 3H, CH3). 
13C {1H} NMR (75 MHz, CDCl3) δ (ppm) 159.9 (C), 130.4 (CH), 130.0 (CH), 123.1 
(CH), 122.0 (CH), 113.9 (CH), 55.3 (CH3), 34.4 (CH3). HRMS (ESI+): m/z 
189.1020 [M + H]+, calculated [M + H]+ 189.1022. 
Consistent with data previously reported.24,42 
viii) Preparation of Ar3 
43 (0.020 g, 0.11 mmol) was dissolved in MeCN (20 mL). 
K2CO3 (0.0073 g, 0.053 mmol) and 2-(bromomethyl) 
pyridine.HBr (0.026 g, 0.11 mmol) were added and the 
reaction mixture was stirred at 75 ºC for 24 hours. The 
mixture was allowed to cool to room temperature and 
filtered. The filtrate volume was reduced to about 2 mL 
in vacuo and Et2O (50 mL) was added to precipitate a 
brown solid. The crude solid was recrystallised in MeCN 
/ Et2O and DCM / Et2O to give a brown solid. Yield: 0.0309 g, 0.086 mmol, 81 %. 
1H NMR (300 MHz, CDCl3) δ (ppm) 8.45 (d, J = 4.3 Hz, 1H, pyH-6), 7.90 (s, 1H, 
imH), 7.73 (s, 1H, imH), 7.66 (t, J = 7.7 Hz, 1H, pH-4), 7.62 (d, J = 8.8 Hz, 2H, 
ArH), 7.45 (d, J = 7.7 Hz, 1H, pyH-3), 7.21 (dd, J = 7.7, 4.3 Hz, 1H, pyH-5), 7.03 
(d, J = 8.8 Hz, 2H. ArH), 5.45 (s, 2H, NCH2-py), 3.84 (s, 3H, CH3), 3.83 (s, 3H, 
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CH3). 13C {1H} NMR (75 MHz, CDCl3) δ (ppm) 162.8 (C), 152.8 (C), 149.9 (CH), 
137.4 (C), 132.4 (CH), 130.9 (C), 123.7 (CH), 123.6 (CH), 123.2 (CH), 122.8 
(CH), 116.5 (CH), 115.3 (CH), 112.2 (CH), 55.7 (CH3), 53.2 (CH2), 36.6 (CH3). 
HRMS (ESI+): m/z 280.1451 [M - Br]+, calculated [M - Br]+ 280.1444. 
3.6.4 Preparation of other aryl species 
i) Preparation of 4-(3,5-dimethylphenoxy)anisole (ArNu) 
4-Iodoanisole (1.6 g, 6.8 mmol), 3,5-dimethylphenol 
(1.0 g, 8.1 mmol), CuI (0.26 g, 1.4 mmol), isobutyryl 
cyclohexanone (0.22 mL, 1.4 mmol) and Cs2CO3 (6.6 
g, 20 mmol) were added to an ampoule. MeCN (5 mL) 
was added and the reaction mixture stirred at 90 °C for 24 hours under Ar. The 
crude mixture was diluted in DCM (50 mL), filtered through Celite and washed 
with EDTA solution (3 × 50 mL), water (3 × 50) and dried with MgSO4. The crude 
product was purified by fractional column chromatography (silica gel), eluting 
with ethyl acetate / hexane (1:20). The product was obtained as an off-white 
solid. Yield: 0.12 g, 0.53 mmol, 25%. 
1H NMR (300 MHz, CDCl3) δ (ppm) 7.00 – 6.94 (m, 2H, ArH), 6.91 – 6.85 (m, 
2H, ArH), 6.69 (t, J = 0.5 Hz, 1H, ArH), 6.56 (d, J = 0.5 Hz, 2H, ArH), 3.81 (s, 3H, 
OCH3), 2.27 (s, 6H, CH3). 13C {1H} NMR (75 MHz, CDCl3) δ (ppm) 158.6 (C), 
155.9 (C), 150.4 (C), 139.6 (C), 124.3 (CH), 120.9 (CH), 115.4 (CH), 114.9 (CH), 
55.8 (CH3), 21.4 (CH3). HRMS (ESI+): m/z 229.1223 [M + H]+, calculated [M + 
H]+ 229.1223. 
ii) Preparation of Bianisolyl (ArAr) 
4-iodoanisole (0.30 g, 1.3 mmol) was added to an 
ampoule. THF (3 mL) was added and the solution cooled 
to - 78 °C under Ar. n-BuLi (1.4 mL, 1.2 M, 1.7 mmol) 
was added dropwise into the stirring solution and stirred 
at - 78°C for 30 minutes. In another ampoule, 
4-iodoanisole (0.20 g, 0.85 mmol) and bis(tri-(t-butyl)-
phosphine)Pd(0) (22 mg, 0.043 mmol) were added, followed by toluene (5 mL). 
The first solution was allowed to warm to room temperature then transferred to 
the Pd mixture dropwise via syringe. The reaction mixture was stirred at room 
temperature for 3 hours. A saturated solution of NH4Cl (30 mL) was added and 
then extracted with Et2O (3 × 50 mL). The crude product was purified by fractional 
column chromatography (silica gel), eluting with ethyl acetate / hexane (1:9). 
Yield: 0.03 g, 0.1 mmol, 16%. 
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1H NMR (300 MHz, CDCl3) δ (ppm) 7.44 – 7.37 (m, 4H, ArH), 6.92 – 6.86 (m, 
4H, ArH), 3.77 (s, 6H, OCH3). 13C {1H} NMR (75 MHz, CDCl3) δ (ppm) 158.7 (C), 
133.5 (CH), 127.7 (C), 114.2 (CH), 55.4 (CH3).  
Consistent with data previously reported.43 
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Chapter 4  
Selective Arylation of Xanthine-Derived Imidazolium Salts 
4.1 Introduction 
Following the deactivation of Cu-NHC catalysts via the reductive elimination of a 
C-2 arylated imidazolium ion (Chapter 3), we were keen to examine if the 
reaction could be exploited to develop the selective arylation of natural 
compounds such as xanthine, guanine and adenine (Figure 4-1). These 
compounds have an imidazole ring incorporated into their structures and may 
potentially be functionalised via a Cu-NHC complex. The Cu-mediated reaction 
would replace multiple-step organic synthetic methods, which involve formation 
of imidazoles via condensation reactions instead of functionalisation of an 
imidazole ring (Scheme 4-1).1-4 Furthermore, the modified arylated products will 
be fluorescent,5 allowing a method to detect xanthine-derived compounds in 
biology (e.g. DNA bases) if the synthetic methods could be extended to these 
systems. 
 
Figure 4-1: Structure of imidazole and purine-based compounds. 
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Scheme 4-1: Preparation of C-8 functionalised xanthine derivative via condensation 
reactions to form an imidazole ring.3 
Understanding the methodology for selective functionalisation of such 
heterocycles under mild conditions may enable selective modification of natural 
compounds such as DNA strands, which comprise adenine and guanine groups 
(i.e. xanthine derivatives). The ability to selectively arylate adenine and guanine 
could be very powerful and may lead to the ability to alternatively distinguish 
between pyrimidine- and purine-derived bases in nucleic acid strands by 
fluorescence (Figure 4-2).6 
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Figure 4-2: Purine and pyrimidine nucleobases. 
Many approaches to the selective arylation of imidazole and its derivatives have 
been developed and studied. In 1998, Nomura showed that 1-methylimidazole 
can be selectively functionalised at either the C-2 or the C-5 position using 
different metal catalysts.7 In the presence of a catalytic amount of Pd, the 
coupling reaction between phenyl iodide and 1-methylimidazole led to the 
formation of I and II (Scheme 4-2A). However, there was no formation of I when 
an excess amount of Cu and catalytic amount of Pd were used in the reaction. 
Instead, III was formed along with II (Scheme 4-2B). Furthermore, with an excess 
amount of Cu but in the absence of Pd, the coupling reaction led to the formation 
of III only (Scheme 4-2C). Similarly, 2-aryl imidazole can be prepared when an 
excess amount of CuI is used with Pd or Co as a co-catalyst. Application of Cu 
and a Pd co-catalyst was essential for the formation of the reductively eliminated 
aryl-imidazolium side-product in the etherification reaction (Chapter 3). 
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Scheme 4-2 Arylation of 1-methylimidazole in the presence of different amounts of 
metals.7 
The regioselectivity of the Pd-catalysed reaction shows the same preference as 
observed in electrophilic substitution.8 Therefore, it is possible that the Pd(II) 
intermediate, resulting from oxidative addition of aryl iodide to Pd(0), may act as 
an electrophile towards imidazole species (Scheme 4-3).9 
 
Scheme 4-3 Modified proposed mechanism for the Pd-catalysed arylation of 
1-methylimidazole.7 
However, when Cu is present, the arylation occurs at the C-2 position 
instead.7,10,11 It was thought that the reaction involved deprotonation at the C-2 
position, which is the most acidic proton.8 The necessity of Cu was later 
explained by the reaction possibly occurring via the formation of a Cu(I)-NHC 
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complex.12 Cu(I)-NHC complexes have been observed to react with aryl iodide 
to give aryl-imidazolium salts (Scheme 4-4). The oxidative addition of imidazole 
to Cu(I) and proton migration, leading to formation of a Cu(I)-NHC intermediate, 
is possibly a key factor in the C-2 selectivity of imidazole arylation (Scheme 4-5). 
 
Scheme 4-4 Arylation of Cu-NHC complexes.12 
 
Scheme 4-5 Suggested mechanism of Cu-mediated arylation of imidazole in the 
absence and presence of Pd.12 
This chapter focuses on the arylation of xanthine-derived imidazolium salts. The 
key factors for the reaction are examined and discussed, such as activation of 
the C-H bond of the imidazolium salts, necessity of Cu and optimisation of 
reaction conditions. Kinetics of the arylation of Cu-NHCs were studied and 
compared to theoretical computational data. 
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4.2 Preparation of xanthine-derived copper-N-heterocyclic 
carbene) complexes 
Previously, our group have utilised natural xanthines to prepare imidazolium 
salts, Ag-NHC and Cu-NHC complexes. The Ag-NHC complexes were screened 
for anticancer properties,13 and the Cu-NHC complexes were examined as 
anticancer agents and as catalysts in the etherification reaction (discussed in 
Chapter 2). The Cu complexes were observed to be stable in air, which is highly 
unusual for Cu(I)-NHCs with non-bulky N-substituents (methyl groups in this 
case). These complexes gave negligible catalytic activity (3 % conversion, 
Scheme 4-6), similar to CuI in the absence of a ligand (5 %).13 
 
Scheme 4-6: Etherification reaction attempted using xanthine-derived NHCs. 
Within this study, it became evident that a major by-product of the reactions was 
C-2 arylated imidazolium compounds, hence the C-2 arylation was investigated 
further using ligands with different N-substituents. Fairlamb and coworkers 
proposed that the C-2 selective arylation of imidazole where excess amount of 
CuI is required for the C-H activation (Scheme 4-5).12 The reaction is thought to 
proceed via a Cu-NHC complex with the proton N-substituent as a resting state 
prior to oxidative addition of aryl iodide and reductive elimination of C-2 aryl 
imidazole. A methyl group is the smallest carbon substituent and most 
comparable to the proton N-substituent, hence was used in this study. 
Theophylline (44) was reacted with one equivalent of 1-bromobutane under basic 
conditions to afford P45 in 69% yield (Scheme 4-7). Methylation of P45 and 
caffeine (P46) to form imidazolium salts HL45I and HL46I were carried out using 
methyl iodide. 
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Scheme 4-7: Preparation of P45, HL45I and HL46I. 
As discussed in Chapter 1, imidazolium salts are used as NHC ligand precursors 
through deprotonation at the C-2 position, or C-H bond activation by either 
oxidative addition to a metal centre or reduction by electrolysis. An 
electrochemical method developed in our laboratory14,15 was used to prepare Cu-
NHCs C45 and C46 using Cu electrodes in MeCN (Scheme 4-8). MeCN is 
generally used as the solvent for the electrochemical method as it can stabilise 
free Cu(I) ions which are generated at the anode prior to NHC coordination. 
Reduction of the imidazolium to form a free NHC is a result of the other half-
reaction occurring at the cathode. A potential was applied to maintain a constant 
current of 30 mA throughout the reaction. The theoretical time was calculated 
from the equation (t =  
n ×mol ×F
I
), where n = 1, as 0.47 hours for the preparation 
of C45 (0.53 mmol) and 2.26 hours for the preparation of C46 (2.54 mmol). 
However, as it has previously been found in the group that the reactions do not 
operate at 100% faradaic efficiency, the actual times were doubled. C45 was 
isolated in 77 % yield (36 % faradaic efficiency) and C46 was isolated in 69 % 
yield (31 % faradaic efficiency). 
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Scheme 4-8: Preparation of C45 and C46 via an electrochemical method. 
Formation of both C45 and C46 was confirmed using 1H NMR spectroscopy 
(300 MHz, d6-DMSO) by the absence of the imidazolium NCHN resonance 
(δ 8.7 – 9.0 ppm). However, the high resolution mass spectra did not show any 
Cu-related species and only the corresponding imidazolium ions were observed, 
hence MS appears to be unsuitable for monitoring these complexes. C45 is more 
soluble in MeCN than C46, with both being more soluble in MeCN at higher 
temperature (75 °C). In addition, both complexes are completely soluble in 
dipolar aprotic solvents (DMF and DMSO) and poorly soluble in non-polar 
solvents (toluene, hexane). 
4.3 Arylation of xanthine-derived copper-N-heterocyclic 
carbene) complexes 
C45 and C46 were reacted with 4-iodoanisole to examine the formation of 
aryl-imidazoliums. Heating C45 and C46 with excess 4-iodoanisole (5 
equivalents) in DMF at 140 °C under N2 afforded novel aryl-imidazolium Ar45 
and Ar46 respectively (Scheme 4-9). EtOAc was added to the reaction mixture, 
which precipitated the product. Ar46 was found to be pure by 1H (Figure 4-3) and 
 
 
111 
 
13C {1H} NMR spectroscopy, HRMS, elemental analysis and IR spectroscopy. 
Ar45 was characterised by 1H NMR spectroscopy and HRMS. 
 
Scheme 4-9: Arylation of C45 and C46. 
 
Figure 4-3: 1H NMR (300 MHz, CD3CN) of Ar46. 
The complete conversion of C46 to Ar46 was successful at 140 °C, though our 
ultimate goal is to arylate natural compounds such as nucleobases, with these 
reaction conditions being too harsh and would result in deformation of DNA 
strands. Therefore, lower reaction temperatures (90 – 32 °C) were investigated. 
It should be noted that in some cases, C46 and Ar46 were isolated as a mixture 
as they are not possible to separate (by addition of EtOAc to DMF or 
recrystallisation in MeCN / Et2O). Hence, % net yield was calculated based on 
the % of product in the recrystallised mixture (according to 1H NMR analysis, 
Figure 4-4) and the total mass of the recrystallised mixture. At 90 °C, >99 % 
purity and 55 % net yield of Ar46 was observed in DMF, whereas only 50 % 
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purity and 23 % net yield was observed in MeCN, with no reaction taking place 
in toluene (Table 4-1). The yield appears to correlate with the solubility of C46, 
which fully dissolved in DMF, partly dissolved in MeCN and did not dissolve in 
toluene. 
 
Figure 4-4: 1H NMR spectrum (300 MHz, CD3CN) of a mixture of Ar46 and C46 from 
the reaction of C46 and 4-iodoanisole in MeCN at 90 °C (entry3) 
entry Cu-NHC solvent T / °C 
time 
/ hr 
Ar45 or Ar46 
(% purity)* 
Ar45 or Ar46 
(% net yield)** 
1 C46 DMF 140 24 >99 80 
2 C46 DMF 90 24 >99 55 
3 C46 MeCN 90 24 50 23 
4 C46 toluene 90 24 0 0 
5 C46 DMF 32 24 10 6 
6 C46 DMF 35 366 75 14 
7 C45 DMF 140 24 >99 60 
Table 4-1: Results of the arylation of C45 and C46 to afford Ar45 and Ar46 under 
different reaction conditions. *calculated from average integration in 1H NMR 
resonances: Ar46 δ 7.62, 7.28, 3.96, 3.94, 3.87, 3.81, 3.40 ppm, C46 δ 4.17, 4.07, 3.73, 
3.31. **based on mass and % purity of the recrystallised product 
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The reaction was also observed to occur at low temperature (32 °C, 6 % net yield 
after 24 h), hence was followed for a longer period of time. It was found that after 
heating at 35 °C for 2 weeks, the % purity of the recrystallised product increases 
to 75 % but the yield was very low (14 %). The low isolated yield is likely due to 
decomposition of C46 during the reaction over a prolonged period, which would 
result in relatively high Ar46 ratio in the isolated mixture (75 %) but low % mass 
recovery. 
In addition to C46 and Ar46, another product with m/z = 252.1460 was observed 
in the HR mass spectra of entries 1, 2, 5 and 6, where the reaction was performed 
in DMF. The mass of the side-product corroborates with dimethylamino-
imidazolium 47 (Scheme 4-10), which is a result of the DMF becoming involved 
in the reaction (calculated m/z = 252.1455). However, this side-product was not 
observed in any 1H NMR spectra, indicating that 47 was formed in very low 
amounts which could not be detected by 1H NMR spectroscopy. Therefore, the 
formation of the amino side-product was not considered a factor that contributed 
to the low isolated yield. 
 
Scheme 4-10: Amination of C46 in DMF. 
Reaction of C46 with DMF was further examined in the absence of aryl iodide. 
C46 (0.075 mmol) was heated in anhydrous, degassed DMF (3 mL) for 196 hours 
(Scheme 4-11), resulting in a mixture of HL46Y, C46 and 47, with a ratio of 2:2:1, 
determined by 1H NMR spectroscopy. In addition to acting as a source of 
dimethylamino group, the DMF may also act as a proton source to form HL46Y. 
 
Scheme 4-11: Reaction of C46 with DMF in the absence of ArI. 
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The formation of amino-imidazolium occurs at 100 °C and even as low as 35 °C 
in the arylation reaction mixture, while the DMF thermal decomposition to carbon 
monoxide and dimethylamine normally occurs at high temperature (350 °C).16 
Hence, the DMF possibly oxidatively adds to the Cu centre of C46 either through 
Ccarbonyl-N or Ccarbonyl-H bonds (Scheme 4-12). H-migration or amino migration 
would then form [Cu(NHC)(CO)(NMe2)H]+ with reductive elimination resulting in 
47 or HL46. Ccarbonyl-N bond activation using a Ni catalyst has recently been 
observed.17,18 Amide, despite being considered an inert substrate due to 
resonance stabilisation,19 can be used as an acyl building block upon C-N bond 
cleavage. In addition, DMF has been used as a cheap CO source in Pd-catalysed 
reactions.20,21 The reactions can be carried out under relatively mild conditions, 
hence DMF Ccarbonyl-N bond oxidative addition is more likely to take place than 
the Ccarbonyl-H bond. 
 
Scheme 4-12: Proposed mechanism of DMF amination of C46. 
Further studies into the arylation of C46 were carried out using PhCN as a 
solvent, which has a high boiling point (191 °C) but is easily removed in vacuo. 
C46 was heated at 120 °C with 4-iodoanisole in PhCN for 12 hours, at which 
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time the [HL46]+ fragment of C46 was no longer observed in the HR mass 
spectrum. The solvent and 4-iodoansiole were removed in vacuo for 2 hours to 
afford a crude product. The 1H NMR spectrum (300 MHz, d6-DMSO) of the 
collected product showed a mixture of Ar46 and a second product. The crude 
mixture was purified by recrystallisation from MeCN/Et2O, with the precipitate 
being identified as pure Ar46 (63 % yield). The solvent of the filtrate was 
removed in vacuo and the solid was characterised by 1H and 13C {1H} NMR 
spectroscopy and HR mass spectrometry. The solid was found to be the novel 
demethylated imidazole compound 48 (37 % yield) (Scheme 4-13). 
 
Scheme 4-13: Arylation of C46 in PhCN at 120 °C. 
The N-demethylation reaction was further investigated on an NMR scale (0.05 
mmol). Ar46 was heated in CD3CN at 110 °C, which showed 9 % conversion to 
48 after 20 hours. Following further heating at 110 °C, the reaction reached 20 
% conversion after 38 hours and 60 % conversion after 97 hours. Furthermore, 
in the presence of 1 and 2 equivalents of 4-iodoanisole, Ar46 was heated at 
110 °C giving the same result as in the absence of 4-iodoanisole, suggesting that 
4-iodoanisole has no effect on the demethylation reaction. To examine if the 
presence of Cu affects the reaction, HL46I was heated at 110 °C in the presence 
and absence of CuI. In each case, demethylation was observed. Another factor 
to consider is the iodide counter ion, which was examined by heating HL46PF6 
under the same conditions. The demethylation was not observed in this case, 
therefore it is proposed that the iodide ion is essential as a nucleophile on the 
methyl N-substituent and iodomethane is formed as the side-product although 
MeI was not observed in 1H NMR spectra. 
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Although the demethylation is a side-reaction in these investigations (which is 
subsequently removed through recrystallisation), it leads to imidazole species, 
which is our ultimate goal. However, the demethylation requires high 
temperatures (110 °C). As the temperature is unsuitable for DNA and other 
natural compounds, further development is still needed to achieve the ultimate 
goal of DNA functionalisation. 
4.4 Utilising trimethylsilyl protecting group to afford 
aryl-imidazole 
The selective C-2 arylation of N-substituted imidazole has been shown to require 
high temperatures via either Bellina's method (140 °C) or Cu-mediated arylation 
(90 °C) and demethylation (110 °C). An alternative route was proposed using 
trimethylsilyl (TMS) as a protecting group (Scheme 4-14) instead of the methyl 
N-substituent with the aim of removal under ambient conditions, which would be 
more suitable for DNA and other natural compounds. The TMS group can be 
cleaved using a fluoride salt at room temperature or under reflux in alcohol.22-25  
 
Scheme 4-14: A proposed alternative C-2 arylation of imidazole using a trimethylsilyl 
protecting group. 
HL49Br was prepared by dropwise addition of freshly distilled 1-methylimidazole 
to an anhydrous solution of bromotrimethylsilane in Et2O under an inert 
atmosphere (Scheme 4-15). A colourless solid formed immediately which was 
collected by filtration and characterised using 1H and 13C {1H} NMR spectroscopy 
(Figure 4-5). The TMS peak appears upfield (1H δ 0.58 and 13C δ -0.9 ppm) due 
to the low electronegativity of Si. 
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Scheme 4-15: Preparation of HL49Br. 
 
Figure 4-5: 1H and 13C {1H} NMR (300 MHz and 75 MHz, CD3CN) spectra of 
HL49Br 
Preparation of C49 was attempted using the electrochemical method to reduce 
the imidazolium ion, however, this resulted in cleavage of the TMS group. The 
product was characterised by 1H NMR spectroscopy (Figure 4-6) and HRMS. 
The TMS peak was absent in the 1H NMR spectrum and the mass ratios (m/z = 
227.0348 (63Cu) and 229.0329 (65Cu)) were observed to be [C50 – Br]+. Another 
attempt at complex synthesis was carried out using Ag2O and CuI to form an 
in situ Ag-NHC complex and transmetallation to Cu. The 1H NMR spectrum 
shows 1-methylimidazole, whereas the TMS peak was absent. The [C50 – Br]+ 
was observed in the HR mass spectrum. In the electrochemical method, the TMS 
group is possibly reduced to a trimethylsilyl radical which dimerises to give 
hexamethyldisilane, whereas the basicity of Ag2O may react with the TMS group 
to give trimethylsilanol or hexamethyldisiloxane. However, these TMS 
derivatives were not observed in any 1H NMR spectra, likely due to their volatility 
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(b.p. hexamethyldisilane = 113 °C, trimethylsilanol = 99 °C and 
hexamethyldisiloxane = 101 °C) and being removed in vacuo during work-up. 
 
 
Figure 4-6: 1H NMR spectrum (300 MHz, d6-DMSO) of the product following 
electrolysis of HL49Br in the presence of Cu. 
4.5 Kinetic study on the arylation of copper-N-heterocyclic 
carbene using NMR spectroscopy 
To further understand the arylation of a xanthine-based NHC coordinated to Cu, 
kinetic studies were carried out. Monitoring the reaction at varying reactant 
stoichiometries, solvents and temperatures allows us to gain more knowledge on 
how the Cu-NHC and aryl iodide are involved in the arylation reaction. Activation 
energy of the reaction can be calculated from the reactions at varying 
temperatures using an Arrhenius plot, and compared to computational studies 
on potential reaction mechanisms. Moreover, we hope to understand which 
factors are contributed to the activation energy and how this might be decreased 
so that the arylation can take place at ambient temperature. 
The arylation of C46 was carried out in an NMR tube and monitored using 1H 
NMR spectroscopy with m-xylene as an internal standard. The reaction was 
performed at 120 °C initially in CD3CN, but the low solubility of C46 in this solvent 
rendered quantification inaccurate. Therefore reactions were conducted in 
d7-DMF, with heating in the NMR spectrometer to avoid delay in transferring the 
reaction vessels from the oil bath (Scheme 4-16). Although the temperature is 
limited to 70 °C using this technique (to prevent degradation of a NMR tube 
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holder), the data can be taken more accurately and frequently allowing more data 
points for the reaction profile. A solution of 0.006 M C46, 0.10 M 4-iodoanisole 
and 0.08 M m-xylene in 0.4 mL d7-DMF was prepared and heated in the NMR 
spectrometer at 70 °C for 16 hours, and the data collected at intervals of 15 
minutes. The concentration of each species was worked out by the average of 
several integrals: m-xylene δ 7.13, 6.99 ppm; C46 δ 4.30, 4.12, 3.31 ppm; 4-
iodoanisole δ 7.62, 6.82 ppm; Ar46 δ 7.82, 7.37, 4.13, 4.08, 3.40 ppm. From the 
concentration profile, it is difficult to determine the rate order of the reaction 
(Figure 4-7). The rate order with respect to C46 can be determined by comparing 
[C46], ln[C46] and 1/[C46] (Figure 4-7, Figure 4-8 & Figure 4-9). The most linear 
plot is ln[C46] (R2 = 0.96), which gives a pseudo 1st order rate constant (k'; rate 
= k'[C46]) of 1.17 × 10-5 s-1 and 2nd order rate constant (k; rate = k[C46][ArI]) of 
1.17 × 10-4 M-1s-1.  
 
Scheme 4-16: Arylation of C46 in an in situ 1H NMR spectroscopy in d7-DMF at 70 °C 
 
Figure 4-7: Concentration profile of C46 and pseudo 0th order plot for C46 in d7-DMF 
at 70 °C derived from 1H NMR integration using m-xylene as an internal standard: m-
xylene δ 7.13, 6.99 ppm; C46 δ 4.30, 4.12, 3.31 ppm; 4-iodoanisole δ 7.62, 6.82 ppm; 
and Ar46 δ 7.82, 7.37, 4.13, 4.08, 3.40 ppm. 
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Figure 4-8: Pseudo 1st order plot for C46 in d7-DMF at 70 °C. 
 
 
Figure 4-9: Pseudo 2nd order plot for C46 in d7-DMF at 70 °C. 
4.6 Kinetic study on the arylation of copper-N-heterocyclic 
carbene using in situ IR spectroscopy 
Due to the temperature limit of monitoring the arylation reaction using NMR 
spectroscopy (mainly the high temperature limit), an alternative technique was 
desired which would allow the reaction to be screened at higher temperature. In 
situ IR spectroscopy was therefore used to monitor the reaction, as reflux 
temperatures can be used. The reaction was performed using 0.05 M C46 and 
0.25 M ArI in MeCN at 78 °C (reflux temperature) (Scheme 4-17). 
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Scheme 4-17: Arylation of C46 in an in situ IR spectroscopy in MeCN at 78 °C 
Data between 1750 – 1220 cm-1 was acquired at 1 minute time intervals over 17 
hours using ReactIR. The frequencies used for monitoring were 1287 cm-1 for 
the 4-iodoanisole, 1715 cm-1 for the C=O of C46, 1536 cm-1 for Ar46 and 1712 
cm-1 for the C=O of Ar46. However, as the peaks are 3 cm-1 apart from each 
other, the overlapping peaks were further investigated with normalised 
absorption graph (Figure 4-10), which visualises the absorption increases at 
1712 cm-1 and the decrease at 1715 cm-1. The 2nd derivative data of both points 
were performed to confirm the change on both sides of the peak resulted from 
the overlap of those 2 peaks. 
 
Figure 4-10: IR spectra change between 1718 – 1709 cm-1; 0.05 M C46 and 0.25 M 
4-iodoanisole in MeCN at 78 °C. 
A 1H NMR spectrum of the crude mixture after 17 hours reaction time shows 39 
% C46 converted to Ar46. The concentration changes of C46 and Ar46 over 
1709171017111712171317141715171617171718
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time are shown in Figure 4-11. The arylation reaction appeared to have an 
induction period (sigmoidal curve), which is likely the result of incomplete 
solubility of C46 under the reaction conditions. Furthermore, the solid-state 
structure of C46 was found to be a dimer,13 which must cleave to form monomers 
in the solution phase which act as an active form of the complex (Scheme 4-18). 
 
Figure 4-11: Concentration profile of C46 (blue) and Ar46 (red and green) in MeCN at 
78 °C derived from the IR absorptions at 1715 (C46), 1536 and 1712 (Ar46) cm-1. 
 
Scheme 4-18: Cleavage of C46 dimer. 
The concentration changes of C46 and Ar46 can then be used to plot ln[C46] vs 
time based on a pseudo-1st and 2nd order (rate = k'[C46] = k[C46][ArI]) using the 
data points from 200 – 450 min, which is after the initiation period. The slope of 
the pseudo 1st order plot of ln[C46] vs time is -0.00109 min-1, which can be 
derived as k = 7.30 × 10-4 M-1s-1 (Figure 4-12, Table 4-2). Other k values were 
derived from [Ar46] using pseudo 1st order plot of ln(1-20[Ar46]) vs time (see 
Appendix), which are 7.62 and 7.32 × 10-4 M-1s-1. The 2nd order calculations were 
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derived from the plot of 5ln(5+(1/[C46])) and 5ln(5+4/(4[Ar46]-1)) vs time (see 
Appendix, Figure 4-13), resulting in rate constants = 7.65, 7.97 and 7.63 × 10-4 
M-1s-1. 
 
Figure 4-12: Pseudo 1st order plots: ln[C46] (blue) and ln(1-20[Ar46]) (red and green) 
vs time of the arylation in MeCN at 78.0 °C, probed by ReactIR. 
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Figure 4-13: 2nd order plots: 5ln(5+(1/[C46])) (blue) and 5ln(5+4/(4[Ar46]-1)) (red and 
green) vs time of the arylation in MeCN at 78.0 °C, probed by ReactIR. 
ν / cm-1 plot equation linear regression k / M-1s-1 
1715 ln[C46] = k't + ln(0.05) y = -0.00109x - 2.91 7.30 × 10-4 
1712 ln(1-20[Ar46]) = -k't y = -0.00114x + 0.12 7.62 × 10-4 
1536 ln(1-20[Ar46]) = -k't y = -0.00110x + 0.12 7.32 × 10-4 
1715 5ln(5+(1/[C46])) = kt + 5ln(25) y = 0.00459x + 15.7 7.65 × 10-4 
1712 5ln(5+4/(4[Ar46]-1)) = -kt y = -0.00478x + 0.50 7.97 × 10-4 
1536 5ln(5+4/(4[Ar46]-1)) = -kt y = -0.00458x + 0.54 7.63 × 10-4 
  average 7.58 × 10-4 
Table 4-2: Linear regression equations and rate constants derived from [C46] and 
[Ar46] based on pseudo 1st order and 2nd order. 
To overcome the temperature limit of MeCN solvent (b.p. 82 °C), the reaction 
was monitored in PhCN (b.p. 191 °C), which also enhances the solubility of C46. 
At 110 °C, the solubility of C46 is above 0.05 M, which is the concentration used 
in the kinetic screening. The reaction was carried out at 120.0 °C using 0.05 M 
C46 and 0.25 M 4-iodoanisole. The sigmoidal curve was no longer observed in 
the concentration profile (Figure 4-14). However, when monitoring C46 the 
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ln[C46] plot is not fitted in with the reaction profile derived from the wavenumber 
1560 cm-1 for C46 as the curve bends at 270 – 280 minutes. Due to solvent 
interference in the C=C / C=O region, the C=O peaks of C46 and Ar46 cannot 
be used. Following recrystallisation of the crude reaction mixture in MeCN/Et2O, 
demethylated imidazole 48 (Scheme 4-19) was observed in the filtrate using 1H 
NMR spectroscopy and HRMS. Formation of this side-product possibly causes 
the concentration profile to bend at 300 minutes because of the overlapping of 
C=O frequencies of C46 and 48. 
 
Figure 4-14: Concentration profile of C46 in PhCN at 120.0 °C, derived from the IR 
absorptions at 1560 cm-1. 
 
Figure 4-15: ln[C46] plot at 100 – 600 minutes 
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Figure 4-16: Sectioned ln[C46] plot at 100 – 250 minutes and 300 – 600 minutes. 
 
Scheme 4-19: Demethylation reaction of Ar46 
The solvent was changed to DMAc as this has a higher polarity than MeCN and 
PhCN and demethylation is less likely to occur. DMAc is more stable at higher 
temperatures and more electron rich than DMF, which makes the possibility of 
C-N oxidative addition at Cu and amination less likely to occur. The reaction was 
screened at 120 °C using 0.05 M C46 and 0.25 M 4-iodoanisole in DMAc for 270 
minutes (Scheme 4-20). Following the reaction, EtOAc was added to precipitate 
the crude mixture, which was analysed using 1H NMR spectroscopy. The 1H 
NMR spectrum showed full conversion to Ar46 and there was no evidence of 
either aminated (47) or demethylated (48) product.  
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Scheme 4-20: Arylation of C46 in an in situ IR spectroscopy in DMAc at 120 °C 
The absorption changes between 1750 – 1220 cm-1 were used to determine the 
concentrations of C46, Ar46 and 4-iodoanisole, which can be divided into 
3 regions. C=O stretching frequencies are in the 1st region, between 1740 – 1680 
cm-1, the peaks of C46 at 1719 and 1682 cm-1 decreased over time, whereas the 
peaks of Ar46 at 1734 and 1701 cm-1 increased over time as expected (Figure 
4-17). The C46 peak at 1538 and the Ar46 peaks at 1562, 1541 and 1523 cm-1 
are in the region between 1600 – 1520 cm-1, which may be C=C aromatic 
stretching frequencies (Figure 4-18). In the last region between 1320 – 1230 
cm-1, the C-O stretching frequency of 4-iodoanisole at 1246 cm-1 decreased 
slightly over time (Figure 4-19). The Ar46 peak at 1303 cm-1 is also observed in 
this region, which is likely the C-O or C-N stretching. However, some of these 
peaks are noisy and therefore omitted from the calculation. In this case (120 °C), 
the peaks used are 1246 (4-iodoanisole), 1719 (C46), 1734 (Ar46) and 1303 
(Ar46) cm-1 were used for monitoring. 
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Figure 4-17: IR spectra change between 1750 – 1670 cm-1; 0.05 M C46 and 0.25 M 
4-iodoanisole in DMAc at 120 °C. 
 
Figure 4-18: IR spectra change between 1600 – 1520 cm-1; 0.05 M C46 and 0.25 M 
4-iodoanisole in DMAc at 120 °C. 
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Figure 4-19: IR spectra change between 1340 – 1220 cm-1; 0.05 M C46 and 0.25 M 
4-iodoanisole in DMAc at 120 °C. 
The concentration profiles (Figure 4-20) show that there was no induction period 
observed at 120 °C in DMAc, as C46 was fully dissolved instantly. The profiles 
fit the exponential plot and ln[C46], ln(1-20[Ar46]), 5ln(5+(1/[C46])) and 
5ln(5+4/(4[Ar46]-1)) vs time were plotted (Figure 4-21 and Figure 4-22, see 
Appendix). These plots fit linear regression and give the rate constant of 1.01, 
1.05, 1.11, 1.17, 1.23 and 1.30 × 10-3 M-1s-1. The rate constant obtained from the 
pseudo 1st order calculation is lower than that from the 2nd order calculation 
because in the pseudo 1st order calculation, the [ArI] is constantly at 0.25 M. 
However, [ArI] decreases from 0.25 to 0.20 M during the reaction and has the 
average concentration of 0.225 M, which is lower than the concentration used in 
pseudo 1st order calculation. As the [ArI] of the pseudo 1st order is higher than 
the more realistic 2nd order that [ArI] decreases over time, the rate constant (k = 
k' / [ArI]) from pseudo 1st order reaction is lower than 2nd order reaction. 
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Figure 4-20: Concentration profile of C46 (red), Ar46 (green and violet) and 
4-iodoanisole (blue) in DMAc at 120.0 °C, probed by ReactIR 
 
Figure 4-21: Pseudo 1st order plots: ln[C46] and ln(1-20[Ar46]) vs time of the 
arylation in DMAc at 120.0 °C, probed by ReactIR. 
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Figure 4-22: 2nd order plots: 5ln(5+(1/[C46])) and 5ln(5+4/(4[Ar46]-1)) vs time of the 
arylation in DMac at 120.0 °C, probed by ReactIR. 
4.7 Arrhenius plot 
The arylation of C46 in DMAc were repeated at 70, 90, 100 and 140 °C so that 
the activation energy could be calculated. At 90 °C and above, the concentration 
profiles were exponential (Figure 4-23) and the same method was utilised to 
obtain rate constants (Table 4-3). However, at 70 °C, C46 was not completely 
dissolved and the sigmoidal curve was observed in the concentration profile 
(Figure 4-24). In addition, the fluctuation at 250 – 300 minutes was due to liquid 
nitrogen being filled to the probe. Hence, the calculation is based on the data 
points after the delay curve (400 – 1200 minutes) and the rate constant (0.9 × 
10-4 M-1s-1) is similar to the rate constant obtained from the NMR screening in 
DMF at the same reaction temperature (1.1 × 10-4 M-1s-1).
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Figure 4-23: Concentration profile of C46 and Ar46 in DMAc at 90, 100, 120 and 140 
°C, derived from the IR absorptions (see Table 4-3). 
 
Figure 4-24: Concentration profile of C46 in DMAc at 70.0 °C, derived from the IR 
absorptions at 1718 cm-1. 
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T / °C 
used time 
range 
/ min 
ν / cm-1 
k / M-1s-1 
(pseudo 1st 
order) 
k / M-1s-1 
(2nd order) 
70* 0 – 900 N/A 1.17 × 10-4 N/A 
70.0 400 – 1200  1718 (C46) 9.13 × 10-5 N/A 
90.0 60 – 728 
1719 (C46) 
1303 (Ar46) 
2.03 × 10-4 
1.92 × 10-4 
2.32 × 10-4 
2.17 × 10-4 
100.0 30 – 420 
1538 (C46) 
1719 (C46) 
1303 (Ar46) 
3.96 × 10-4 
2.64 × 10-4 
3.87 × 10-4 
4.60 × 10-4 
2.98 × 10-4 
4.53 × 10-4 
120.0 0 – 200 
1719 (C46) 
1734 (Ar46) 
1302 (Ar46) 
1.01 × 10-3 
1.05 × 10-3 
1.11 × 10-3 
1.17 × 10-3 
1.23 × 10-3 
1.30 × 10-3 
140.0 0 – 40 
1716 (C46) 
1303 (Ar46) 
2.06 × 10-3 
2.70 × 10-3 
2.25 × 10-3 
3.01 × 10-3 
Table 4-3: Rate constants from 0.05 M C46 and 0.25 M 4-iodoanisole in DMAc at 70 – 
140 °C, probed by ReactIR. *Rate constant from the reaction in d7-DMF, monitored by 
in situ 1H NMR spectroscopy. 
Since the rate constants for the arylation of C46 have been obtained across the 
temperature range 70 – 140 °C, the activation energy of the reaction was 
calculated from these values by plotting an Arrhenius graph (lnk = Ea/R(1/T) + 
lnA) (Figure 4-25, Table 4-4). When the activation energies are calculated in the 
temperature range 90 – 140 °C, values of 63.1 (pseudo 1st order) and 62.5 (2nd 
order) kJ mol-1 are obtained, which are very similar to each other. However, when 
the data point at 70 °C is included in the calculation, the activation energy drops 
to 58.9 kJ mol-1. The activation energy obtained from the experimental data is 
significantly higher than the calculated activation energies for the arylation of 
other Cu-NHC complexes with iodobenzene (C49, C50 and C51, Figure 4-26) in 
toluene (38.5, 39.4 and 27.5 kJ mol-1, respectively).12 This is likely due to the 
electron-withdrawing amide backbone of the xanthine-derived ligand L46. which 
stabilises Cu(I) rather than Cu(III). As a result, both oxidative addition of ArI and 
reductive elimination of Ar46 become more difficult. Moreover, the DFT 
calculations cited were based on iodobenzene, whereas 4-iodoanisole was used 
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in our experimental work. The oxidative addition of a more electron rich 
4-iodoanisole is less favourable. 
 
Figure 4-25: Arrhenius plot based rate constants of pseudo 1st and 2nd order reaction of 
the arylation of C46 in DMAc at 90 – 140 °C and 1st order reaction at 70 – 140°C.  
T / °C type Ea / kJ mol-1 
70 – 140 pseudo 1st order 58.9 
90 – 140 pseudo 1st order 63.1 
90 – 140 2nd order 62.5 
Table 4-4: The activation energy of the arylation of C46 from pseudo 1st order and 2nd 
order data. 
 
Figure 4-26: Calculated activation energies for the arylation for the arylation of Br-Cu-
NHC complexes with iodobenzene in toluene.12 
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4.8 Conclusions 
In summary, xanthine-based imidazolium salts can be arylated via formation of 
a Cu-NHC complex, which can be generated electrochemically using Cu 
electrodes in MeCN. The arylation of Cu-NHC complexes occur efficiently at high 
temperature in DMF. DMF can also act as a substrate, leading to H-imidazolium 
and amino-imidazolium side-products. Demethylation of the imidazolium to give 
an arylated imidazole was also found to occur in some instances. Monitoring the 
reaction using 1H NMR spectroscopy allows straightforward calculation of the 
concentrations of each species. Side-products can also be identified using this 
technique. However, the spectrometer is limited by the temperature and/or large 
delaying in transferring the sample to the spectrometer. Using in situ IR 
absorption overcomes these issues, though higher concentrations of reaction 
species are required. IR absorption of C=O, C=C, C-N and C-O stretches were 
used to calculate rate constants, and the activation energy of the arylation of C46 
in DMAc, which was found to be 58.9 – 63.1 kJ mol-1. 
4.9 Future work 
The ultimate aim for this work is to find a lower energy pathway to arylate 
imidazole/imidazolium so that the methodology can be applied to more delicate 
systems. A potential way to do this could be to use electrochemical reaction i.e. 
arylation of an imidazolium salt under electrochemical conditions via a Cu-NHC 
formed in situ. This may also be carried out ʻmetal freeʼ using inert electrodes 
which will reduce an imidazolium salt to a free NHC. The NHC may act as a 
nucleophile and attack aryl iodide to give an aryl-imidazolium ion. Moreover, 
variation of N-substituents, imidazole-backbones and aryl species would 
potentially give more insights into the arylation reaction. 
4.10 Experimental 
4.10.1 Preparation of substituted imidazoles 
i) Preparation of P45 
Theophylline (1.5 g, 8.32 mmol) and K2CO3 (1.27 g, 9.16 mmol) were added a 
round-bottomed flask, followed by MeCN (20 mL) and 1-iodobutane (3.8 mL, 
33.3 mmol). The reaction mixture was heated and stirred at 80 ºC under N2 and 
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hydrous conditions for 48 hours. The mixture was allowed to 
cool to room temperature and filtered. The solvent was removed 
from the filtrate in vacuo, which resulted in a white solid. Yield: 
1.35 g, 5.7 mmol, 69 % 
1H NMR (300 MHz, CDCl3) δ (ppm) 7.71 (s, 1H, XnH-8), 4.32 (t, 
J = 7.2 Hz, 2H, NCH2CH2CH2CH3), 3.68 (s, 3H, NCH3), 3.41 (s, 
3H, NCH3), 1.86 (quintet, J = 7.2 Hz, 2H, NCH2CH2CH2CH3), 1.36 (sext, J = 7.2 
Hz, 2H, NCH2CH2CH2CH3), 0.94 (q, J = 7.2 Hz, 3H, NCH2CH2CH2CH3). 13C {1H} 
(75 MHz, CDCl3) δ (ppm) 115.2 (C), 151.8 (C), 148.7 (C), 140.7 (CH), 110.1 (C), 
47.4 (CH2), 33.0 (CH3), 30.1 (CH3), 28.2 (CH2), 19.7 (CH2), 13.6 (CH3). HRMS 
(ESI+): m/z 237.1356 [M + H]+, calculated [M + H]+ 237.1346. 
Consisted with data previously reported.13  
4.10.2 Preparation of imidazolium salts 
i) Preparation of HL45I 
P45 (1.3 g, 5.5 mmol), MeI (2 mL, 32 mmol) and DMF (5 mL) 
were added to an ampoule and stirred at 70°C in a sealed 
system for 24 hours. EtOAc (50 mL) was added to precipitate 
a yellow solid, which was collected by filtration. The solid was 
recrystallised from DCM / Et2O and dried in vacuo. Yield: 
1.69 g, 4.47 mmol, 81 % 
1H NMR (300 MHz, CD3CN) δ 8.95 (s, 1H, XnH), 4.44 (t, J = 7.2 Hz, 2H, 
NCH2CH2CH2CH3), 4.07 (s, 3H, NCH3), 3.68 (s, 3H, NCH3), 3.27 (s, 3H, NCH3), 
1.82 (quint, J = 7.2 Hz, 2H, NCH2CH2CH2CH3), 1.33 (sext, J = 7.2 Hz, 2H, 
NCH2CH2CH2CH3), 0.90 (t, J = 7.3 Hz, 3H, NCH2CH2CH2CH3). 13C {1H} (75 MHz, 
CD3CN) δ 154.3 (C), 151.4 (C), 140.9 (C), 139.2 (C), 139.1 (CH), 50.1 (CH3), 
38.3 (CH2), 32.4 (CH3), 32.3 (CH3), 39.1 (CH2), 19.8 (CH2), 13.7 (CH3). HRMS 
(ESI+): m/z 251.1522 [M - I]+, calculated [M - I]+ 251.1503. 
Consisted with data previously reported.13 
ii) Preparation of HL46I 
Caffeine (1.0 g, 5.1 mmol) was added to an ampoule, 
followed by DMF (10 mL) and MeI (1.6 mL, 25.7 mmol). The 
reaction mixture was stirred in a sealed system at 90 ºC for 
48 hours. The mixture was allowed to cool to room 
temperature, during which white time a solid was 
precipitated. EtOAc (60 mL) was added to the mixture and filtered. The solid was 
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washed with EtOAc(3 × 30 mL) and Et2O (30 mL), dried in vacuo to give the 
product as an off-white solid. Yield: 0.37 g, 1.1 mmol, 21 %. 
1H NMR (300 MHz, CD3CN) δ 8.67 (s, 1H, XnH), 4.10 (s, 3H, NCH3), 4.09 (s, 
3H, NCH3), 3.74 (s, 3H, NCH3), 3.34 (s, 3H, NCH3). 13C {1H} (75 MHz, CD3CN) 
δ 153.0 (C), 150.0 (C), 141.1 (C), 138.0 (CH), 110.0 (C), 36.5 (CH3), 35.8 (CH3), 
30.3 (CH3), 25.3 (CH3). HRMS (ESI+): m/z 209.1031 [M - I]+, calculated [M - I]+ 
209.1033. 
Consisted with data previously reported.13 
iii) Preparation of HL49Br 
Under Ar, a freshly distilled 1-methylimidazole (1.0 mL, 
12.5 mmol) was added dropwise via syringe to a stirring 
solution of bromotimethylsilane (1.7 mL, 12.5 mmol) in Et2O (5 
mL) at 0 °C. A colourless solid as immediately formed. It was 
collected from cannula filtration, washed with anhydrous Et2O (2 × 5 mL) and 
dried in vacuo. The colourless solid was stored in a Glovebox. Yield: 2.89 g, 12.2 
mmol, 98 %. 
1H NMR (300 MHz, CD3CN) δ 9.05 (s, 1H, imH), 7.50 (s, 1H, imH), 7.41 (s, 1H, 
imH), 3.91 (s, 3H, NCH3), 0.58 (s, 9H, Si(CH3)3). 13C {1H} NMR (75 MHz, CD3CN) 
δ 139.6 (N-C-N), 124.9 (N-C-C-N), 123.4 (N-C-C-N), 36.2 (NCH3), -0.9 
(Si(CH3)3).  
Consistent with data previously reported.26 
4.10.3 Preparation of Cu-NHC complexes 
i) Preparation of C45 
HL45I (0.2 g, 0.53 mmol) was added a flame-dried three-
necked round-bottomed flask. MeCN (20 mL) was added 
via syringe and two Cu electrodes were inserted. A 
voltage was applied to achieve a current of 30 mA, which 
was maintained for 1 hour. The reaction mixture was 
filtered and washed with excess MeCN. The filtrate was 
concentrated in vacuo and Et2O was added to precipitate 
the product, which was collected by filtration as a greyish green solid. Yield: 0.18 
g, 0.41 mmol, 77 %. 
1H NMR (300 MHz, CD3CN) δ 4.47 (t, J = 7.3 Hz, 2H, NCH2CH2CH2CH3), 4.36 
(s, 3H, NCH3), 3.71 (s, 3H, NCH3), 3.28 (s, 3H, NCH3), 1.79 (quint, J = 7.3 Hz, 
2H, NCH2CH2CH2CH3), 1.39 (sext, J = 7.3 Hz, 2H, NCH2CH2CH2CH3), 0.93 (t, J 
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= 7.3 Hz, 2H, NCH2CH2CH2CH3). 13C {1H} (75 MHz, CD3CN) δ 210.0 (C), 153.0 
(C), 152.0 (C), 151.5 (C), 149.8 (C), 41.1 (CH3), 38.5 (CH2), 32.9 (CH3), 28.0 
(CH3), 21.3 (CH2), 21.1 (CH2), 19.9 (CH3). 
Consistent with data previously reported.13 
ii) Preparation of C46 
HL46I (0.90 g, 2.54 mmol) was added to a flame-dried 
three-necked round-bottomed flask. MeCN (20 mL) was 
added via syringe and two Cu electrodes were inserted. A 
voltage was applied to achieve a current of 30 mA, which 
was maintained for 5 hours. The product was collected by 
filtration, washed with MeCN (10 mL) and Et2O (50 mL) and dried in vacuo to 
give pale green solid. Yield: 0.66 g, 1.65 mmol, 65 %. 
1H NMR (300 MHz, d6-DMSO) δ 4.17 (s, 3H, NCH3), 4.00 (s, 3H, NCH3), 3.73 (s, 
3H, NCH3), 3.23 (s, 3H, NCH3). 13C {1H} (75 MHz, d6-DMSO) δ 206.5 (C), 153.1 
(C), 150.0 (C), 140.1 (C), 108.2 (C), 64.9 (CH3), 54.9 (CH3), 30.6 (CH3), 28.1 
(CH3). 
Consistent with data previously reported.13 
iii) Cu-metallation of L49 via an electrochemical method 
Under Ar, solution of HL49Br (0.1 g, 0.42 mmol) in MeCN (5 mL) was transferred 
to a 3-necked round-bottomed flask. Cu electrodes were inserted into the 
solution and a voltage was applied to give a current of 30 mA for 46 minutes. 
The solvent was removed in vacuo to give a greyish green solid. 
1H NMR (300 MHz, d6-DMSO) δ 8.11 (s, 1H, imH), 7.37 (s, 1H, imH), 7.15 (s, 
1H, imH), 3.73 (s, 3H, NCH3). HRMS (ESI+): m/z 227.0348 and 229.0329 
[Cu(methylimidazole)2]+, calculated [Cu(methylimidazole)2]+ 227.0352 and 
229.0334. 
iv)  Cu-metallation of L49 via in situ silver transmetallation 
Under Ar, to freshly activated molecular sieves (4 Å), were added Ag2O (0.2 g, 
0.82 mmol) DCM or MeOH (10 mL) and an solution of HL49Br (0.2 g, 0.82 mmol) 
in DCM (2 mL). The reaction was stirred in the absence of light for 2 hours. CuI 
(0.16 g, 0.82 mmol) was added and the mixture stirred for a further 1 hour. The 
reaction mixture was filtered by cannula filtration to give a green solution. The 
solvent was removed from the filtrate in vacuo to give a green solid.  
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HRMS (ESI+): m/z 227.0348 and 229.0329 [Cu(methylimidazole)2]+, calculated 
[Cu(methylimidazole)2]+ 227.0352 and 229.0334. 
4.10.4 Arylation reactions 
i) Preparation of Ar45 
C45 (0.070 g, 0.159 mmol) and 4-iodoanisole 
(0.372 g, 1.59 mmol) were added to an ampoule. 
DMF (10 mL) was added via a syringe and the 
reaction mixture was heated at 140 ºC for 24 
hours. The mixture was filtered and concentrated 
in vacuo. Et2O (50 mL) was added to precipitate 
the light brown solid, which was collected by 
filtration and washed with Et2O and dried in air. Yield: 0.064 g, 0.095 mmol, 60 % 
1H NMR (300 MHz, CD3CN) δ 7.59 (d, J = 9.0 Hz, 2H, ArH), 7.28 (d, J = 9.0 Hz, 
2H, ArH), 4.32 (t, J = 7.2 Hz, 2H, NCH2CH2CH2CH3), 3.95 (s, 3H, CH3), 3.81 (s, 
3H, CH3), 3.80 (s, 3H, CH3), 3.40 (s, 3H, CH3), 1.72 (quint, J = 7.2 Hz, 2H, 
NCH2CH2CH2CH3), 1.23 (sext, J = 7.2 Hz, 2H, NCH2CH2CH2CH3), 0.81 (t, J = 
7.4 Hz, 3H, NCH2CH2CH2CH3). HRMS (ESI+): m/z 357.1920 [M – CuI2]+, 
calculated [M – CuI2]+ 357.1921. 
ii) Preparation of Ar46  
C46 (0.030 g, 0.075 mmol) and 4-iodoanisole 
(0.175 g, 0.75 mmol) added to an ampoule. 
Anhydrous and degassed solvent (toluene, 
MeCN or DMF, 5 mL) was added via a syringe. 
The reaction mixture was heated (35, 90 or 140 
ºC) under nitrogen for 24 hours or 168 hours. The 
mixture was filtered and concentrated in vacuo. Et2O (50 mL) was added to 
precipitate the light brown solid, which was collected from filtration and washed 
by Et2O and dried in air. Yield (in the case of heating in DMF at 140 ºC for 24 
hours): 0.038 g, 0.060 mmol, 80 % 
1H NMR (300 MHz, CD3CN) δ 7.56 (d, J = 8.9 Hz, 2H, ArH), 7.26 (d, J = 8.9 Hz, 
2H, ArH), 3.98 (s, 3H, CH3), 3.91 (s, 3H, CH3), 3.83 (s, 3H, CH3), 3.78 (s, 3H, 
CH3), 3.37 (s, 3H, CH3). 13C {1H NMR (126 MHz, CD3CN) δ 164.5 (C), 154.9 (C), 
151.7 (C), 148.6 (C), 141.0 (C), 134.0 (CH), 116.4 (CH), 112.1 (C), 109.1 (C), 
56.8 (CH3), 37.7 (CH3), 36.3 (CH3), 33.3 (CH3), 29.3 (CH3). HRMS (ESI+): m/z 
315.1471 [M – CuI2]+, calculated [M – CuI2]+ 315.1452. Analysis Calculated for 
C16H19N4O3CuI2 + 0.2CuI: C, 28.71; H 2.90; N, 7.93. Found: C, 28.65; H, 2.86; 
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N, 8.35. IR νmax/cm-1 (solid): 1715 (C=O), 1669 (C=O), 1633, 1604, 1542, 1298 
(C-N), 1256 (C-O). 
4.10.5 1H NMR monitoring of the arylation reaction 
A solution of C46, 4-iodoanisole and m-xylene in anhydrous / degassed d7-DMF 
was prepared in a Glovebox and transferred into a Young's-tap NMR tube. The 
reaction mixture was transferred into an NMR spectrometer (500 MHz) and 
screened with 15-minute interval time for 16 hours at 70 °C. 
4.10.6 IR monitoring of the arylation reaction 
General procedure. An oven dried, 100 mL three-necked round-bottomed flask 
equipped with a small stirrer bar was attached to the ReactIR diamond tipped 
probe, dried and degassed in vacuo and back-filled with N2. A background 
spectrum was then collected and solvent (MeCN, PhCN or DMAc) (5.5 mL) was 
added. At this point a reference spectrum was recorded whilst stirring. The 
solvent was heated to the desired temperature (70, 78, 90, 100, 120, 140 °C), 
stirred at the temperature for 5 minutes and another reference spectrum was 
recorded. After that, 4-Iodoanisole (351 mg, 1.5 mmol) was added and more 
solvent (0.5 mL) was added to rinse the starting material on the side of the flask. 
The mixture was stirred at the desired temperature for 5 minutes, then C46 
(120 mg, 0.3 mmol) was added. The reaction progress was monitored by 
measuring the decrease in absorbance of C46 and 4-iodoanisole, and the 
increases in absorbance of Ar46 (specific wavenumbers for each experiment are 
listed in the table below). All peak absorption data were exported into Excel in 
three forms: i) with no reference subtraction; ii) after subtraction of a reference 
spectrum of the solvent at room temperature; iii) after subtraction of a reference 
spectrum of the solvent at the reaction temperature. All subsequent 
manipulations were carried out on dataset iii). MeCN/PhCN was removed in 
vacuo and subsequent analysis carried out on the crude reaction mixture. The 
crude mixture (of the reaction in PhCN) was recrystallised in MeCN/Et2O and the 
solvent removed from the filtrate in vacuo. Both precipitate and solid obtained 
from the filtrate were analysed by 1H NMR spectroscopy and HRMS. In the case 
of reactions in DMAc, EtOAc was added to precipitate a brown solid, which was 
collected by filtration, washed with EtOAc and Et2O, dried in air and analysed by 
1H NMR spectroscopy. 
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solvent T / °C 
ν / cm-1 
C46 4-iodoanisole Ar46 
MeCN 78 1715 1287 1712, 1536 
PhCN 120 1560 1247 (1515, 1567) 
DMAc 120 1719 1247 1302, 1734 
DMAc 70 1718 - (1301) 
DMAc 90 1719 1245 
1303, 
(1702, 1735) 
DMAc 100 1538, 1719 1247 1303 
DMAc 140 1716 1246 1303, (1728) 
Table 4-5: Wavenumbers used to monitor reactions at different conditions. 
(wavenumbers) monitored but not used in the calculation of the reaction profile. 
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Chapter 5  
Higher Oxidation States of Copper-(N-Heterocyclic Carbene) 
Complexes 
5.1 Introduction 
Previous chapters have demonstrated the diverse reactivity of Cu(I)-NHCs, as 
catalysts and through ligand participation in reactivity. To further understand 
these reaction mechanisms, attempts have been made to prepare Cu(II)-NHC 
and Cu(III)-NHC complexes,1 which can potentially be used as reaction 
intermediate mimics. Due to the unsuitable interaction between Cu in higher 
oxidation states and a soft basic NHC, reductive elimination of halo-imidazolium 
often occurs during preparation.2-4 Arnold achieved the preparation a Cu(II)-NHC 
in 2004, in which the ligand has an anionic alkoxy group as an N-substituent.5 
Later, Nechaev used a neutral NHC ligand together with acetate counterions to 
successfully prepare a Cu(II)-NHC in 2011.2 Willans, in 2014, successfully 
prepared Cu(II)-NHC bromide complexes bearing neutral NHC ligands.6 In all 
these (Figure 5-1) chelating ligands were used: anionic-tethered-NHCs, 
bidentate acetate ligands or pyridyl-tethered-NHCs, which stabilise the Cu centre 
as 17 or 19 electron complexes. Attempts to prepare Cu(III)-NHC halide 
complexes have so far proved futile, with one report leading to the reductive 
elimination of a halo-imidazolium ion.3 
 
Figure 5-1: Structures of stable Cu(II)-NHC complexes.2,5,6 
Despite the stability of the Cu(II)-NHC bromide complexes reported by Willans,6 
the outcome of the reaction changed when excess CuBr2 was present. The 
CuBr2 can form a (μ-Br)2-bridge with the complex, which results in 
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disproportionation and reductive elimination of bromo-imidazolium from the 
Cu(III) centre (Scheme 5-1).7  
 
Scheme 5-1: Decomposition of Cu(II)-NHC bromide via disproportionation and 
reductive elimination of bromo-imidazolium salt.7 
Whilst working with Cu complexes of the pyridyl, allyl substituted NHC shown in 
Scheme 5-1, a previous group member observed another side-product that 
appeared to derive from the bromo-imidazolium salt. The structure of this was 
not fully elucidated, but was thought to be an annulated product. This 
transformation may be related to a similar Ni-catalysed annulation of an alkenyl-
imidazolium salt (Scheme 5-2).8,9 The Ni-catalysed annulation occurs via 
oxidative addition of Cimidazolium-H to Ni(0), which formed a Ni(II)-NHC, followed 
by H-migration and reductive elimination of the annulated product. This part of 
the project will investigate if the allyl-bromo-imidazolium salt can undergo similar 
reactions at Cu, where Cimidazolium-Br is oxidatively added, followed by 
Br-migration and reductive elimination of a similar annulated product. 
 
Scheme 5-2: Ni-catalysed annulation of allyl-imidazolium salt.8 
In addition to adding knowledge to the understanding of higher oxidation state 
Cu, this transformation could provide a valuable route to annulated compounds 
that are used in the pharmaceutical and agrochemical industries. For example, 
α1A adrenoceptor partial agonists have specific imidazole frameworks and are 
synthesised via multiple steps by functionalising a lactam to form an imidazole 
ring (Scheme 5-3).10,11  
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Scheme 5-3: Our predicted annulated product (lef) and synthetic route to α1A 
adrenoceptor partial agonists.11 
A further aim of this part of the project is to prepare a Cu(III)-NHC complex, which 
would be the first example of such type. Based on previous literature, Cu(III) 
species generally feature square planar and occasionally elongated octahedral 
geometries.12-15 In recent times, chelating and macrocyclic ligands have been 
used to form Cu(III) complexes such as thio-oxalate, alkoxide polyanionic and 
aryl-amino-macrocyclic ligands (Figure 5-2). Our aim is to design square planar 
macrocyclic NHC-containing ligands and utilise them in the stabilisation of Cu(III) 
complexes, with the macrocyclic ligand helping prevent reductive elimination in 
which the NHC is involved. 
 
Figure 5-2: Examples of Cu(III) complexes using chelating and macrocyclic ligands.13-
15  
5.2 Reactivity of 1-alkenyl-2-bromo-3-pyridylimidazolium salts 
Bromoimidazolium salt S8.a was prepared via transmetallation from a Ag(I)-NHC 
complex, AgL8Br, with 2 equivalents of CuBr2 (Scheme 5-4). S8.a was obtained 
as a dark green solid and characterised using HRMS and 1H NMR spectroscopy. 
The 1H NMR spectrum of the product showed a mixture of S8.a and another 
species, which was later identified (by comparing 1H NMR resonances) as a 
annulated product Cy8 (Figure 5-3). However, the elemental analysis of the 
sample illustrated otherwise, a mixture of a bromoimidazolium (C11H11BrN3) and 
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H-imidazolium (C11H12N3) (1: 1) were observed with a mixture of Cu2Br3
-
 and 
CuBr2
-
 ions at the ratio of 3: 1. Still the elemental analysis and HRMS cannot 
distinguish between the S8 and its annulated product Cy8 due to the same 
formula. Single crystals suitable for X-ray diffraction analysis were grown by the 
vapour diffusion of Et2O into a concentrated solution of the product in MeCN. 
S8.a crystallised as a dimer of bromo-imidazolium cation with Cu4Br5- counter 
ion and MeCN in the monoclinic crystal system and the structural solution was 
performed in the space group P21/n (Figure 5-4). As the counter ion results 
obtained from elemental analysis and x-ray crystallography are different, Cu2Br3
-
 
or Cu4Br5
-
 cannot be concluded as the real circumstance. It is likely that the 
crystallographic data is a result from just one crystal and not the overall product, 
which might have a mixture of CuxBrx+1
-
 as counter ions (x = 0, 1, 2, …). 
 
Scheme 5-4: Preparation of S8.a via AgL8Br transmetallation. 
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Figure 5-3: 1H NMR spectra of a mixture of S8.a and Cy8 (300 MHz, CD3CN), S8.b 
(300 MHz, CDCl3) and Cy8 (300 MHz, CD3CN). S8.b is a non-Cu containing 
derivative of S8.a i.e. with a Br- counterion. 
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Figure 5-4: Molecular structure of S8.a. Ellipsoids are drawn at the 50% probability 
level and H atoms are omitted for clarity.  
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C(2)-Br(12) 1.856(13) N(1)-C(2)-N(3) 110.8(11) 
N(1)-C(2) 1.359(17) N(3)-C(13)-C(14) 111.8(15) 
C(2)-N(3) 1.281(17) C(13)-C(14)-C(15) 144(3) 
C(13)-C(14) 1.52(3) N(7)-C(6)-N(1)-C(5) -58.6(17) 
C(14)-C(15) 1.02(4)   
Cu(1)-N(7) 1.993(17)   
Br(1)-Cu(2) 2.440(8) Cu(2)-Br(1)-Cu(4) 63.2(2) 
Br(1)-Cu(4) 2.382(7)   
Br(2)-Cu(1) 2.503(5) Cu(1)-Br(2)-Cu(2) 66.3(2) 
Br(2)-Cu(2) 2.290(8)   
Cu(1)-Br(3) 2.380(4) Cu(1)-Br(3)-Cu(3) 68.67(17) 
Cu(3)-Br(3) 2.381(7)   
Br(4)-Cu(1) 2.815(5) Cu(1)-Br(4)-Cu(2) 60.9(2) 
Br(4)-Cu(2) 2.286(9) Cu(1)-Br(4)-Cu(3) 60.73(16) 
Br(4)-Cu(3) 2.464(6) Cu(2)-Br(4)-Cu(3) 84.4(3) 
Br(5)-Cu(3) 2.795(7) Cu(3)-Br(5)-Cu(4) 117.2(2) 
Br(5)-Cu(4) 2.332(4) Cu(3)-Br(5)-Cu(4)' 161.6(3) 
Br(5)-Cu(4)' 2.432(4) Cu(4)-Br(5)-Cu(4)' 61.8(3) 
Table 5-1: Selected bond distances (Å) and angles (deg) in the solid-state structure of 
bromoimidazolium salt S8.a. 
The C(2)-Br(12) bond length of 1.856(13) Å in S8.a is in the normal range for 
Csp2-Br bond lengths.16 A significant difference between S8.a and L8 is that there 
is a distortion plane between the pyridyl and imidazolium rings in the case of 
S8.a, whereas in L8 they lie almost coplanar.6 The cluster of Cu8Br102- is a dimer 
of Cu4Br5-, in which most of the Cu-Br-Cu angles are in the range of 60 – 68 °. 
However, the Cu(2)-Br(4)-Cu(3) and Cu(3)-Br(5)-Cu(4) angles are much larger 
(84 and 117 ° respectively). The Cu(4)s and Br(5) act as the bridge that connects 
2 Cu4Br5
-
 clusters together Hence, the Cu(3)-Br(5)-Cu(4)' is near linear (162 °). 
This bridging structure is similar to the neutral aggregate of Cu8I8 in Feng's 
work.17 
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S8.a was heated at 95 ºC for 6 days in the absence of solvent with the aim of 
promoting the annulation reaction. The product was analysed by 1H NMR 
spectroscopy (Figure 5-5) and was found to contain a dihydropyrrolyl bearing a 
bromine atom (Cy8, Scheme 5-5) in addition to several other decomposition 
products. 1H COSY NMR experiment was used to determine the geminal and 
vicinal coupling among the protons of the annulated ring (HA – HE) (Figure 5-6). 
The 2D spectrum shows that HC couples with HA, HB, HD and HE as there are 
four cross peaks corresponding to those protons horizontal to the diagonal peak 
of HC. Furthermore, HA and HB couple each other (likely geminal) but not the 
other pair of HD and HE and likewise. This illustrates that the methylene pairs are 
not adjacent to each other as the COSY technique does not take a long range 
coupling into account. The coupling constants of the region were further 
analysed from the 1H NMR spectrum. There are two pairs of diastereotopic 
protons (HA and HB, and HD and HE), in which 2J coupling constants of 19.5 and 
13.5 Hz were observed respectively (Figure 5-7). HA and HD each couples with 
HC, which is cis to them, with a 3J coupling constant 2.9 Hz for both. The small 
coupling constants resulted in the absence of two cross peaks corresponding to 
HC coupled by HB and HE. HB and HE each couples with HC with a 3Jtrans coupling 
constant of 7.2 Hz and 6.4 Hz respectively. When S8.a was heated in microwave 
oven at 90 ºC for 15 minutes, the same reaction took place, with evidence of 
decomposition in addition to Cy8 formation. 
 
Scheme 5-5: Annulation reaction of S8.a.  
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Figure 5-5: 1H NMR spectrum (300 MHz, CD3CN) of crude Cy8. 
 
Figure 5-6: 2D 1H COSY spectrum (500 MHz, CD3CN) of Cy8. 
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Figure 5-7: Assignment of the 1H spectrum of Cy8 in the dihydropyrrolyl region, 
showing 2J and 3J coupling constants (Hz). 
To investigate the necessity of Cu in this reaction, a novel Cu-free analogue of 
S8.a was prepared (S8.b). Imidazole P8 was brominated using NBS to give a 
novel PS8 (Scheme 5-6a), with the bromination reaction occurring predominantly 
at the most acidic position (H-2). However, further bromination was observed at 
other positions, with column chromatography being required to isolate the 
desired product. PS8 was allylated to give bromo-imidazolium salt S8.b (Scheme 
5-6b). In the 1H NMR spectra of PS8 and S8.b, the H-2-imidazole and H-2-
imidazolium peaks were no longer observed, compared to P8 and L8, the non-
brominated analogues (Figure 5-8). Moreover, the backbone imidazole and 
imidazolium peaks are more upfield than the non-brominated 
imidazole/imidazolium analogues. 
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Scheme 5-6: Preparation of S8.b via bromination of P8. 
 
Figure 5-8: 1H NMR spectra (300 MHz, CDCl3) of P8, PS8, L8 and S8.b. 
Crystals suitable for X-ray diffraction analysis were grown of both PS8 and S8.b 
(Figure 5-9 and Figure 5-10). Single crystals of PS8 were grown by the vapour 
diffusion of pentane into a concentrated solution of the product in CHCl3, and 
those of S8.b were grown by the vapour diffusion of Et2O into a concentrated 
solution of the product in MeCN/MeOH.  
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Figure 5-9: Molecular structure of PS8. Ellipsoids are drawn at the 50% probability 
level and H atoms are omitted for clarity. 
C(2)-Br(12) 1.870(3) N(1)-C(2)-N(3) 114.0(3) 
N(1)-C(2) 1.374(4)   
C(2)-N(3) 1.304(4)   
Table 5-2: Selected bond distances (Å) and angles (deg) in the solid-state structure of 
brominated pyridylimidazole, PS8. 
 
Figure 5-10: Molecular structure of the bromoimidazolium salt S8.b. Ellipsoids are 
drawn at the 50% probability level and H atoms are omitted for clarity. 
Br(15)-C(2) 1.862(3) N(1)-C(2)-N(3) 108.3(3) 
N(1)-C(2) 1.337(3) N(7)-C(6)-N(3)-C(2) -53.4(4) 
C(2)-N(3) 1.333(4)   
Br(15)-Br(16) 3.149   
Table 5-3: Selected bond distances (Å) and angles (deg) of S8.b. 
In the absence of solvents, the substrate S8.b was heated with 0, 1 and 2 
equivalents of CuBr for 168 hours. Only when 2 equivalents of CuBr were 
incorporated in the reaction mixture did the annulation reaction occur to any 
significant extent (Scheme 5-7). In the presence of 1 equivalent of CuBr, there 
was only 16 % conversion, as calculated from 1H integrals in 1H NMR spectrum 
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of the crude product at δ 6.10, 5.50 ppm for S8.b and at δ 5.28 ppm for Cy8 
(Figure 5-11). 
 
Scheme 5-7: Annulation reaction of S8.b in the presence of CuBr.  
 
Figure 5-11: 1H NMR spectra (300 MHz, CD3CN) of a crude mixture when S8.b was 
heated with 1 and 2 equivalents of CuBr at 95 °C for 168 hours in the absence of 
solvents. 
This suggests that C-Br activation through oxidative addition, and alkene 
coordination occur at different Cu atoms, which are possibly bridged by a 
bromide ion. Bromide migration to the alkene will form an anionic alkyl ligand, 
which is a hard base and more suitable to bond to Cu(III) than Cu(I). Hence, the 
alkyl species coordinates to Cu(III) to form a 6-membered metallacycle. 
Reductive elimination of Cy8 would form a 5-membered ring, giving the 
suggested product (Scheme 5-8). DFT calculations would determine the 
feasibility of the hypothesised mechanism.  
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Scheme 5-8: Proposed mechanism for the annulation reaction of S8. 
5.3 Reactivity of other 2-bromoimidazole derivatives 
To compare the Cu-mediated annulation reaction with a reported Rh-catalysed 
annulation of 1-allylimidazole (Scheme 5-9),18 the novel brominated imidazoles 
S52 and S53 were to be prepared. The annulated product of 1-allyl-2-
bromoimidazole would be neutral, leading to more facile isolation from Cu and 
other side-products when compared to imidazolium species (i.e. Cy8). 
 
Scheme 5-9: Rh-catalysed annulation of 1-alkenylimidazole (top) 18 and imidazoles 
S52 and S53 prepared to investigate the Cu-mediated process (bottom). 
Many methods were attempted to prepare S52. Direct bromination of 
1-allylimidazole using NBS gave a mixture of various brominated products as 
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observed by LCMS, with at least 3 bromoimidazole isomers, 2 dibromoimidazole 
isomers and 1 tribromoimidazole species (Scheme 5-10, Figure 5-12). 
Mono-brominated isomers can be separated from the starting material, and other 
brominated species by column chromatography. However, S52 cannot be 
separated from other mono-brominated species in the mixture despite using 
gradient eluents, as they have very similar physical properties. 
 
Scheme 5-10: Attempted synthesis of 1-allyl-2-bromoimidazole S52 and other products 
formed. 
 
Figure 5-12: LCMS chromatograms of the crude mixture following bromination 
1-allylimidazole (top) and a mixture of monobromo-allylimidazole isomers (bottom). 
Another approach used was to protect one nitrogen of imidazole using a trityl 
group,19,20 or a tetrahydropyranyl (THP) group,21 and brominate at the C-2 
position to afford 55 or 56 (Scheme 5-11). Deprotection of the trityl or THP group 
in a presence of acid would afford 57, which would be functionalised to prepare 
S52. However, bromination of these protected imidazoles (P5' and P54) with 
n-BuLi and NBS was unsuccessful. Expected molecular ions [55 + H]+, [56 + H]+ 
or [57 + H]+ were not observed in HRMS of either crude products. It is unclear 
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what occurred in the case of the trityl protected imidazole. However, the 1H NMR 
spectrum of the crude product from the reaction involving imidazole P54 
indicated that bromination may have occurred on the THP ring, as the proton 
resonance corresponding to the C-2 position was no longer observed in the 
crude product. Another possibility is that the protecting group was cleaved to 
form THP-Br, as the integrations of the imidazole resonances are significantly 
lower than those of the THP ring (1:7 instead of the expected 1:1). 
 
Scheme 5-11: Attempted synthetic route to 2-bromoimidazole using trityl or THP as 
the imidazole protecting group 
Another reported brominating agent is perbromide ionic liquid (59), which can 
also be used as a solvent.22 This reagent was prepared from addition of a slight 
excess of Br2 to 1-butyl-3-methylpyridinium bromide (58) (Scheme 5-12a). The 
excess Br2 was removed in vacuo, while the product was obtained as a bright 
orange liquid. Addition of a stoichiometric amount of imidazole to the ionic liquid 
resulted in a formation of tribromoimidazole, as observed in HRMS 
m/z = 304.7734. A modification of the method involved using ionic liquid 59 in 
anhydrous MeCN, which was added dropwise to a anhydrous solution of 
imidazole in MeCN at 0 ºC (Scheme 5-12b). After 15 minutes, water was added 
to quench the reaction. Following extraction by organic solvent and purification 
using column chromatography, it was found that the product obtained was 
5-bromoimidazole (60) rather than the desired 2-bromoimidazole (57), 
characterised using 1H NMR and 13 C {1H} NMR spectroscopies and HRMS. 
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Scheme 5-12: Preparation of the ionic liquid 59 and attempts to apply in the 
bromination of imidazole. 
As bromination by the ionic liquid 59 occurred at the undesired position, 
benzimidazole was used instead of imidazole, with the rationale that the arene 
ring will block bromination from taking place at the backbone position. However, 
the characterisation of the purified product of the reaction of benzimidazole with 
59 suggest the formation of 5-bromobenzimidazole or 6-bromobenzimidazole 
(Scheme 5-13). This suggests that bromination occurs via the bromo cation 
which selectively attacks the aromatic ring with the most electrophilic site. 
 
Scheme 5-13: Bromination of benzimidazole by 59. 
Due to difficulties in selective C-2 bromination, 2-bromobenzimidazole (P53) was 
purchased and deprotonated in anhydrous, degassed THF using NaH, followed 
by nucleophilic substitution with allyl bromide to obtain 
1-allyl-2-bromobenzimidazole, which was characterised by 1H and 13C {1H} NMR 
spectroscopies and HRMS (S53) (Scheme 5-14).  
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Scheme 5-14: Preparation of S53. 
To mimic the Rh-catalysed annulation of 1-allylbenzomidazole (Scheme 5-9), 
S53 was heated with a catalytic amount (10 mol%) of CuI in CD3CN at 70 ºC. 
However, the resonances attributed to a dihydropyrrolyl (i.e. the annulated 
product) were not observed in 1H NMR spectra (Figure 5-13), whereas the allyl 
peaks split into more than one set, which suggests that more than one allyl-
containing species has been formed. The crude reaction mixture was analysed 
by LCMS, with the spectra indicating that a benzimidazole-dimer and 
bis(benzimidazolyl) ether have formed (Scheme 5-15).  
 
Scheme 5-15: Dimerisation of S53. 
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Figure 5-13: 1H NMR spectra (300 MHz, CD3CN) of S53 following reaction with 10 % 
CuI and 20 % DL-proline at 0, 3, 21 and 71 hours. 
Although the annulation of 1-allylbenzimidazole by a Rh catalyst (10 % loadings) 
was successful (25 % yield),18 the annulation of S53 did not occur, likely due to 
the bromine atom replacing the H-2 in benzimidazole. DFT calculations for the 
Rh-catalysed reaction were performed and the most facile mechanism (152 kJ 
mol-1) was proposed to take place via a stable Rh-NHC intermediate, following 
concerted proton migration to the N-3 position of the imidazole to form a Rh-NHC 
complex (Scheme 5-16).23 However, Br-migration in a similar manner to form an 
NHC complex might not be possible. 
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Scheme 5-16: Proposed mechanism of Rh-catalysed annulation of 
1-allylbenzimidazole.18,23 
Another bromo-imidazolium salt, S64, in which the pyridyl group of S8 was 
replaced by a methyl group, was investigated. S64 was prepared from the 
selective bromination of P3. Unlike the bromination of P8 to obtain PS8, the 
bromination of P3 requires the presence of NaH, otherwise the reaction would 
occur at the C-5 position instead of the desired C-2 position (Scheme 5-17). 
Without prior deprotonation, the electrophilic addition occurs at the most 
electrophilic site, which is the C-5 position of the aliphatic N-substituted imidazole 
and the C-2 position of the aromatic N-substituted imidazole. The deprotonation 
of P3 occurs at the C-2 position and hence leads to the bromination at the desired 
position. S64 was prepared by allylation of P64 and tested for the annulation 
reaction in the presence of 2 equivalents of CuBr. However, the expected 
resonances attributed to the cyclised bromodihydropyrrolyl were not observed in 
the1H NMR spectra of the reaction product.  
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Scheme 5-17: Bromination reactions of P8 and P3. 
 
Scheme 5-18: No reactivity of S64 when heated in the presence of excess CuBr. 
The lack of reactivity in S64 demonstrates that the pyridyl N-substituent is 
essential for the annulation reaction to occur. The pyridine group can co-ordinate 
to Cu, which brings the Cu into close proximity for the C-Br activation to take 
place. 
5.4 Attempts to synthesise a Cu(III)-NHC via oxidative addition 
As discussed previously, high-oxidation-state Cu is unsuitable for forming stable 
complexes with NHC ligands. However, we have endeavoured to overcome this 
challenge by intelligent ligand design and use of the macrocyclic effect. Cu(III) is 
d8 and would usually prefer square planar geometry. One of the literature 
examples of a Cu(III) organometallic complex utilises an aryl-triamino-
macrocyclic ligand, which relies on deprotonation of H-Caryl and dispro-
portionation from Cu(II) to form a macrocyclic Cu(III)-aryl complex and a Cu(I) 
complex (Scheme 5-19).24 Another report discusses oxidative addition of Caryl-Cl 
to Cu(I) to form a macrocyclic Cu(III) complex, with DFT calculations supporting 
the feasibility of such reaction (Scheme 5-20).25 
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Scheme 5-19: Disproportionation of a Cu(II) complex to form a macrocyclic Cu(III)-
aryl complex and a Cu(I) complex.24 
 
Scheme 5-20: Oxidative addition of a macrocyclic Cl-aryl ligand to Cu(I) to form a 
macrocyclic Cu(III) complex.25 
The design of our NHC ligand involves a macrocyclic structure, which contains 
4 binding sites for square planar geometry and a Caryl-Br for oxidative addition. 
The first strategy involved the bromine being at the C-2 position of one of the 
imidazoliums (H2L65X2) (Figure 5-14). It was anticipated that Cu(I) coordination 
would occur from 1 NHC and 2 pyridine sites that are arranged in a T-shape 
position, with oxidative addition of the Cimidazolium-Br bond occurring to give the 
desired Cu(III)-(macrocyclic NHC) complex. 
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Figure 5-14: Structure of the proposed H2L65X2. 
Attempts to prepare the ligand precursor started from transforming pyridine 
derivative 66 to 67 via an SN1 reaction under acidic conditions. 2 equivalents of 
imidazole were deprotonated by NaH in THF and reacted with 67 to obtain 68 
(53 % yield). The selective bromination of 68 proved challenging. Reacting 68 
with NBS in MeCN gave the desired product P65 in a very small amount (2 %) 
as the bromination is more selective towards the imidazole backbone positions. 
Another attempt was carried out using n-BuLi to selectively deprotonate the H-2 
imidazole ring prior to addition of NBS. However, there was no evidence of either 
68, brominated product or any species containing a bromine atom observed in 
HRMS. Instead an alternative ligand was proposed. 
 
Scheme 5-21: Synthetic route to H2L65Br2. 
 
 
166 
 
Another macrocyclic NHC ligand was proposed, in which a bromo-aryl replaced 
one of the pyridine rings (Figure 5-15). This ligand is very similar to the 
macrocyclic ligand in Ribas's work on Cu(III) complexes, which has one anionic 
aryl and three neutral N-coordination sites (C70). 
 
Figure 5-15: Structures of the proposed H2L69X2 (NHC ligand precursor, left) and 
Ribas's Cu(III) complex C70 (right). 
The ligand precursor was prepared stepwise via bromination of 71 using radical 
initiation by heating dibenzoyl peroxide in the presence of NBS to generate a Br• 
radical. The Br• radicals react with the aliphatic carbon atoms to produce a 
mixture of 72 and other aliphatically brominated products (Scheme 5-22). The 
desired product was isolated from the mixture using flash column 
chromatography (silica gel), eluting with hexane. TLC spotting was used to 
observe the reaction products, which were characterised by 1H and 13C {1H} NMR 
spectroscopies (Figure 5-16). The macrocyclic imidazolium bromide salt 
H2L69Br2 was precipitated from a dilute mixture of 68 and 72 in anhydrous 
MeCN. H2L69Br2 is soluble in water, MeOH and acetone, and was characterised 
by 1H and 13C {1H} NMR spectroscopy and HRMS. 
 
Scheme 5-22: Bromination of 71 to obtain 72. 
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Figure 5-16: 1H (300 MHz, CDCl3) and 13C {1H} NMR (75 MHZ, CDCl3) spectra 
of 72. 
Metallation of H2L69Br2 was first attempted by deprotonation with Ag2O in 
anhydrous DCM (Scheme 5-23) [AgL69]+ was observed in a HRMS of the 
reaction sample after 3 hours reaction time. However, isolation of AgL69Br was 
not possible, and thought that decomposition may occur through Caryl-Br 
oxidative addition to the Ag centre to form an unstable Ag(III) complex. The 
reaction was also attempted with the presence of CuI so that silver 
transmetallation (and potentially oxidative addition of C-Br at Cu(I)) occurs in situ 
to form the desired Cu(I) or Cu(III) products. However, the resonances from 
HRMS were not assignable to any of the expected products, including [HL69]+, 
[CuL69]+, [CuL69 – Br]2+ or any Ag derivatives. 
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Scheme 5-23: Preparation of H2L69Br2 and attempted synthesis of AgL69Br. 
Another method that can be used for the preparation of Cu-NHC complexes is 
electrochemical synthesis. These reactions are often conducted in MeCN which 
stabilises Cu(I). As H2L69Br2 is not soluble in MeCN, anion exchange was 
carried out. Excess NH4PF6 was added to an aqueous solution of H2L69Br2 to 
afford a colourless precipitate and assumed as a complete reaction. H2L69(PF6)2 
was characterised using 1H and 13C {1H} NMR spectroscopies and HRMS 
(Scheme 5-24). An electrochemical reaction was performed with H2L69(PF6)2 
(0.125 mmol) and Cu electrodes, a voltage was applied to achieve a current of 
30 mA, which was maintained for 20 minutes (calculated time = 
0.125 𝑚𝑚𝑜𝑙 ×𝐹×2
0.03
=
13 𝑚𝑖𝑛𝑢𝑒𝑠). At 5 minutes, the solution turned pale yellow and to deep green 
within 15 minutes. The solvent were removed in vacuo and the crude product 
characterised using 1H NMR spectroscopy (CD3CN) and HRMS. The 1H NMR 
spectrum was broad, suggesting the formation of paramagnetic Cu(II), while the 
MS resonance were not assignable to any of the expected products including 
[CuL69]+/2+, [L69]2+, [HL69]+ or [CuL69 – Br]+/2+. Another electrochemical 
reaction was performed with H2L69(PF6)2 (0.37 mmol) and Cu electrodes at a 
current of 20 mA for 60 minutes (1.5 times the calculated time i.e. 40 minutes), 
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which gave the yellow and green colour, and the same unassignable analytical 
results.  
 
Scheme 5-24: Anion exchange to afford H2L69(PF6)2 and attempted electrochemical 
synthesis of [CuL69](PF6). (i) H2L69(PF6)2 (0.125 mmol), I = 0.03 A, time = 20 
minutes; (ii) H2L69(PF6)2 (0.269 mmol), I = 0.02 A, time = 60 minutes. 
To investigate if the C-Br bond is being activated in these process and potentially 
leading to decomposition, the C-Br bond was replaced by a C-H bond. 68 was 
added to 1,3-dibromoethylbenzene 74 in anhydrous MeCN at low concentrations 
resulting in the precipitation of H2L75Br2, which was used to prepare 
H2L75(PF6)2 by anion exchange (Scheme 5-25). Both Br
-
 and PF6
-
 salts were 
characterised by 1H and 13C {1H} NMR spectroscopies and HRMS, where the 
metathesis was assumed to go to completion by the precipitation of the PF6
-
 salt. 
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Scheme 5-25: Preparation of macrocycles H2L75Br2 and H2L75(PF6)2. 
Metallation of H2L75(PF6)2 was attempted by deprotonation with Ag2O in MeCN 
and stirred for 4 hours, after which time [AgL75]+ was not observed. MeOH was 
added to the reaction mixture and stirred for 20 hours, after which time [AgL75]+ 
was observed in the HRMS of a reaction sample. The complex [AgL75](PF6) was 
isolated as a light brown solid (quantitative yield) and was characterised using 
1H NMR spectroscopy and HRMS. The 13C {1H} NMR spectrum was too weak to 
assign. 
 
Scheme 5-26: Preparation of [AgL75](PF6). 
The isolated [AgL75](PF6) was added to CuI in MeCN, with precipitation of AgI 
being observed. The reaction was filtered, the solvent removed from the filtrate 
and the green solid was recrystallised in MeCN / Et2O to afford a pale green solid 
(57 % yield, Scheme 5-27). The [CuL75](PF6) was characterised using 1H NMR 
spectroscopy and HRMS, with [CuL75]+ and [CuL75 + H]+2 being observed in 
the mass spectrum.  
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Scheme 5-27: Preparation of [CuL75](PF6). 
The preparation of [CuL75](PF6) was successful, when the Caryl-H was utilised 
whereas when Caryl-Br is present (L69) the reactions become more complicated. 
This provides a strong indication that the C-Br is being activated (through either 
oxidative addition or radical pathway), possibly leading to unstable higher 
oxidation state species which could not be detected due to decomposition. 
5.5 Attempts to synthesise a Cu(III)-NHC via oxidation of 
Cu(II)-NHC 
Another potential route to prepare a Cu(III)-NHC involves chemical oxidation of 
a Cu(II)-(macrocyclic NHC). A macrocyclic ligand precursor void of a C-Br bond 
was synthesised from 67 and 68 to afford H2L76Br2 followed by anion exchanged 
to obtain H2L76(PF6)2 (Scheme 5-28). 
 
Scheme 5-28: Preparation of H2L76Br2 and H2L76(PF6)2. 
H2L76(PF6)2 was dissolved in DMSO in the presence of Ag2O and heated at 
55 °C for 2 hours to afford AgL76(PF6), with [AgL76]+ being observed in the 
HRMS after 1 hour of reaction time. The reaction was filtered through Celite. The 
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filtrate was poured into excess amount of water to afford precipitation of the 
product AgL76(PF6), which was collected by filtration and characterised by 1H 
NMR spectroscopies and HRMS. The data were consistent with literature 
(Scheme 5-29).26  
 
Scheme 5-29: Preparation AgL76(PF6). 
AgL76(PF6) was added to CuBr2 in MeCN to afford a dark green mixture which, 
upon addition of AgPF6, immediately changed to purple. The purple solid was 
precipitated upon addition of Et2O and collected via cannula filtration. Analysis 
by HRMS revealed the presence of [CuL76]2+ (Scheme 5-30). 
 
Scheme 5-30: Preparation of [CuL76](PF6)2. 
In addition, a crystal of [CuL76](PF6)2 suitable for X-ray diffraction analysis was 
grown via vapour diffusion of Et2O into a concentrated solution in MeCN (Figure 
5-17). The crystal structure shows that the complex has a square planar 
geometry around the Cu(II) (angle CNHC-Cu-Npyridine = 89.92 °, Table 5-4). The 
Cu-Npyridine distances are 2.14 Å, which are longer than Cu-CNHC distances (1.90 
Å). This is similar to previous Cu-NHC-Br2 complexes reported in the group, 
which have Cu-Npyridine distances of 2.04 – 2.13 Å and Cu-CNHC distances of 
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1.93 – 1.98 Å.6 However, the Cu-CNHC distance in our case is shorter, likely due 
to L76 being in a more fixed orientation. Furthermore, when compared to Meyer's 
[FeL76(NCMe)2](PF6)2, which has Fe-CNHC distance (1.94 Å) is also shorter than 
Fe-Npyridine (2.02 – 2.03 Å). Moreover, in both cases the NHC rings and pyridines 
are not coplanar, but the macrocyclic ligand is puckered and adopts C2 
symmetry. [FeL76(NCMe)2](PF6)2 also complex has 2 NCMe coordinated to Fe2+ 
at the axial positions at 1.93 – 1.94 Å and forms an octahedral complex. 
Differently, in our case of [CuL76](PF6)2, there are 2 PF6
-
 ions located near the 
axial position at a further distance of 3.56 Å with the nearest Cu-F(20). The 
fluoride atom is at 10.831 ° off the axis perpendicular to the plane of ligand 
coordination.  
 
Figure 5-17: Molecular structure of [CuL76](PF6)2. Ellipsoids are drawn at the 50% 
probability level, one of 2 PF6
-
 ions and H atoms are omitted for clarity. 
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Cu(1) – C(2) 1.904(3) C(2) – Cu(1) – N(8) 90.08(4) 
Cu(1) – C(5) 1.906(3) C(2) – Cu(1) – C(5) 180.0(0) 
Cu(1) – N(8) 2.1433(16) N(8) – Cu(1) – C(2) – N(3) 26.546 
Cu(1) – N(8') 2.1433(16) C(2) – Cu(1) – N(8) – C(9) 22.991 
C(2) – N(3) 1.339(2) F(20) – Cu(1) – C(2) 82.049 
Cu(1) – F(20) 3.561 F(20) – Cu(1) – C(2) 82.693 
  calculated 
F(20) – Cu(1) – Z-axis 
 
10.831 
Table 5-4: Selected bond distances (Å) and angles (deg) in the solid-state structure of 
the bromoimidazolium salt [CuL76](PF6)2. 
The [CuL76](PF6)2 should have been analysed further using 1H NNR 
(paramagnetic) spectroscopy and EPR (electron paramagnetic resonance), in 
order to determine that the Cu centre of the complex has the oxidation state of 
+2 and would have an unpaired electron regardless of geometry. In addition, 
magnetic susceptibility would help confirm the one unpaired electron of the Cu(II) 
centre. The edge peak from X-ray absorption spectroscopy would also allow the 
determination of the Cu oxidation state. 
[CuL76](PF6)2 was examined using cyclic voltammetry. The measurements were 
performed under an atmosphere of Ar using a MeCN solution of [N(n-Bu)4]PF6 
as the supporting electrolyte (0.10 M), scanning at 0.10 V•s-1 from - 1.3 V to + 
2.0 V (Figure 5-18). The cyclic voltammogram shows two irreversible oxidations 
at Eox = - 0.13 V and + 0.32 V versus the Ag/AgCl reference. The latter may be 
corresponding to the oxidation of Cu(II) to an unstable Cu(III) species, rendering 
the oxidation irreversible. 
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Figure 5-18: Cyclic voltammogram of [CuL76](PF6)2 illustrating its irreversible 
oxidation at -0.13 V and + 0.32 V. Conditions: [[CuL76](PF6)2] = 0.4 mM, media = 
N(n-Bu)4PF6 0.10 M in MeCN, scan rate = 100 mV•s-1, T = 298 K. 
To assess the chemical oxidation of [CuL76](PF6)2, an oxidant was selected that 
would give a neutral product so that the anticipated charged Cu(III) complex 
could be easily separated. Previously, the Fe(II) complex FeL76(PF6)2 was 
oxidised by thianthrenyl PF6 77 to yield an Fe(III) complex FeL76(PF6)3.27 77 was 
prepared by addition of [NO]PF6 salt to thianthracene in MeCN under an inert 
atmosphere and obtained as a dark blue solid, which was stored in a Glovebox 
(Scheme 5-31). 
 
Scheme 5-31: Preparation of the oxidant 77. 
Reaction of [CuL76](PF6)2 with 77 in CD3CN showed that 77 was reduced, as 
there are sharp peaks corresponding to 78 in the 1H NMR spectrum. Other 
changes in the 1H NMR spectrum were unassignable. The HR mass spectrum 
did not give signals corresponding to the starting material [CuL76]2+ or 
anticipated products such as [CuL76]3+, [CuL76]+ or [L76 + H]2+, with only 
[78 + H]+ being assigned. This suggests that the reduction of 77 to 78 occurred, 
and it is likely that the oxidation of Cu(II) to Cu(III) also took place but with the 
desired product being unstable. This was also inferred in the CV studies. 
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It is possible that the PF6
-
 anion is too weak to stabilise the Cu(III)-NHC due to 
distributed charge among 6 fluoride atoms, with a triflate ion (OTf
-
) being used in 
Ribas's work.24 H2L76(OTf)2 was prepared via anion exchange by addition of 2 
equivalents of AgOTf to a stirring suspension of H2L76Br2 in MeCN. The product 
was characterised by 1H and 13C {1H} NMR spectroscopies and HRMS. Attempts 
were made to prepare a Ag complex for transmetallation, though the desired Ag-
NHC did not appear to form (Scheme 5-32). 
 
Scheme 5-32: Attempted synthesis of [AgL76](OTf). 
Instead, anion exchange was carried out at the last step following 
transmetallation, and the imidazolium Br
-
 salt was used as the starting material. 
The preparation of [CuL76](OTf)2 was achieved via the formation of [Ag2L762]Br2 
using Ag2O in MeOH, followed by transmetallation on to CuBr2. AgOTf was 
added to a MeCN solution of [CuL76Br2] resulting in a grey mixture, which was 
filtered and the solvent removed from the filtrate to afford [CuL76](OTf)2 as a 
greyish green solid (25 % yield, Scheme 5-33). The complex was characterised 
by 1H NMR spectroscopy and HRMS, which showed the [CuL76(OTf)]+ peak in 
the mass spectrum. 
 
Scheme 5-33: In situ preparation of [CuL76](OTf)2. 
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As previously, CuL76(OTf)2 was reacted with 77 in an NMR tube, resulting in a 
1H NMR spectrum similar to that following the reaction of the PF6
-
 derivative with 
77. Therefore, it is likely that the neutral macrocyclic ligand was not stable 
enough to stabilise the Cu(III) ion and an alternative ligand design is required. 
[CuL76](OTf)2 was examined using cyclic voltammetry. The measurements were 
performed under an atmosphere of Ar using a MeCN solution of N(n-Bu)4PF6 as 
the supporting electrolyte (0.10 M), scanning at 0.10 V•s-1 from – 2.0 V to + 2.0 V. 
The cyclic voltammogram shows one oxidation at Eox = + 0.6 V versus the 
Ag/AgCl reference, which may be corresponding to the oxidation of Cu(II) to a 
Cu(III) species. However, the reduction at Ered = - 0.2 V was unknown. This may 
be the reversed reduction of Cu(III) to Cu (II) but the chemical oxidation 
experiments using [CuL76](OTf)2 with 77 suggested that the Cu(III) was not 
stable enough. 
 
Figure 5-19: A single-round cyclic voltammogram of [CuL76](OTf)2 using Electrasyn. 
Conditions: [[CuL76(OTf)2]] = 0.4 mM, media = N(n-Bu)4PF6 0.10 M in MecN, scan 
rate = 100 mV•s-1, T = 298 K. 
5.6 Conclusions 
Previously, Willans had demonstrated that 1-allyl-3-pyridylimidazol-2-ylidene 
(L8) can form an isolable complex with CuBr2 with stabilisation through the 
pyridyl N-substituent, but undergoes reductive elimination of bromo-imidazolium 
in the presence of excess CuBr2.6,7 In this chapter, we have investigated further 
reactivity of the reductively eliminated bromo-imidazolium salt, which undergoes 
an annulation reaction. 1-Allyl-2-bromo-3-pyridylimidazolium (S8) was prepared 
by the selective C-2 bromination of pyridyl-imidazole and allylation, and was 
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examined with the presence and absence of CuBr. This demonstrated that the 
annulation reaction only occurs when 2 equivalents of CuBr are present. The 
proposed mechanism involves oxidative addition of the Cimidazolium-Br bond at one 
Cu, which is held in close proximity by the coordinated pyridine ring, and alkene 
coordination at a second Cu centre. DFT calculations are in progress to 
determine if the proposed mechanism is feasible. Understanding the mechanism 
provides valuable knowledge for ligand design in catalysis, in addition to potential 
synthetic route to common scaffolds in pharmaceutical and agrochemical 
compounds. 
Attempts have been carried out to prepare a Cu(III)-NHC using different 
macrocyclic ligands and various approaches, including oxidative addition of C-Br 
to Cu(I) and oxidation of preformed Cu(II)-NHC complexes. Preparation of novel 
Cu(II)-NHC complexes with PF6
-
 and OTf
-
 counterions were successful, although 
confirming their oxidation was challenging, likely due to the formation of unstable 
complexes.  
5.7 Future work 
A new ligand design to stabilise a Cu(II)-NHC may involve an anionic-tethered 
macrocycle, as the negative charge would help stabilise the hard acid. L79 
(Figure 5-20), which is macrocyclic and has an anionic amide functional group, 
could be formed by deprotonation of the corresponding secondary amine. 
However, the preparation of the ligand precursor might be troublesome due to 
the selectivity of nucleophilic substitution occurring at the sp3-amine over the sp2-
imidazole. The tertiary amide may be used to form a macrocyclic precursor, 
which can be reduced to the desired amine with LAH. 
 
Figure 5-20: Structure of proposed anionic macrocyclic L79. 
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5.8 Experimental 
5.8.1 Preparation of S8.a (via reductive elimination) 
i) Preparation of AgL8Br 
HL8Br (1.0 g, 3.76 mmol) and Ag2O (0.56 g, 2.40 
mmol) were added to freshly activated 4Å molecular 
sieves. DCM (50 mL) was added, and the reaction 
mixture was stirred at room temperature in the absence 
of light for 4 hours. The mixture was filtered through Celite, and the solvent was 
removed from the filtrate in vacuo to give a brown oil. The oil was recrystallised 
in CHCl3 / pentane to obtain a brown solid. Yield: 0.456 g, 1.22 mmol, 34 %. 
1H NMR (300 MHz, CDCl3) δ (ppm) 8.53 (dd, J = 4.8, 1.1 Hz, 1H, pyH-6), 8.11 
(d, J = 8.2 Hz, 1H, phH), 7.95 – 7.83 (m, 2H, pyH and imH), 7.38 (ddd, J = 7.4, 
4.9, 0.8 Hz, 1H, pyH-5), 7.16 (d, J = 1.9 Hz, 1H, imH), 6.02 (ddt, J = 16.3, 10.3, 
6.0 Hz, 1H, CH=CH2), 5.35 (dd, J = 24.3, 7.1 Hz, 2H, CH=CH2), 4.89 (dt, J = 6.0, 
1.3 Hz, 2H, NCH2-vinyl). 13C {1H} NMR (75 MHz, CDCl3) δ (ppm) 150.8, 149.1, 
139.4, 132.2, 123.9, 121.5, 120.4, 115.4, 55.3. HRMS (ESI+): m/z 477.0844 
[Ag(NHC)2]+, calculated [Ag(NHC)2]+ 477.0951. 
Consistent with data previously reported.28 
ii) Preparation of S8.a 
AgL8Br (0.30 g, 0.80 mmol) and CuBr2 (0.36 g) were 
added to a Schlenk flask, and the mixture dried and 
degassed in vacuo. Anhydrous MeCN (30 mL) was 
added, and the reaction mixture was stirred at room 
temperature in the absence of light for 1.5 hours. The mixture volume was 
reduced in vacuo to 10 mL. Et2O (100 mL) was added to precipitate a dark-green 
oil-solid. The crude product was recrystallised in CHCl3 / Et2O. Dark green 
crystals were collected by filtration and dried in vacuo as a mixture. Yield: 0.30 
g, 0.48 mmol, (59 %). 
HRMS (ESI+): m/z 263.9967 [S8.a – Cu2Br3]+, calculated [S8.a – Cu2Br3]+ 
264.0131. 1H NMR spectrum (300 MHz, CD3CN) was obtained as a mixture of 
S8.a and Cy8. Analysis Calculated for C11H11N3BrCu2Br3: C, 20.91; H, 1.75; 
N, 6.65. Analysis Calculated for C11H11N3BrCu4Br5.MeCN: C, 16.27; H, 1.47; 
N, 5.84. Analysis Calculated for ½ C11H11N3Br + ½ C11H12N3 + ¾ Cu2Br3 + ¼ 
CuBr2: C, 23.74; H, 2.08; N, 7.55. Found: C, 23.60; H, 2.05; N, 7.30. 
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Single crystals suitable for X-ray diffraction analysis were grown via the vapour 
diffusion of Et2O into a concentrated solution of the product in MeCN. 
5.8.2 Bromination of imidazoles 
i) Preparation of PS8 
NBS (1.27 g, 7.21 mmol) was added to a Schlenk flask. MeCN 
(20 mL) was added, followed by P8 (1.0 g, 6.9 mmol) whilst 
vigorously stirring. The reaction was heated at 70 ºC for 2 
hours and allowed to cool to room temperature. The solvent was removed in 
vacuo. The crude mixture was suspended in DCM (50 mL) and washed with 5% 
NaHCO3 solution (50 × 5 mL), dried over Na2SO4 and solvent removed in vacuo 
to give a dark brown solid. The crude product was purified by fractional column 
chromatography (silica gel), eluting by EtOAc / petroleum ether 40 (50: 50) to 
obtain a pale yellow solid. Yield: 0.643 g, 2.86 mmol, 42%. 
1H NMR (300 MHz, CDCl3) δ (ppm) 8.52 (ddd, J = 4.9, 1.9, 0.9 Hz, 1H, pyH-6), 
7.83 (ddd, J = 8.1, 7.5, 1.9 Hz, 1H, pyH-4), 7.53 (dt, J = 8.1, 0.9 Hz, 1H, pyH-3), 
7.41 (d, J = 1.6 Hz, 1H, imH), 7.32 (ddd, J = 7.5, 4.9, 0.9 Hz, 1H, pyH-5), 7.07 
(d, J = 1.6 Hz, 1H, imH). 13C {1H} NMR (75 MHz, CDCl3) δ (ppm) 149.4 (C), 138.5 
(C), 138.0 (CH), 130.4 (CH), 123.5 (CH), 122.7 (CH), 119.3 (CH), 117.4 (CH). 
HRMS (ESI+): m/z 223.9815 [M + H]+, calculated [M + H]+ 223.9818. Analysis 
Calculated for C8H6N3Br + 1/8EtOAc : C, 43.43; H 3.00; N, 17.88. Found: C, 
43.40; H, 3.00, N, 17.90. 
Single crystals suitable for X-ray diffraction analysis were grown via the vapour 
diffusion of pentane into a concentrated solution of the product in chloroform. 
ii) Attempted bromination of P6 
1-Tritylimidazole (P6, 0.10 g, 0.32 mmol) was added to an 
ampoule and THF (3 mL) added. The solution was cooled 
to -78 ºC. n-Buli in hexane (0.34 mL, 1M, 0.34 mmol) was added 
slowly, which turned the reaction mixture deep red. The reaction mixture was 
stirred at room temperature for 1.5 hours. It was cooled to -78 ºC again and 
solution of NBS (0.060 g, 0.34 mmol) in dry/degassed THF (3 mL) was added 
slowly via a syringe. The reaction was stirred for further 30 mins at the low 
temperature. After that, it was poured into water (10 mL) and concentrated in 
vacuo. The mixture was extracted with Et2O (3 × 10 mL). The organic extracts 
were combined, dried over MgSO4 and the solvent removed in vacuo. However, 
either 1-trityl-2-bromoimidazole or 2-bromoimidazole was not observed in LCMS 
or HRMS. 
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iii) Preparation of THP-imidazole 
Imidazole (0.2 g, 2.94 mmol) was added to an ampoule. 
Anhydrous THF (15 mL), 3,4-dihydro-2H-pyran (2.7 mL, 29.4 
mmol) and sulfuric acid (7 μL, 0.15 mmol) were added. The 
colourless reaction mixture was stirred at 60 ºC for 22 hours and the solvent and 
excess pyran removed in vacuo. The crude colourless crystals were dissolved in 
EtOAc (100 mL), washed with saturated NaHCO3 solution (50 mL), water (50 
mL) and brine (50 mL), dried over Na2SO4 and solvent removed in vacuo. The 
colourless oil was dissolved in Et2O (1 mL) and hexane (20 mL) was added 
slowly to precipitate a colourless oil, which was collected by decanting off the 
solvents. Yield: 0.060 g, 0.39 mmol, 13%. 
1H NMR (300 MHz, CDCl3) δ (ppm) 7.66 (s, 1H, imH-2), 7.07 (s, 2H, imH), 5.55 
(d, J = 2.3 Hz, 1H, THP), 4.11 – 3.97 (m, 1H, THP), 3.83 (dd, J = 13.9, 7.3 Hz, 
1H, THP), 2.34 (ddd, J = 23.2, 15.9, 8.0 Hz, 1H, THP), 2.13 – 1.77 (m, 5H, THP). 
13C {1H NMR (75 MHz, CDCl3) δ (ppm) 135.1 (CH), 121.7 (CH), 120.0 (CH), 98.3 
(CH), 67.3 (CH2), 33.3 (CH2), 23.5 (CH2), 22.2 (CH2). There were no 
corresponding peaks in HRMS, likely due to cleavage of the protecting group. 
Consistent with data previously reported.29 
iv) Attempted bromination of THP-imidazole 
1-THP-imidazole (0.06 g, 0.39 mmol) was added to an 
ampoule, THF (1 mL) added and the colourless solution was 
cooled to -78ºC. n-BuLi in hexane (0.47 mL, 1M, 0.47 mmol) 
was added dropwise resulting in a pale yellow solution. The solution was stirred 
at -78ºC for 25 minutes and a solution of NBS (0.11 g, 0.59 mmol) in THF (1 mL) 
was added dropwise. The solution was stirred at -78 ºC for 1.5 hr and stirred for 
a further 1 hour at room temperature. The reaction mixture was quenched with 
saturated NaHCO3 solution (10 mL) and extracted with DCM (3 × 20 mL). The 
organic layers were combined, dried over MgSO4 and the solvents removed in 
vacuo. However, there was neither 1-THP-2-bromoimidazole nor 
2-bromoimidazole in HRMS. 
v) Preparation of ionic liquid 54 
1-Butyl-3-metylpyridinium bromide (1.0 g, 4.3 mmol) was ground 
and added to a Schlenk flask. Bromine (0.3 mL, 5.81 mmol) was 
added whilst stirring and the reaction was stirred for 2 hours. Excess 
bromine was removed in vacuo for 3 hours. Due to the viscosity of 
the product, the ionic liquid was dissolved in MeOH to support the transfer and 
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collection. The MeOH was removed in vacuo to give deep-orange liquid. Yield: 
1.41 g, 3.61 mmol, 83 %. 
1H NMR (CDCl3, 300 MHz): δ (ppm) 8.64 (s, 1H, pyH-2), 8.62 (d, J = 7.8 Hz, 1H, 
pyH-6), 8.07 (d, J =7.8 Hz, 1H, pyH-4), 7.74 (t, J = 7.8 Hz, 1H, pyH-5), 4.41 (t, J 
= 7.5 Hz, 2H, NCH2CH2CH2CH3), 2.40 (s, 3H, CH3), 1.72 (m, 2H, 
NCH2CH2CH2CH3), 1.16 (m, 2H, NCH2CH2CH2CH3), 0.72 (t, J = 7.5 Hz, 3H, 
NCH2CH2CH2CH3). 13C {1H} NMR (CDCl3, 75 MHz): δ (ppm) 145.5 (CH), 143.4 
(CH), 141.1 (C), 139.0 (CH), 128.5, 61.3 (CH2), 32.9 (CH2), 18.7 (CH3), 17.9 
(CH2), 12.8 (CH3). 
Consistent with data previously reported.22 
vi) Attempted bromination of imidazole by brominating reagent 54 
Imidazole (0.70 g, 10.3 mmol) and 54 (2.5 g, 6.4 mmol) were to 
Schlenk flasks. MeCN (15 mL) was added to the imidazole and MeCN 
(40 mL) was added to 54. Both solutions were cooled to 0 ºC and the 
54 solution was transferred to the imidazole solution via cannula, and the mixture 
stirred at 0 ºC for 15 minutes. Then water was added and the mixture was 
concentrated in vacuo. Et2O (100 × 3 mL) were used to extract bromoimidazole 
species. The solvent was removed from the combined organic solution in vacuo. 
The product was purified by fractional column chromatography (silica gel) eluting 
by DCM / MeOH (95:5) → DCM / MeOH (90:10). Bromoimidazole was obtained 
as a colourless solid and analysed to be the compound 60 instead of the desired 
57 (2-bromoimidazole). Yield: 0.19 g, 1.29 mmol, 20 % 
1H NMR (300 MHz, d6-DMSO) δ (ppm) 12.39 (s, broad, 1H, NH), 7.62 (s, 1H, 
imH-2), 7.24 (s, 1H, imH-4). 13C {1H} NMR (126 MHz, d6-DMSO) δ (ppm) 135.9 
(CH), 115.6 (CH), 113.5 (C). HRMS (ESI+): m/z 146.9546 [M + H]+, calculated 
[M + H]+ 146.9552. Analysis Calculated for C3H3BrN2 ¼CH3OH: C, 24.86; H 2.34; 
N, 18.55. Found: C, 25.10; H, 2.10, N, 18.40. 
Inconsistent with reported NMR data (for 2-bromoimidazole): 1H NMR (400 MHz, 
CDCl3) δ 12.76 (sl, 1H), 7.11 (s, 2H).30 
vii) Attempted bromination of benziimidazole by brominating reagent 54 
Benzimidazole (0.24 g, 2.05 mmol) and 54 (0.5 g, 1.28 mmol) were 
separately to Schlenk flask. MeCN (2 mL) was added to the 
benzimidazole and MeCN (2 mL) was added to 54. Both solutions 
were cooled to 0 ºC and the 54 solution was transferred to the 
imidazole solution, and the mixture stirred at 0 ºC for 1 hour. The reaction mixture 
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was stirred at room temperature for 1 hour and at 40 °C for 20 hours and the 
MeCN was removed in vacuo. The crude yellow liquid was partitioned in water 
(25 mL) and Et2O (25 mL). The organic layer was dried over Na2SO4 and solvent 
removed in vacuo to afford an off-white solid. Yield: 0.05 g, 0.25 mmol, 20 % 
1H NMR (300 MHz, CDCl3) δ (ppm) 9.35 (s, 1H, NH), 8.08 (s, 1H, imH-2), 7.75 
(d, J = 1.7 Hz, 1H, BzmH), 7.46 (d, J = 8.6 Hz, 1H, BzmH), 7.33 (dd, J = 8.6, 1.6 
Hz, 1H, BzmH). 13C {1H} NMR (75 MHz, CDCl3) δ (ppm) 141.6 (C), 139.0 (CH), 
136.7 (C), 126.3 (CH), 118.5 (CH), 116.8 (C), 116.1 (CH). HRMS (ESI+): m/z 
196.9723 [M + H]+, calculated [M + H]+ 196.9709.  
viii) Preparation of P64 
 1-Methylimidazole (0.5 mL, 6.3 mmol) and anhydrous THF (10 mL) 
were added to an ampoule. The reaction mixture was cooled to -78 
°C and n-BuLi (1.6 M, 4 mL, 6.3 mmol) was added slowly and stirred 
for 1 hour. A solution of CBr4 (0.2 g, 0.63 mmol) and NBS (1.12 g, 6.3 mmol) in 
THF (10 mL) was added. The mixture was stirred at -78 °C for 2 hours, then at 
room temperature for 1 hour. EtOAc (20 mL) was added and washed with NH4Cl 
solution. The organic layer was dried over Mg2SO4 and the solvent removed in 
vacuo to give a brown solid. The crude product was purified by fractional column 
chromatography (silica gel), eluting with EtOAc / petroleum ether 40 (50: 50) to 
obtain an off-white solid. Yield: 0.47 g, 2.9 mmol, 46 %. 
1H NMR (300 MHz, CDCl3) δ (ppm) 6.95 (d, J = 1.1 Hz, 1H, imH), 6.92 (d, J = 
1.1 Hz, 1H, imH), 3.58 (s, 3H, NCH3). 13C {1H} NMR (75 MHz, CDCl3) δ (ppm) 
129.8 (CH), 123.1 (CH), 120.1 (C), 34.6 (CH3). HRMS (ESI+): m/z 160.9710 [M 
+ H]+, calculated [M + H]+ 160.9709. 
Consistent with data previously reported.31 
5.8.3 Preparation of bromo-imidazolium/imidazole substrates 
i) Preparation of S8.b 
PS8 (0.5 g, 2.23 mmol) was dissolved in MeCN (20 mL) 
and then allyl bromide (1.0 mL, 11.1 mmol) was added 
dropwise, and the reaction mixture was stirred at 80 ºC 
under N2 and hydrous conditions for 24 hours. The 
mixture was allowed to cool to room temperature. Et2O (150 mL) was added to 
precipitate a pale brown solid which was collected by filtration. The solid was 
washed with Et2O (100 mL) and dried in vacuo. Yield: 0.71 g, 2.06 mmol, 92 %. 
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1H NMR (300 MHz, CDCl3) δ (ppm) 8.66 (ddd, J = 4.9, 1.9, 0.9 Hz, 1H, py-H6), 
8.33 (dt, J = 7.8 Hz, 0.9Hz, 1H, pyH-3), 8.10 (td, J = 7.8, 1.9 Hz, 1H, pyH-4), 8.03 
(d, J = 2.3 Hz, 1H, imH), 7.98 (d, J = 2.3 Hz, 1H, imH), 7.62 (ddd, J = 7.8, 4.9, 
0.9 Hz, 1H, pyH-5), 6.14 (ddt, J = 16.5, 10.1, 6.3 Hz, 1H, CH=CH2), 5.64 – 5.54 
(m, 2H, CH=CH2), 5.13 (dt, J = 6.3, 1.2 Hz, 2H, NCH2-vinyl). 13C {1H} NMR (75 
MHz, CDCl3) δ (ppm) 149.9 (C), 149.9 (C), 149.8 (CH), 140.2 (CH), 128.5 (CH), 
126.3 (CH), 124.6 (CH), 124.2 (CH), 123.3 (CH), 121.3 (terminal CH2), 53.6 
(CH2). HRMS (ESI+): m/z 264.0133 [M – Br]+, calculated [M – Br]+ 264.0131. 
Analysis Calculated for C11H11N3Br2: C, 38.29; H 3.21; N, 12.18. Found: C, 37.95; 
H, 3.10, N, 12.00. 
Single crystals suitable for X-ray diffraction analysis were grown by the vapour 
diffusion of Et2O into a concentrated solution of the product in MeCN/MeOH. 
ii) Preparation of S53 
NaH (67 mg, 2.79 mmol) was added to a Schlenk flask and 
cooled to 0 ºC. Dry THF (1 mL) was added, followed by 
2-bromobenzimidazole (0.50 g, 2.53 mmol) while stirring. The 
white suspension was left to reach room temperature then allyl 
bromide (0.26 mL) was added, and the reaction mixture was 
stirred at 60 ºC for 24 hours. Water (10 mL) was added to quench excess NaH. 
The aqueous solution was extracted with DCM (3 × 20 mL), which were 
combined, dried over MgSO4 and the solvents removed in vacuo. The product 
was obtained as a pale yellow solid. Yield: 0.60 g, 2.53 mmol, 100 % 
1H NMR (400 MHz, CDCl3) δ (ppm) 7.73 – 7.58 (m, 1H, BzmH), 7.31 – 7.11 (m, 
3H, BzmH), 5.85 (ddt, J = 17.1, 10.3, 5.2 Hz, 1H, CH=CH2), 5.18 (dtd, J = 10.3, 
1.6, 0.8 Hz, 1H, CH=CH2 trans), 5.00 (dtd, J = 17.1, 1.8, 0.7 Hz, 1H, CH=CH2 
cis), 4.73 (dt, J = 5.1, 1.7 Hz, 2H, N-CH2-vinyl). 13C {1H} NMR (101 MHz, CDCl3) 
δ (ppm) 143.0 (C), 135.4 (C), 130.8 (CH), 129.9 (C), 123.3 (CH), 122.8 (CH), 
119.4 (CH), 118.3 (CH2), 109.8 (CH), 47.6 (CH2). HRMS (ESI+): m/z 237.0020 
[M + H]+, calculated [M + H]+ 237.0022. Analysis Calculated for C10H9N2Br: C, 
50.66; H 3.83; N, 11.82. Found: C, 50.30; H, 3.80, N, 11.60. 
iii) Preparation of S64 
PS64 (0.47 g, 2.9 mmol) was dissolved in MeCN (20 mL) and 
allyl bromide (1.25 mL, 14.5 mmol) was added dropwise, and 
the reaction mixture was stirred at 80 ºC under N2 and 
hydrous conditions for 24 hours. The mixture was allowed to 
reach room temperature and Et2O (150 mL) was added to precipitate a pale 
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brown solid which was collected by filtration. The solid was washed in Et2O (100 
mL) and dried in vacuo. Yield: 0.53 g, 1.88 mmol, 67 %. 
1H NMR (300 MHz, CD3CN) δ (ppm) 7.73 (s, 1H, imH), 7.71 (s, 1H, imH), 6.02 
(ddt, J = 16.7, 10.6, 5.7 Hz, 1H, CH=CH2), 5.44 (d, J = 10.6 Hz, 1H, CH=CH2 
trans), 5.33 (d, J = 16.7 Hz, 1H, CH=CH2 cis), 4.86 (d, J = 5.7 Hz, 2H, NCH2-
vinyl), 3.87 (s, 3H). 13C {1H} NMR (CD3CN) δ (ppm) 130.3 (CH), 125.7 (C), 124.1 
(CH), 123.8 (CH), 120.7 (CH2), 52.8 (CH2), 37.6 (CH3). HRMS (ESI+): m/z 
201.0033 [M – Br]+, calculated [M – Br]+ 201.0022. 
5.8.4 Reactivity of bromo-imidazoliums/imidazole at Cu 
i) Annulation of S8.a to afford Cy8 
S8.a (0.05 g, 79 mmol) was added an ampoule and the solid was heated at 95 
ºC for 6 days (above melting point). When the system was cooled to room 
temperature, the solid stuck to the glassware. The solid was collected by 
suspension in MeCN and the solvent removed in vacuo. Yield: 0.042 g, 84 %. 
The product was obtained as a mixture of Cy8 and S8.a. 
iv) Annulation of S8.b to afford Cy8 (with 2 equivalents of CuBr) 
S8.b (0.12 g, 0.35 mmol) and CuBr (0.1 g, 0.70 mmol) were added, followed by 
MeCN (1 mL). The green reaction mixture was stirred at room temperature for 
30 mins and the solvent was removed in vacuo. The dark solid was heated at 
90 ºC for 7 days. The crude mixture was recrystallised in MeCN / Et2O to obtain 
a dark green-grey solid. Yield: 0.14 g, 0.22 mmol, 64%. 
1H NMR (501 MHz, CD3CN) δ (ppm) 8.64 (d, J = 4.7 Hz, 1H, pyH-6), 8.12 (t, J = 
7.4 Hz, 1H, pyH-4), 8.06 (s, 1H, imH), 7.80 (d, J = 7.4 Hz, 1H, pyH-3), 7.63 (s, 
1H, imH), 7.58 (dd, J = 7.4, 4.7 Hz, 1H, pyH-5), 5.37 – 5.28 (m, 1H, pyrrolH-6), 
4.95 (dd, J = 13.5, 6.4 Hz, 1H, pyrrolH-5 trans), 4.66 (dd, J = 13.5, 2.9 Hz, 1H, 
pyrrolH-5 cis), 4.37 (dd, J = 19.5, 7.2 Hz, 1H, pyrrolH-7 trans), 4.01 (dd, J = 19.5, 
2.9 Hz, 1H, pyrrolH-7 cis). 13C {1H} NMR (126 MHz, CD3CN) δ (ppm) 150.6 (C), 
150.2 (CH), 147.9 (C), 141.4 (CH), 126.0 (CH), 124.3 (CH), 120.3 (CH), 115.8 
(CH), 59.4 (CH2), 44.3 (CH), 40.4 (CH2). HRMS (ESI+): m/z 264.0127 [Cy8 – 
Cu2Br3]+, calculated [Cy8 – Cu2Br3]+ 264.0131. 
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v) Cu-catalysed reaction of S53 (to give 62 and 63) 
To a solution of S53 (30 mg, 0.19 
mmol) in CD3CN (0.4 mL) in a 
Young's-tap NMR tube was added CuI 
(3.6 mg, 0.019 mmol) and DL-proline 
(4.4 mg, 0.038 mmol). The reaction 
was heated at 75 °C for 24 hours and 
samples were analysed using 1H NMR 
spectroscopy and HRMS. Multiple 
allyl peaks were observed in the 1H NMR spectrum and 62 and 63 were observed 
in HRMS.  
vi) Reactivity of S64 (no reaction) 
S64 (0.1 g, 0.35 mmol) was added to an ampoule and CuBr (0.102 g, 0.71 mmol) 
was added, folllowed by MeCN (3 mL). The green reaction mixture was stirred 
at room temperature for 30 mins, the solvent was removed in vacuo and the 
resulting oily solid was heated to 90 ºC for 169 hours. The crude mixture was 
dissolved in CD3CN for NMR analysis. 
1H NMR (300 MHz, CD3CN) δ (ppm) 7.61 (d, J =1.8 Hz, 1H, imH), 7.58 (d, J = 
1.8 Hz, 1H, imH), 6.00 (ddt, J = 17.3, 10.2, 5.7 Hz, 1H, CH=CH2), 5.44 (d, J = 
10.2 Hz, 1H, CH=CH2 trans), 5.33 (d, J = 17.3 Hz, 1H, CH=CH2 cis), 4.81 (d, J = 
5.7 Hz, 1H, NCH2-vinyl). 
Data was the same as the starting material (S64), suggesting there was no 
change in the imidazolium cation. 
5.8.5 Preparation of ligand precursors 
i) Preparation of 67 
An HBr solution (≥ 48 %w, 20 mL) was added slowly to 66 (2.0 
g, 14.4 mmol), followed by addition of H2SO4 (5 mL) and NaBr 
(4.0 g) to the stirring solution. The reaction mixture was heated 
at 120 °C for 24 hours. The reaction mixture was allowed to cool 
to room temperature and poured into deionised water (20 mL). A saturated 
NaHCO3 solution was added dropwise until pH = 8 was reached. The mixture 
was extracted with DCM (4 × 50 mL) and the organic layers were combined, 
dried over Na2SO4 and the solvent removed in vacuo to give a pale pink solid. 
The crude product was purified by flash column chromatography (silica gel), 
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eluting with EtOAc / hexane (1: 9)  EtOAc / hexane (1: 4) to give a colourless 
solid. Yield: 2.7 g, 10 mmol, 71 %. 
1H NMR (300 MHz, CDCl3) δ (ppm) 7.64 (t, J = 7.7 Hz, 1H, pyH-4), 7.31 (d, J = 
7.7 Hz, 2H, pyH-3 and pyH-5), 4.47 (s, 4H, 2(py-CH2-Br)). 13C {1H} NMR (75 
MHz, CDCl3) δ (ppm) 156.8 (C), 138.1 (CH), 122.8 (CH), 33.5 (CH2). HRMS 
(ESI+): m/z 265.8989 [M + H]+, calculated [M + H]+ 265.8996. 
Consistent with data previously reported. 
ii) Preparation of 68 
Imidazole (0.61 g, 8.98 mmol) was added to an ampoule, 
followed by THF (5 mL). NaH (0.22 g, 8.98 mmol) was 
slowly added to the stirring imidazole solution and the 
reaction mixture was stirred for a further 1 hour. 67 (1.19 
g, 4.49 mmol) was added and stirred for at room 
temperature 20 hours. The reaction mixture was filtered 
and the solvent was removed from the filtrate in vacuo to afford the product as 
an off-white solid. Yield: 0.56 g, 2.37 mmol, 53 %. 
1H NMR (300 MHz, CDCl3) δ (ppm) 7.54 (t, J = 7.8 Hz, 1H, pyH-4), 7.51 (s, 2H, 
imH), 6.99 (s, 2H, imH), 6.89 (s, 2H, imH), 6.83 (d, J = 7.8 Hz, 2H, pyH-3 and 
pyH-5), 5.12 (s, 4H, 2(py-CH2-im)). 13C {1H} NMR (75 MHz, CDCl3) δ (ppm) 
156.2, 138.5, 137.6, 129.7, 120.4, 119.5, 52.1. HRMS (ESI+): m/z 240.1245 [M 
+ H]+, calculated [M + H]+ 240.1244; 120.5655 [M + 2H]2+, calculated [M + 2H]2+ 
120.5658; 479.2420 [2M + H]+, calculated [2M + H]+ 479.2415. 
Consistent with data previously reported. 
iii) Bromination of 68 (preparation of P65) 
68 (0.30 g, 1.25 mmol) was added to a Schlenk flask, 
followed by MeCN (5 mL) via syringe and slow addition of 
a solution of NBS (0.23 g, 1.32 mmol) in MeCN (10 mL) via 
cannula transfer. The reaction was stirred at room 
temperature for 24 hours and the solvent was removed in 
vacuo and the crude product was suspended in DCM (50 
mL) and washed with 5 % NaHCO3 solution (3 × 50 mL), dried over Na2SO4 and 
the solvent removed in vacuo to afford a dark brown solid. The solid was purified 
by fractional column chromatography (silica gel), eluting with 5 % MeOH in DCM 
to obtain a light brown solid. Yield: 8 mg, 0.025 mmol, 2 %. 
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1H NMR (500 MHz, CDCl3) δ (ppm) 7.76 (s, 1H, imH), 7.65 (t, J = 7.7 Hz, 1H, 
pyH-4), 7.14 (s, 1H, imH), 7.07 (s, 1H, imH), 7.06 (s, 1H, imH), 7.00 (s, 1H, imH), 
6.95 (d, J = 7.7 Hz, 1H, pyH), 6.90 (d, J = 7.7 Hz, 1H, pyH), 5.24 (s, 2H, NCH2-
py), 5.21 (s, 2H, NCH2-py). 13C {1H} NMR (126 MHz, CDCl3) δ (ppm) 156.4 (C), 
156.4 (C), 155.8 (C), 138.7 (CH), 138.6 (CH), 130.7 (CH), 122.9 (CH), 122.9 
(CH), 121.2 (CH), 120.8 (CH), 120.7 (CH), 52.8 (CH2), 52.6 (CH2). HRMS (ESI+): 
m/z 318.0362 [M + H]+, calculated [M + H]+ 318.0349; 637.0612 [2M + H]+, 
calculated [2M + H]+ 637.0604. 
iv) Preparation of 72 
In air, a mixture of 71 (5 mL, 37.5 mmol), NBS (13.4 g, 75.1 
mmol) and 73 (0.50 g, 1.88 mmol) in CCl4 (20 mL) and CHCl3 
(50 mL) was heated at 75 °C under hydrous conditions for 24 
hours. The reaction mixture was allowed to cool to room 
temperature and the solvents removed in vacuo. The crude colourless oil was 
suspended in CHCl3 (20 mL) and filtered. The filtrate was washed with water 
(3 × 20 mL) and the aqueous layers were combined and extracted with CHCl3 
(3 × 60 mL). The combined organic layers were dried over Na2SO4 and the 
solvent removed in vacuo. The crude product was purified by fractional column 
chromatography eluting with hexane to obtain a colourless solid. Yield: 2.9 g, 
8.5 mmol, 22 %.  
1H NMR (300 MHz, CDCl3) δ (ppm) 7.35 (d, J = 7.8 Hz, 2H, ArH-4 and ArH-6), 
7.22 (dd, J = 8.3, 7.0 Hz, 1H, ArH-5), 4.58 (s, 4H, NCH2Br). 13C {1H} NMR (75 
MHz, CDCl3) δ (ppm) 138.6, 131.5, 128.2, 126.8, 33.9. There were no relevant 
peaks observed in HRMS as 72 is unlikely to be ionised with either Na+ or K+ ion. 
Consistent with data previously reported. 
5.8.6 Preparation of macrocyclic imidazolium salts 
General procedure for preparation of imidazolium Br
-
 salts. Corresponding 
dibromide (1 equivalent) and 68 (1 equivalent) were added separately to Schlenk 
flasks. MeCN (10 mL) was added to each flask. The solution of dibromide was 
slowly transferred into the 68 solution via a syringe. The reaction mixture was 
stirred for 16 hours, during which time a colourless solid. The colourless solid 
was collected by filtration, washed with Et2O and dried in vacuo. 
  
 
 
189 
 
i) Preparation of H2L69Br2 
68 (0.090 g, 0.38 mmol) and 72 (0.129 g, 0.38 mmol) were reacted according to 
the general procedure to afford a colourless solid. Yield: 0.16 g, 0.275 mmol, 
73 %. 
1H NMR (300 MHz, d6-DMSO) δ (ppm) 8.71 (s, 2H, imH-2), 8.03 – 7.28 (m, 10H, 
ArH, pyH and imH), 5.57 – 5.50 (m, 8H, NCH2-py and NCH2-Ar). 13C {1H} NMR 
(75 MHz, d6-DMSO) δ (ppm) 158.0 (C), 140.9 (C), 138.3 (CH), 135,8 (CH), 128.5 
(CH), 127.3 (C), 127.1 (CH), 122.9 (CH), 122.7 (CH), 120.5 (CH), 58.4 (CH2), 
54.3 (CH2). HRMS (ESI+): m/z 210.5461, 211.5451 [M – 2Br]2+, calculated 
[M – 2Br]2+ 210.5446, 211.5435. 
ii) Preparation of H2L75Br2 
68 (0.6 g, 2.5 mmol) and 74 (0.66 g, 2.5 mmol) were reacted according to the 
general procedure to afford a sticky solid, on which anion exchange was 
subsequently carried out to afford H2L75(PF6)2 (see below). 
iii) Preparation of H2L76Br2 
67 (1.33 g, 5.01 mmol) and 68 (1.20 g, 5.01 mmol) were reacted according to 
the general procedure to afford a colourless solid. Yield: 1.70 g, 3.37 mmol, 
67 %. 
1H NMR (300 MHz, d4-MeOH) δ (ppm) 8.95 (t, J = 1.4 Hz, 2H, imH-2), 7.86 (t, J 
= 7.6 Hz, 2H, pyH-4), 7.53 (d, J = 7.6 Hz, 4H, pyH-3 and pyH-5), 7.43 (d, J =1.4 
Hz, 4H, imH-4 and imH-5), 5.50 (s, 4H, NCH2-py). 13C {1H} NMR (75 MHz, dd-
MeOH) δ (ppm) 154.0, 140.3, 133.3, 124.6, 122.8, 54.2. HRMS (ESI+): m/z 
172.0869 [M – 2Br]2+, calculated [M – 2Br]2+ 172.0869. 
General procedure for anion exchange to form imidazolium PF6
-
 salts. The 
corresponding bromide salt (1 equivalent) was dissolved in a minimum volume 
of water, followed by addition of NH4PF6 (10 equivalents) whilst vigorously 
stirring in air under hydrous conditions, to afford a colour less solid. The solid 
was collected by filtration, washed with MeOH and Et2O, and dried in vacuo. The 
process was assumed to go to completion as the precipitation of  
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i) Preparation of H2L69(PF6)2 
H2L69Br2 (0.10 g, 0.14 mmol) and NH4PF6 (0.22 g, 
1.4 mmol) were reacted according to the general 
procedure to afford a colourless solid. Yield: 0.060 g, 
0.095 mmol, 68 %. 
1H NMR (300 MHz, CD3CN) δ (ppm) 8.15 (s, 2H, 
imH-2), 7.92 (t, J = 7.8 Hz ,1H, pyH-4), 7.83 (d, J = 7.8 
Hz, 2H, pyH-3 and pyH-5), 7.70 (t, J = 7.8 Hz ,1H, ArH-
4), 7.56 (d, J = 7.8 Hz, 2H, ArH-3 and ArH-5), 7.49 (d, J 
= 1.7 Hz, 2H, imH), 7.42 (d, J = 1.7 Hz, 2H, imH), 5.55 (d, J = 14.6 Hz, 2H, NCH2-
py), 5.34 (d, J = 15.1 Hz, 2H, NCH2-Ar), 5.32 (d, J = 14.6 Hz, 2H, NCH2-py), 5.17 
(d, J = 15.1 Hz, 2H, NCH2-Ar). 13C {1H} NMR (75 MHz, CD3CN) δ (ppm) 154.3 
(C), 140.2 (C), 136.5 (CH), 135.9 (CH), 135.5 (CH), 130.6 (CH), 125.0 (C), 124.9 
(CH), 124.9 (CH), 123.8 (CH), 55.3 (CH2), 54.7 (CH2). HRMS (ESI+): m/z 
210.5485, 211.5476 [M – 2PF6]2+, calculated [M – 2PF6]2+ 210.5446, 211.5435. 
ii) Preparation of H2L75(PF6)2 
The sticky H2L75Br2 was dissolved in water and NH4PF6 
(3.9 g, 25 mmol) was added. The mixture was reacted 
according to the general procedure to afford a colourless 
solid. Yield: 1.22 g, 1.92 mmol, 77 %. 
1H NMR (300 MHz, CD3CN) δ (ppm) 8.5 (s, 2H, imH-2), 
7.97 (t, J = 7.7 Hz, 1H, pyH-4), 7.60 – 7.35 (m, 10 H, pyH, 
ArH and imH), 5.43 (s, 4H, NCH2-py), 5.39 (s, 4H, NCH2-
Ar). 13C {1H} NMR (75 MHz, CD3CN) δ (ppm) 154.0 (C), 
140.0 (CH), 139.7 (C), 137.1 (CH), 136.5 (CH), 135.7 (CH), 131.1 (CH), 130.6 
(CH), 130.2 (CH), 130.0 (CH), 129.5 (CH), 125.1 (CH), 124.6 (CH), 124.3 (CH), 
123.9 (CH), 123.4 (CH), 123.1 (CH), 118.3 (CH), 54.4, 54.2, 53.4, 53.1. HRMS 
(ESI+): m/z 171.5901 [M – 2PF6]2+, calculated [M – 2PF6]2+ 171.5893. 
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iii) Preparation of H2L76(PF6)2 
H2L76Br2 (1.30 g, 2.6 mmol) and NH4PF6 (4.2 g, 26 
mmol) were reacted according to the general procedure 
to afford a colourless solid. Yield: 1.158 g, 1.83 mmol, 70 
%. 
1H NMR (300 MHz, CD3CN) δ (ppm) 8.55 (s, 2H, imH-2), 
7.96 (t, J = 7.7 Hz, 2H, pyH-4), 7.54 (d, J = 7.7 Hz, 4H, 
pyH-3 and pyH-5), 7.34 (s, 4H, imH-4 and imH-5), 5.44 
(s, 8H, NCH2-py). 13C {1H} NMR (75 MHz, CD3CN) 
δ (ppm) 153.8 (C), 139.7 (CH), 137.6 (CH), 124.1 (CH), 123.7 (CH), 54.0 (CH2). 
HRMS (ESI+): m/z 172.0867 [M – 2PF6]2+ calculated [M – 2PF6]2+ 172.0869. 
Preparation of an imidazolium OTf salt. 
H2L76Br2 (0.40 g, 0.79 mmol) was added to ampoule. 
MeCN (10 mL) was added, followed by AgOTf (0.41 g, 
1.59 mmol) whilst vigorously stirred and the mixture 
stirred for a further 1 hour, during which time a yellow 
precipitate was observed. The precipitate was 
removed by cannula filtration and the volume of the 
filtrate was reduced to about 2 mL in vacuo. Et2O (50 
mL) was added to precipitate a colourless solid, which 
was collected via cannula filtration. The colourless product was washed with 
anhydrous Et2O (10 mL) and dried in vacuo. Yield: 0.40 g, 0.66 mmol, 84 %. 
1H NMR (300 MHz, CD3CN) δ (ppm) 8.65 (t, J = 1.5 Hz, 2H, imH-2), 7.92 (t, J = 
7.7 Hz, 2H, pyH-4), 7.52 (d, J = 7.7 Hz, 4H, pyH-3 and pyH-5), 7.34 (d, J = 1.5 
Hz, 4H, imH-4 and imH-5), 5.44 (s, 8H, NCH2-py). 13C {1H} NMR (75 MHz, 
CD3CN) δ (ppm) 153.2 (C), 138.6 (CH), 136.6 (CH), 124.0 (CH), 123.4 (CH), 
53.8 (CH2). HRMS (ESI+): m/z 172.0871 [M – 2OTf]2+ calculated [M – 2OTf]2+ 
172.0869. 
5.8.7 Preparation of complexes using the electrochemical method 
i) Preparation of [CuL69](PF6): 1st attempt 
H2L(PF6)2 (80 mg, 0.126 mmol) was added to a flame-dried three-necked round-
bottomed flask. MeCN (20 mL) was added via syringe and two Cu electrodes 
were inserted into the solution. A voltage was applied to achieve a current of 30 
mA, which was maintained for 15 minutes. The solvent was removed in vacuo to 
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give a green solid, which was analysed in anhydrous CD3CN or MeCN prepared 
in a Glovebox. 
ii) Preparation of [CuL69](PF6): 2nd attempt 
H2L69(PF6)2 (235 mg, 0.37 mmol) was added to a flame-dried three-necked 
round-bottomed flask. MeCN (20 mL) was added via syringe and two Cu 
electrodes were inserted into the solution. A voltage was applied to achieve a 
current of 20 mA, which was maintained for 60 minutes. The solvent was 
removed in vacuo to give a green solid, which was analysed in anhydrous 
CD3CN or MeCN prepared in a Glovebox. 
5.8.8 Preparation of complexes via silver transmetallation 
i) Attempted preparation of [AgL69](PF6) 
H2L69(PF6)2 (0.2 g, 0.28 mmol) and Ag2O (0.065 g, 0.28 mmol) were added to 
freshly activated 4Å molecular sieves. In the absence of light, DCM (5 mL) was 
added via syringe and the mixture stirred for 3 hours, after which time a HRMS 
of the reaction sample showed the formation of [AgL69]+ ion. The reaction 
mixture was filtered via cannula filtration. The solvent was removed from the 
filtrate in vacuo and recrystallised by DCM / hexane to obtain a sticky light brown 
solid. Yield: undetermined. The [AgL69]+ was no longer observed from the 
product sample. 
ii) Attempted preparation of CuL69Br via in situ [AgL69]+ 
H2L69(PF6)2 (0.05 g, 0.070 mmol) and Ag2O (0.016 g, 0.070 mmol) were added 
to freshly activated 4Å molecular sieves and dried in vacuo. In the absence of 
light, DCM (5 mL) was added via syringe and the mixture stirred for 1 hour. CuBr 
(0.010 g, 0.070 mmol) was added and the mixture stirred for 2 hours. Neither 
[AgL69]+ nor [CuL69]+ was observed in the HRMS of the reaction sample. 
iii) Preparation of [AgL75](PF6) 
H2L75(PF6)2 (0.2 g, 0.32 mmol) and Ag2O (0.073 g, 0.32 mmol) were added to 
the freshly activated 4Å molecular sieves. In the absence of light, MeCN (10 mL) 
was added via syringe and stirred for 4 hours. MeOH (10 mL) was added and 
stirred for 16 hours. The mixture was filtered through Celite and the solvents 
were removed from the filtrate in vacuo to afford a brown oil. The crude brown 
oil was recrystallised in MeCN (3 mL) / Et2O (50 mL) to give a light brown solid. 
Yield: 0.20 g, over theoretical yield (likely with a trace of Ag(PF6)) 
1H NMR (300 MHz, CD3CN) δ (ppm) 7.91 – 6.85 (m, 11H), 5.48 – 5.00 (m, 8H). 
13 C {1H} NMR (126 MHz, CD3CN) resonance was too weak and noisy despite 
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6000-scan experiment. HRMS (ESI)+: m/z 448.0682 [AgL75]+, calculated 
[AgL75]+ 448.0691. 
iv) Preparation of [CuL75](PF6) 
In the absence of light, [AgL75](PF6) (0.050 g, 0.084 mmol) and CuI (0.016 g, 
0.084 mmol) were mixed in MeCN (50 mL) for 24 hours. The mixture was filtered 
through Celite. The filtrate was concentrated to about 2 mL in volume and Et2O 
(70 mL) was added to precipitate a pale green solid, which was collected by 
cannula filtration and dried in vacuo. Yield: 0.0265 g, 0.048 mmol, 57 %. 
1H NMR (300 MHz, CD3CN) δ (ppm) 7.91 – 6.85 (m, 11H), 5.48 – 5.00 (m, 8H). 
13C {1H} NMR (126 MHz, CD3CN) resonance was too weak and noisy despite 
6000-scan experiment. HRMS (ESI)+: m/z 404.0932 [CuL75]+, calculated 
[CuL75]+ 404.0931; 202.5509 [CuL75 + H]+2, calculated [CuL75 + H]+2 202.5502. 
v) Preparation of [AgL76](PF6) 
H2L76(PF6)2 (1.0 g, 1.58 mmol) and Ag2O (0.37 g, 1.58 mmol) were added to the 
freshly activated 4Å molecular sieves. In the absence of light, DMSO (5 mL) was 
added via a syringe and stirred for 3 hours at 55 °C. The mixture was filtered 
through Celite and the filtrate poured into water (100 mL) to afford a colourless 
precipitate. The solid was collected by filtration and dried in vacuo. Yield: 0.66 g, 
1.11 mmol, 70 %. 
1H NMR (300 MHz, d6-DMSO) δ (ppm) 7.99 (t, J = 7.7 Hz, 2H), 7.77 (s, 4H, imH), 
7.69 (d, J = 7.7 Hz, 4H), 5.52 (s, 8H). 13C {1H} NMR resonances were very weak 
despite at 126 MHz (500 MHz machine). HRMS (ESI+): m/z 449.0796 [M – PF6]+, 
calculated [M – PF6]+ 449.0644. 
Consistent with data previously reported. 
vi) Preparation of [CuL76](PF6)2 
In the absence of light, [AgL76](PF6) (0.30 g, 0.50 mmol) and CuBr2 (0.113 g, 
0.51 mmol) were stirred at room temperature in MeCN (10 mL) under Ar for 2 
hours. AgPF6 (0.127 g, 0.51 mmol) was added, with the colour immediately 
changing to purple. The reaction mixture was filtered via cannula filtration. The 
filtrate was concentrated to about 2 mL in vacuo and anhydrous Et2O (70 mL) 
was added to precipitate a purple solid, which was collected by cannula filtration 
and dried in vacuo. Yield: 0.30 g, 0.43 mmol, 86 %. 
1H NMR (300 MHz, CD3CN) δ (ppm) 7.98 (t, J = 7.7 Hz, 2H), 7.77 (s, 4H, imH), 
7.69 (d, J = 7.7 Hz, 4H), 5.54 – 5.46 (m, 4H), 5.46 – 5.36 (m, 4H). 13C {1H} NMR 
resonances were very weak despite at 126 MHz (500 MHz machine). HRMS 
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(ESI+): m/z 202.5437 [M – 2PF6]2+, calculated [M – 2PF6]2+ 202.5439. Analysis 
Calculated for C20H18N6CuP2F12 + 2/5CuP2F12: C, 28.69; H 2.17; N, 10.04. 
Found: C, 28.66; H 2.20; N, 10.24. 
Single crystals suitable for X-ray diffraction analysis were grown via the vapour 
diffusion of Et2O into a concentrated solution of the product in MeCN. 
vii) Attempted preparation of [AgL76(OTf)] 
H2L76(PF6)2 (1.0 g, 1.58 mmol) and Ag2O (0.37 g, 1.58 mmol) were added to 
freshly activated 4Å molecular sieves. In the absence of light, DMSO or MeCN 
(5 mL) was added via syringe and stirred for 3 hours at 55 °C.  
viii) Preparation of [CuL76(OTf)2] 
H2L76Br2 (0.50 g, 1.0 mmol) and Ag2O (0.23 g, 1.0 mmol) were added to freshly 
activated 4Å molecular sieves. In the absence of light, MeOH (20 mL) was added 
and stirred at 50 °C under Ar for 4.5 hours. The reaction mixture was filtered via 
cannula and concentrated to about 5 mL in vacuo. MeCN (10 mL) was added 
followed by CuBr2 (0.22 g, 1.0 mmol) and the reaction mixture stirred at room 
temperature for 4.5 hours. The yellow precipitate was removed by cannula 
filtration and the solvents removed from the filtrate in vacuo. MeCN (10 mL) was 
added, followed by AgOTf (0.51 g, 2.0 mmol) to afford a grey mixture. The 
mixture was stirred for 30 minutes, filtered via cannula and the solvent removed 
in vacuo to obtain a greenish grey solid. Yield: 0.25 g, 0.36 mmol, 36 %. 
1H NMR spectrum resonances were very weak (300 MHz and 500 MHz, CD3CN) 
but approximately at δ 7.97 – 7.72, 7.62 – 7.38 and 5.55 – 5.35. HRMS (ESI+): 
m/z 554.0397 [M – Otf]+, calculated [M – OTf]+ 554.0404. 
5.8.9 Preparation of oxidant 77 
78 (0.20 g, 0.92 mmol) and NOPF6 (0.16 g, 0.92 mmol) 
were added to an ampoule. Under Ar, MeCN (5 mL) was 
added and stirred at room temperature for 2 hours, 
during which time a brown fume was observed and the 
colour of the mixture changed to beep blue. Et2O (100 mL) was added to 
precipitate a deep blue solid, which was collected by cannula filtration, washed 
with Et2O (2 × 25 mL) and dried in vacuo. Yield: 0.19 g, 0.52 mmol, 57 %.  
1H NMR spectrum (300 MHz and 500 MHz, CD3CN) was very weak. HRMS 
(ESI+): m/z 216.0057 [M – PF6]+, calculated [M – PF6]+ 216.0067. 
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5.8.10 Oxidation of Cu-L76 complexes 
Chemical Oxidation Procedure. [CuL75](PF6)2 or [CuL75(Otf)2] (0.05 mmol) 
was dissolved in CD3CN (0.4 mL). A solution of 77 (0.05 mmol) in CD3CN (0.5 
mL) was added in portions of 0.1, 0.15 and 0.25 mL and analysed using 1H NMR 
spectroscopy after each addition. 
i) [CuL76](PF6)2 (35 mg, 0.05 mmol) was reacted with 77 according to 
the oxidation procedure, with colour changed from purple to orange. 
HRMS (ESI+): m/z 404.0800 [CuL76 – H]+, calculated [CuL76 – H]+ 
404.0805; 436.0695 [CuL76 – H + 2O]+, calculated [CuL76 – H + 2O]+ 
436.0695.  
ii) [CuL76(Otf)2] (34 mg, 0.05 mmol) was reacted with 77 according to 
the oxidation procedure, with the grey colour being bleached. 
HRMS (ESI+): m/z 554.9120, 556.9114 [CuL76 + OTf + H]+, calculated 
[CuL76 + OTf + H]+ 555.0482; 570.9070, 572.9065 [CuL76 + OTf + H 
+ O]+, calculated [CuL76 + OTf + H + O]+ 571.0431. However, those 
m/z peaks were not corresponding to Cu isotope ratio pattern (63Cu: 
65Cu = 2.2: 1). 
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Conclusions 
N-Heterocyclic carbenes (NHCs) are examples of stable singlet carbenes, which 
can be used in coordination chemistry. Their unique structural, steric and 
electronic properties can enhance the catalytic performance such as Grubbs II 
catalyst. However, there has also been non-innocent reactivity that such ligand 
get involved in reactions, for example, reductive elimination of aryl-imidazolium 
or halo-imidazolium ions.  
In this project, a great variety of NHC ligands, N,N'-donors and O,O'-donors were 
investigated for their catalytic activity when coordinated with Cu(I) in situ in an 
Ullmann-type etherification reaction. The Cu complex that were observed to 
show good activity are with 1-allyl-3-picolylbenzimidazol-2-ylidene. We proposed 
that it was due to the balance of electronic and structural properties of the ligand 
that enhance all nucleophilic substitution, oxidative addition and reductive 
elimination steps assuming that the catalytic cycle takes place via such 
Cu(I)/Cu(III) mechanism. 
Further investigations were carried out on side reactions during the catalysis, 
which aryl-imidazolium formation, dehalogenation and homocoupling reactions 
were explored under variations of nucleophile, base and metal/ligand 
concentrations. The etherification is favoured by a sufficient amount of 
nucleophile and metal/ligand, and can be increased with excess base. However, 
the aryl-imidazolium formation is favoured by a minimal base and excess 
metal/ligand. 
We had then exploit the side reaction of aryl-imidazolium formation to selectively 
functionalise xanthine-based imidazolium compounds, which were activated 
electrochemically to form Cu-NHC complexes. The arylation reactions were 
monitored by in situ 1H NMR and IR spectroscopy, which the activation energy 
of the arylation was calculated to be 58.9 – 63.1 kJ mol-1. Further investigation 
on the reaction mechanism is under process to understand the rate determining 
step of the reaction and thence the activation energy may be lowered so that the 
arylation reaction may be performed efficiently at lower temperatures. 
Other part of the project inspected the further reaction of the 1-allyl-2-bromo-3-
pyridyl imidazolium dicuprate(I)tribromide, which was generated by reductive 
elimination when excess CuBr2 is present with the Cu(NHC)Br2 complex of 
1-allyl-3-picolylimidazol-2-ylidene. The bromo-imidazolium salt can undergo 
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annulation reaction to form 7-bromo-5,6-dihydro-3-pyridyl-pyrolloimidazolium 
salt, which excess of Cu and pyridyl group were observed to be essential for the 
reaction. 
As most of the reactions discussed in the project were proposed to proceed via 
a Cu(III) intermediate, attempts were made to stabilise a Cu(III)-NHC using the 
macrocyclic effect. The attempt to synthesise Cu(III) complexes via either 
oxidative addition of C-X bond to Cu(I) complexes or oxidation of preformed 
Cu(II)-NHC complexes was not successful. However, the cyclic voltammetry 
data suggested that the oxidation of Cu(II) to Cu(III) is possible but still lack of 
sufficient stabilisation.  
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Appendix 
Supplementary Information on Compound NMR Analysis 
P14* 
 
P14*: 1H & 13C {1H} NMR (300/75 MHz, CDCl3) 
 
P14: 1H and 13C {1H} NMR (300/75 MHz, CDCl3) 
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P17: 1H and 13C {1H} NMR (300/75 MHz, CDCl3) 
 
P23: 1H and 13C {1H} NMR (300/75 MHz, CDCl3) 
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HL5Br: 1H and 13C {1H} NMR (300/75 MHz, CDCl3) 
 
HL7Br: 1H NMR (300 MHz, CDCl3) 
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HL7Br: 13C {1H} NMR (75 MHz, CDCl3) 
 
HL14Br: 1H and 13C {1H} NMR (300/75 MHz, CDCl3) 
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HL15Br: 1H NMR (300 MHz, CDCl3) 
 
HL15Br: 13C {1H} NMR (75 MHz, CDCl3) 
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HL17Br: 1H and 13C {1H} NMR (400/101 MHz, CDCl3) 
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HL21Br: 1H and 13C {1H} NMR (300/75 MHz, CDCl3) 
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HL23Br: 1H and 13C {1H} NMR (300/75 MHz, CDCl3) 
 
39: 1H and 13C {1H} NMR (500/126 MHz, CDCl3) 
 
40: 1H and 13C {1H} NMR (300/75 MHz, CDCl3) 
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Ar1: 1H and 13C {1H} NMR (300/75 MHz, CDCl3) 
 
Ar3: 1H and 13C {1H} NMR (300/75 MHz, CDCl3) 
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ArNu: 1H and 13C {1H} NMR (300/75 MHz, CDCl3) 
 
Ar46: 1H and 13C {1H} NMR (300/126 MHz, CD3CN) 
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PS8: 1H and 13C {1H} NMR (300/75 MHz, CDCl3) 
 
S8.b: 1H and 13C {1H} NMR (300/75 MHz, CDCl3) 
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S8.b: 1H and 13C {1H} NMR (400/101 MHz, CDCl3) 
 
P65: 1H and 13C {1H} NMR (500/126 MHz, CDCl3) 
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H2L69(PF6)2: 1H and 13C {1H} NMR (300/126 MHz, CD3CN) 
 
H2L75(PF6)2: 1H and 13C {1H} NMR (300/126 MHz, CD3CN) 
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AgL75(PF6): 1H = NMR (300 MHz, CD3CN) 
 
CuL75(PF6): 1H = NMR (300 MHz, CD3CN) 
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Supplementary Information on Compound X-ray Crystallography Analysis 
S8.a: 
Identification code  RW49a  
Empirical formula  C14.33HN11.33Cu2Br4.67  
Formula weight  830.92  
Temperature/K  120.0(2)  
Crystal system  monoclinic  
Space group  P21/n  
a/Å  10.0973(4)  
b/Å  18.5632(7)  
c/Å  12.1813(5)  
α/°  90.00  
β/°  102.343(4)  
γ/°  90.00  
Volume/Å3  2230.46(15)  
Z  6  
ρcalcg/cm3  3.712  
μ/mm-1  15.444  
F(000)  2320.0  
Crystal size/mm3  ? × ? × ?  
Radiation  MoKα (λ = 0.71073)  
2Θ range for data collection/°  6.3 to 62.4  
Index ranges  -14 ≤ h ≤ 13, -26 ≤ k ≤ 26, -16 ≤ l ≤ 17  
Reflections collected  17703  
Independent reflections  6356 [Rint = 0.0586, Rsigma = 0.0862]  
Data/restraints/parameters  6356/0/244  
Goodness-of-fit on F2  1.766  
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Final R indexes [I>=2σ (I)]  R1 = 0.1166, wR2 = 0.2891  
Final R indexes [all data]  R1 = 0.1660, wR2 = 0.3124  
Largest diff. peak/hole / e Å-3  8.45/-7.66  
 
PS8: 
Identification code  RW37  
Empirical formula  C8H6BrN3  
Formula weight  224.07  
Temperature/K  120.1(4)  
Crystal system  monoclinic  
Space group  P21/n  
a/Å  3.85834(19)  
b/Å  17.1193(12)  
c/Å  11.9087(5)  
α/°  90.00  
β/°  90.029(4)  
γ/°  90.00  
Volume/Å3  786.60(8)  
Z  4  
ρcalcg/cm3  1.892  
μ/mm-1  5.164  
F(000)  440.0  
Crystal size/mm3  ? × ? × ?  
Radiation  Mo Kα (λ = 0.71073)  
2Θ range for data collection/°  6.84 to 62.42  
Index ranges  -5 ≤ h ≤ 5, -22 ≤ k ≤ 23, -17 ≤ l ≤ 13  
Reflections collected  5035  
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Independent reflections  2203 [Rint = 0.0507, Rsigma = 0.0782]  
Data/restraints/parameters  2203/0/109  
Goodness-of-fit on F2  1.024  
Final R indexes [I>=2σ (I)]  R1 = 0.0470, wR2 = 0.0763  
Final R indexes [all data]  R1 = 0.0743, wR2 = 0.0838  
Largest diff. peak/hole / e Å-3  0.66/-0.58  
 
S8.b: 
Identification code  RW38  
Empirical formula  C11H11Br2N3  
Formula weight  345.05  
Temperature/K  119.97(16)  
Crystal system  monoclinic  
Space group  P21/c  
a/Å  10.2246(7)  
b/Å  7.7322(4)  
c/Å  15.8412(7)  
α/°  90.00  
β/°  103.205(6)  
γ/°  90.00  
Volume/Å3  1219.27(12)  
Z  4  
ρcalcg/cm3  1.880  
μ/mm-1  6.624  
F(000)  672.0  
Crystal size/mm3  0.21 × 0.08 × 0.03  
Radiation  MoKα (λ = 0.71073)  
 
 
215 
 
2Θ range for data collection/°  6.68 to 56.56  
Index ranges  -12 ≤ h ≤ 13, -10 ≤ k ≤ 10, -21 ≤ l ≤ 20  
Reflections collected  7751  
Independent reflections  3037 [Rint = 0.0380, Rsigma = 0.0500]  
Data/restraints/parameters  3037/0/145  
Goodness-of-fit on F2  1.058  
Final R indexes [I>=2σ (I)]  R1 = 0.0342, wR2 = 0.0641  
Final R indexes [all data]  R1 = 0.0536, wR2 = 0.0708  
Largest diff. peak/hole / e Å-3  0.46/-0.67  
 
[CuL76](PF6)2: 
Identification code  RW302-1  
Empirical formula  C20H18CuF12N6P2  
Formula weight  695.88  
Temperature/K  119.97(17)  
Crystal system  monoclinic  
Space group  C2/c  
a/Å  13.5194(6)  
b/Å  11.8103(3)  
c/Å  17.2239(7)  
α/°  90  
β/°  111.094(5)  
γ/°  90  
Volume/Å3  2565.83(19)  
Z  4  
ρcalcg/cm3  1.801  
μ/mm-1  3.438  
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F(000)  1388.0  
Crystal size/mm3  0.1572 × 0.1072 × 0.0709  
Radiation  CuKα (λ = 1.54184)  
2Θ range for data collection/°  10.26 to 147.326  
Index ranges  -16 ≤ h ≤ 14, -13 ≤ k ≤ 14, -18 ≤ l ≤ 21  
Reflections collected  4598  
Independent reflections  2509 [Rint = 0.0174, Rsigma = 0.0232]  
Data/restraints/parameters  2509/0/223  
Goodness-of-fit on F2  1.074  
Final R indexes [I>=2σ (I)]  R1 = 0.0307, wR2 = 0.0818  
Final R indexes [all data]  R1 = 0.0331, wR2 = 0.0836  
Largest diff. peak/hole / e Å-3  0.33/-0.40  
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Calculations on ln plots for the kinetics of the arylation of C46 
i) Pseudo 1st order on [C46] using [C46] versus time 
[𝑪𝟒𝟔] = 𝑥 
−
𝑑𝑥
𝑑𝑡
= 𝑘′𝑥 
∫ 𝑘′𝑑𝑡
𝑡
0
= − ∫
1
𝑥
𝑥
𝑥0
𝑑𝑥 
𝑘′𝑡 − 0 = 𝑙𝑛𝑥0 − 𝑙𝑛𝑥 
𝑙𝑛𝑥 = −𝑘′𝑡 + 𝑙𝑛𝑥0 
ii) Pseudo 1st order on [C46] using [Ar46] versus time 
[𝑨𝒓𝟒𝟔] = 𝑦 
[𝑪𝟒𝟔] = 0.05 − 𝑦 
𝑑𝑦
𝑑𝑡
= 𝑘′(0.05 − 𝑦) 
∫ 𝑘′𝑑𝑡
𝑡
0
= ∫
1
0.05 − 𝑦
𝑦
0
𝑑𝑦 
𝑘′𝑡 − 0 = ln(1 − 20𝑦) − ln (1) 
ln(1 − 20𝑦) = −𝑘′𝑡 
iii) 2nd order on [C46] and [4-iodoanisole] using [C46] versus time 
[𝑪𝟒𝟔] = 𝑥 
[𝐴𝑟𝐼] = 0.25 − 0.05 + 𝑥 = 0.2 + 𝑥 
−
𝑑𝑥
𝑑𝑡
= 𝑘(𝑥)(0.2 + 𝑥) 
∫ 𝑘𝑑𝑡
𝑡
0
= − ∫
1
𝑥(0.2 + 𝑥)
𝑥
0.05
𝑑𝑥 
𝑘𝑡 − 0 = − (−5 ln (5 +
1
𝑥
) + 5 ln(100)) 
𝑘𝑡 = 5 ln (5 +
1
𝑥
) − 5ln (100) 
5 ln (5 +
1
𝑥
) = 𝑘𝑡 + 5ln (100) 
iv) 2nd order on [C46] and [4-iodoanisole] using [Ar46] versus time 
[𝑨𝒓𝟒𝟔] = 𝑦 
[𝑪𝟒𝟔] = 0.05 − 𝑦 
[𝐴𝑟𝐼] = 0.25 − 𝑦 
𝑑𝑦
𝑑𝑡
= 𝑘(0.05 − 𝑦)(0.25 − 𝑦) 
∫ 𝑘𝑑𝑡
𝑡
0
= ∫
1
(0.05 − 𝑦)(0.25 − 𝑦)
𝑑𝑦
𝑦
0
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𝑘𝑡 − 0 = −5 ln (5 +
4
4𝑦 − 1
) + 5 ln(1) 
5 ln (5 +
4
4𝑦 − 1
) = −𝑘𝑡 
Calculation on structures of [CuL76](PF6)2 
𝑘𝑛𝑜𝑤𝑛; ‹(𝑁𝐻𝐶 − 𝐶𝑢 − 𝑝𝑦) = 𝜃 = 90.08° 
‹(𝑁𝐻𝐶 − 𝐶𝑢 − 𝐹) = 𝜑 = 82.049° 
‹(𝑝𝑦 − 𝐶𝑢 − 𝐹) = 𝜔 = 82.693° 
𝑎𝑠𝑠𝑢𝑚𝑒;      𝐶𝑢 − 𝐹 = 𝑎 
  𝑥 = 𝑎 𝑐𝑜𝑠𝜑 
𝑦 = 𝑎 𝑐𝑜𝑠𝜔𝑠𝑖𝑛𝜃 
𝑧2 = 𝑎2𝑠𝑖𝑛2𝜑 − 𝑎2𝑐𝑜𝑠2𝜔𝑠𝑖𝑛2𝜃 
𝑧 = √𝑎2𝑠𝑖𝑛2𝜑 − 𝑎2𝑐𝑜𝑠2𝜔𝑠𝑖𝑛2𝜃 
𝑋𝑌 = √𝑎2𝑐𝑜𝑠2𝜑 + 𝑎2𝑐𝑜𝑠2𝜔𝑠𝑖𝑛2𝜃 
‹(𝑍 − 𝐶𝑢 − 𝐹) = 𝑡𝑎𝑛−1
√𝑎2𝑐𝑜𝑠2𝜑 + 𝑎2𝑐𝑜𝑠2𝜔𝑠𝑖𝑛2𝜃
√𝑎2𝑠𝑖𝑛2𝜑 − 𝑎2𝑐𝑜𝑠2𝜔𝑠𝑖𝑛2𝜃
 
= 10.831° 
 
 
